<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archivearticle1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4546629</article-id><article-id pub-id-type="pmid">26296200</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0135281</article-id><article-id pub-id-type="publisher-id">PONE-D-15-20343</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>The Epidemiology of Hepatitis C Virus in the Fertile Crescent: Systematic Review and Meta-Analysis</article-title><alt-title alt-title-type="running-head">Hepatitis C Epidemiology in the Fertile Crescent</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chemaitelly</surname><given-names>Hiam</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref><xref rid="cor001" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Chaabna</surname><given-names>Karima</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Abu-Raddad</surname><given-names>Laith J.</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="aff001">
<label>1</label>
<addr-line>Infectious Disease Epidemiology Group, Weill Cornell Medical College in Qatar, Cornell University, Qatar Foundation, Education City, Doha, Qatar</addr-line>
</aff><aff id="aff002">
<label>2</label>
<addr-line>Department of Healthcare Policy &#x00026; Research, Weill Cornell Medical College, Cornell University, New York, New York, United States of America</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Ciccozzi</surname><given-names>Massimo</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">
<addr-line>National Institute of Health, ITALY</addr-line>
</aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="con" id="contrib001"><p>Conceived and designed the experiments: LJA-R. Analyzed the data: HC KC. Wrote the paper: HC LJA-R.</p></fn><corresp id="cor001">* E-mail: <email>hsc2001@qatar-med.cornell.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>21</day><month>8</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>10</volume><issue>8</issue><elocation-id>e0135281</elocation-id><history><date date-type="received"><day>11</day><month>5</month><year>2015</year></date><date date-type="accepted"><day>20</day><month>7</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; 2015 Chemaitelly et al</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Chemaitelly et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="pone.0135281.pdf"/><abstract><sec id="sec001"><title>Objective</title><p>To characterize hepatitis C virus (HCV) epidemiology in countries of the Fertile Crescent region of the Middle East and North Africa (MENA), namely Iraq, Jordan, Lebanon, Palestine, and Syria.</p></sec><sec id="sec002"><title>Methods</title><p>We systematically reviewed and synthesized available records of HCV incidence and prevalence following PRISMA guidelines. Meta-analyses were implemented using a DerSimonian-Laird random effects model with inverse weighting to estimate the country-specific HCV prevalence among the various at risk population groups.</p></sec><sec id="sec003"><title>Results</title><p>We identified eight HCV incidence and 240 HCV prevalence measures in the Fertile Crescent. HCV sero-conversion risk among hemodialysis patients was 9.2% in Jordan and 40.3% in Iraq, and ranged between 0% and 3.5% among other populations in Iraq over different follow-up times. Our meta-analyses estimated HCV prevalence among the general population at 0.2% in Iraq (range: 0&#x02013;7.2%; 95% CI: 0.1&#x02013;0.3%), 0.3% in Jordan (range: 0&#x02013;2.0%; 95% CI: 0.1&#x02013;0.5%), 0.2% in Lebanon (range: 0&#x02013;3.4%; 95% CI: 0.1&#x02013;0.3%), 0.2% in Palestine (range: 0&#x02013;9.0%; 95% CI: 0.2&#x02013;0.3%), and 0.4% in Syria (range: 0.3&#x02013;0.9%; 95% CI: 0.4&#x02013;0.5%). Among populations at high risk, HCV prevalence was estimated at 19.5% in Iraq (range: 0&#x02013;67.3%; 95% CI: 14.9&#x02013;24.5%), 37.0% in Jordan (range: 21&#x02013;59.5%; 95% CI: 29.3&#x02013;45.0%), 14.5% in Lebanon (range: 0&#x02013;52.8%; 95% CI: 5.6&#x02013;26.5%), and 47.4% in Syria (range: 21.0&#x02013;75.0%; 95% CI: 32.5&#x02013;62.5%). Genotypes 4 and 1 appear to be the dominant circulating strains.</p></sec><sec id="sec004"><title>Conclusions</title><p>HCV prevalence in the population at large appears to be below 1%, lower than that in other MENA sub-regions, and tending towards the lower end of the global range. However, there is evidence for ongoing HCV transmission within medical facilities and among people who inject drugs (PWID). Migration dynamics appear to have played a role in determining the circulating genotypes. HCV prevention efforts should be targeted, and focus on infection control in clinical settings and harm reduction among PWID.</p></sec></abstract><funding-group><funding-statement>This publication was made possible by NPRP grant number 4-924-3-251 from the Qatar National Research Fund (a member of Qatar Foundation), url: <ext-link ext-link-type="uri" xlink:href="http://www.qnrf.org/en-us/">http://www.qnrf.org/en-us/</ext-link>. Additional support was provided by the Biostatistics, Epidemiology, and Biomathematics Research Core at the Weill Cornell Medical College in Qatar, url: <ext-link ext-link-type="uri" xlink:href="http://qatar-weill.cornell.edu/research/laboratories/biostatistics.html">http://qatar-weill.cornell.edu/research/laboratories/biostatistics.html</ext-link>. The statements made herein are solely the responsibility of the authors. The funders had no role in the design, conduct, or analysis of the study.</funding-statement></funding-group><counts><fig-count count="1"/><table-count count="5"/><page-count count="30"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and its Supporting Information files.</p></notes></front><body><sec sec-type="intro" id="sec005"><title>Introduction</title><p>Hepatitis C virus (HCV) is a main risk factor for liver cancer and cirrhosis and is estimated to affect 1&#x02013;3% of the population in most countries globally [<xref rid="pone.0135281.ref001" ref-type="bibr">1</xref>, <xref rid="pone.0135281.ref002" ref-type="bibr">2</xref>]. The vast majority of HCV transmission is blood-borne and largely preventable [<xref rid="pone.0135281.ref003" ref-type="bibr">3</xref>, <xref rid="pone.0135281.ref004" ref-type="bibr">4</xref>]. Recent breakthroughs in HCV treatment research suggest promising prospects for treating and containing the infection, and raise hope for an improved quality of life among infected individuals [<xref rid="pone.0135281.ref005" ref-type="bibr">5</xref>].</p><p>In few countries of the Middle East and North Africa (MENA) region, namely Egypt and Pakistan, HCV is prevalent at high levels: 14.7% in Egypt [<xref rid="pone.0135281.ref006" ref-type="bibr">6</xref>, <xref rid="pone.0135281.ref007" ref-type="bibr">7</xref>] and 4.8% in Pakistan [<xref rid="pone.0135281.ref008" ref-type="bibr">8</xref>, <xref rid="pone.0135281.ref009" ref-type="bibr">9</xref>]. Meanwhile, infection levels remain poorly estimated for most MENA countries including those in the Fertile Crescent (FC). Geographically, for this study, we define the FC subregion of MENA to include Iraq, Jordan, Lebanon, Palestine, and Syria. Since Egypt was covered by a separate systematic review published recently [<xref rid="pone.0135281.ref007" ref-type="bibr">7</xref>], we did not include Egypt as part of our study. FC countries share historical, socio-cultural, and geo-political similarities, and their health care systems are often directly or indirectly interlinked or affected by decades of political turmoil and refugee waves within this territory.</p><p>Our study primarily aims at characterizing HCV epidemiology in these countries by 1) systematically reviewing and synthesizing all available published and unpublished records of HCV incidence and prevalence among the different population groups, and 2) estimating the population-level country-specific HCV prevalence by pooling available HCV prevalence measures among the general population in each country. A secondary outcome of our study is an analysis of HCV genotype diversity. This work is conducted under the umbrella of the MENA HCV Epidemiology Synthesis Project; an ongoing effort to characterize HCV epidemiology and inform key public health research, policy, and programming priorities in MENA [<xref rid="pone.0135281.ref007" ref-type="bibr">7</xref>, <xref rid="pone.0135281.ref010" ref-type="bibr">10</xref>&#x02013;<xref rid="pone.0135281.ref015" ref-type="bibr">15</xref>].</p></sec><sec sec-type="materials|methods" id="sec006"><title>Materials and Methods</title><sec id="sec007"><title>Data sources and search strategy</title><p>We systematically reviewed all HCV incidence (<xref rid="pone.0135281.t001" ref-type="table">Table 1</xref>) and prevalence (Tables <xref rid="pone.0135281.t002" ref-type="table">2</xref> and <xref rid="pone.0135281.t003" ref-type="table">3</xref> and <xref rid="pone.0135281.s011" ref-type="supplementary-material">S2 Table</xref>) data in FC following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines [<xref rid="pone.0135281.ref016" ref-type="bibr">16</xref>]. The PRISMA checklist can be found in <xref rid="pone.0135281.s001" ref-type="supplementary-material">S1 Fig</xref>. The methodology was adapted from a recently published protocol for a systematic review of HCV incidence and prevalence measures for countries in the Horn of Africa subregion of MENA [<xref rid="pone.0135281.ref010" ref-type="bibr">10</xref>, <xref rid="pone.0135281.ref017" ref-type="bibr">17</xref>]. Our search criteria can be found in <xref rid="pone.0135281.s002" ref-type="supplementary-material">S2 Fig</xref>. Briefly, we surveyed PubMed and Embase (up to April 23, 2015), different regional databases (up to November 5&#x02013;16, 2014), the abstract archives of the International AIDS Society conferences (up to November 16, 2014), and country-level and international organizations&#x02019; reports available through the MENA HIV/AIDS Epidemiology Synthesis Project database (up to April 23, 2015) [<xref rid="pone.0135281.ref018" ref-type="bibr">18</xref>, <xref rid="pone.0135281.ref019" ref-type="bibr">19</xref>]. We used a broad search criteria with no language restrictions. PubMed and Embase were searched using text terms and MeSH/Emtree terms exploded to cover all subheadings. Our search was restricted to articles published after 1989, the year when HCV was first discovered [<xref rid="pone.0135281.ref020" ref-type="bibr">20</xref>, <xref rid="pone.0135281.ref021" ref-type="bibr">21</xref>].</p><table-wrap id="pone.0135281.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0135281.t001</object-id><label>Table 1</label><caption><title>Studies reporting hepatitis C virus (HCV) incidence in countries of the Fertile Crescent.</title></caption><alternatives><graphic id="pone.0135281.t001g" xlink:href="pone.0135281.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">First author, year of publication [citation]</th><th align="center" rowspan="1" colspan="1">Year of data collection</th><th align="center" rowspan="1" colspan="1">Study site</th><th align="center" rowspan="1" colspan="1">Population&#x02019;s classification based on risk of HCV exposure</th><th align="center" rowspan="1" colspan="1">Population</th><th align="center" rowspan="1" colspan="1">Sample size at recruitment</th><th align="center" rowspan="1" colspan="1">Lost to follow-up</th><th align="center" rowspan="1" colspan="1">HCV sero-conversion risk (relative to total sample size)</th><th align="center" rowspan="1" colspan="1">Duration of follow-up</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Jordan</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Batieha, 07 [<xref rid="pone.0135281.ref039" ref-type="bibr">39</xref>]</td><td align="center" rowspan="1" colspan="1">2003</td><td align="center" rowspan="1" colspan="1">Dialysis units/National</td><td align="center" rowspan="1" colspan="1">High risk population</td><td align="center" rowspan="1" colspan="1">Hemodialysis patients</td><td align="center" rowspan="1" colspan="1">1300</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">9.2%</td><td align="center" rowspan="1" colspan="1">12 months</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Iraq</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Al-Rubaie, 11 [<xref rid="pone.0135281.ref040" ref-type="bibr">40</xref>]</td><td align="center" rowspan="1" colspan="1">2009</td><td align="center" rowspan="1" colspan="1">Hospital</td><td align="center" rowspan="1" colspan="1">High risk population</td><td align="center" rowspan="1" colspan="1">Hemodialysis patients</td><td align="center" rowspan="1" colspan="1">57</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">40.3%</td><td align="center" rowspan="1" colspan="1">12 months</td></tr><tr><td align="left" rowspan="1" colspan="1">Al-Jadiry, 08 [<xref rid="pone.0135281.ref042" ref-type="bibr">42</xref>]</td><td align="center" rowspan="1" colspan="1">2007</td><td align="center" rowspan="1" colspan="1">Hospital</td><td align="center" rowspan="1" colspan="1">Special clinical population</td><td align="center" rowspan="1" colspan="1">Pediatric patients with acute lymphoblastic leukemia</td><td align="center" rowspan="1" colspan="1">123</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">3.2%</td><td align="center" rowspan="1" colspan="1">30 months (median)</td></tr><tr><td align="left" rowspan="1" colspan="1">Al-Kubaisy, 00 [<xref rid="pone.0135281.ref044" ref-type="bibr">44</xref>]</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Hospital</td><td align="center" rowspan="1" colspan="1">High risk population</td><td align="center" rowspan="1" colspan="1">Newborns to HCV infected women</td><td align="center" rowspan="1" colspan="1">26</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0%</td><td align="center" rowspan="1" colspan="1">6 months</td></tr><tr><td align="left" rowspan="1" colspan="1">Al-Ali, 14 [<xref rid="pone.0135281.ref041" ref-type="bibr">41</xref>]</td><td align="center" rowspan="1" colspan="1">2006&#x02013;07</td><td align="center" rowspan="1" colspan="1">Hospital</td><td align="center" rowspan="1" colspan="1">Special clinical population</td><td align="center" rowspan="1" colspan="1">Pediatric cancer patients on chemotherapy</td><td align="center" rowspan="1" colspan="1">85</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">3.2%</td><td align="center" rowspan="1" colspan="1">12 months</td></tr><tr><td align="left" rowspan="1" colspan="1">Al-Ani, 11 [<xref rid="pone.0135281.ref043" ref-type="bibr">43</xref>]</td><td align="center" rowspan="1" colspan="1">2007&#x02013;09</td><td align="center" rowspan="1" colspan="1">Hospital</td><td align="center" rowspan="1" colspan="1">Low risk population</td><td align="center" rowspan="1" colspan="1">Healthy children</td><td align="center" rowspan="1" colspan="1">60</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0%</td><td align="center" rowspan="1" colspan="1">6 months</td></tr><tr><td align="left" rowspan="1" colspan="1">Al-Ani, 11 [<xref rid="pone.0135281.ref043" ref-type="bibr">43</xref>]</td><td align="center" rowspan="1" colspan="1">2007&#x02013;09</td><td align="center" rowspan="1" colspan="1">Hospital</td><td align="center" rowspan="1" colspan="1">Special clinical population</td><td align="center" rowspan="1" colspan="1">Pediatric patients with leukemia on chemotherapy</td><td align="center" rowspan="1" colspan="1">29</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">3.5%</td><td align="center" rowspan="1" colspan="1">6 months</td></tr><tr><td align="left" rowspan="1" colspan="1">Al-Ani, 11 [<xref rid="pone.0135281.ref043" ref-type="bibr">43</xref>]</td><td align="center" rowspan="1" colspan="1">2007&#x02013;09</td><td align="center" rowspan="1" colspan="1">Hospital</td><td align="center" rowspan="1" colspan="1">Special clinical population</td><td align="center" rowspan="1" colspan="1">Pediatric patients with leukemia who have had their baseline screening prior to chemotherapy</td><td align="center" rowspan="1" colspan="1">27</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0%</td><td align="center" rowspan="1" colspan="1">6 months</td></tr></tbody></table></alternatives></table-wrap><table-wrap id="pone.0135281.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0135281.t002</object-id><label>Table 2</label><caption><title>Studies reporting hepatitis C virus (HCV) prevalence among populations at high risk in countries of the Fertile Crescent.</title></caption><alternatives><graphic id="pone.0135281.t002g" xlink:href="pone.0135281.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">First author, year of publication [citation]</th><th colspan="2" align="center" rowspan="1">Years of data collection</th><th align="center" rowspan="1" colspan="1">Study site</th><th align="center" rowspan="1" colspan="1">Study sampling procedure</th><th align="center" rowspan="1" colspan="1">Population</th><th align="center" rowspan="1" colspan="1">Sample size<xref rid="t002fn002" ref-type="table-fn">*</xref>
</th><th align="center" rowspan="1" colspan="1">HCV prev<xref rid="t002fn003" ref-type="table-fn">**</xref>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Iraq (n = 36)</bold>
</td><td colspan="2" align="center" rowspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Abdul-Aziz, 01 [<xref rid="pone.0135281.ref046" ref-type="bibr">46</xref>]</td><td colspan="2" align="center" rowspan="1">1999&#x02013;01</td><td align="center" rowspan="1" colspan="1">Central laboratory</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Hemodialysis patients</td><td align="center" rowspan="1" colspan="1">95</td><td align="center" rowspan="1" colspan="1">0%</td></tr><tr><td align="left" rowspan="1" colspan="1">Abdul-Aziz, 01 [<xref rid="pone.0135281.ref046" ref-type="bibr">46</xref>]</td><td colspan="2" align="center" rowspan="1">1999&#x02013;01</td><td align="center" rowspan="1" colspan="1">Central laboratory</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Thalassemic patients</td><td align="center" rowspan="1" colspan="1">163</td><td align="center" rowspan="1" colspan="1">8%</td></tr><tr><td align="left" rowspan="1" colspan="1">Abdul-Karim, 11 [<xref rid="pone.0135281.ref149" ref-type="bibr">149</xref>]</td><td colspan="2" align="center" rowspan="1">2008</td><td align="center" rowspan="1" colspan="1">Hospital</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Patients with bleeding disorders</td><td align="center" rowspan="1" colspan="1">243</td><td align="center" rowspan="1" colspan="1">40.3%</td></tr><tr><td align="left" rowspan="1" colspan="1">Abdullah, 12 [<xref rid="pone.0135281.ref048" ref-type="bibr">48</xref>]</td><td colspan="2" align="center" rowspan="1">2010</td><td align="center" rowspan="1" colspan="1">Hemodialysis centers</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Hemodialysis patients</td><td align="center" rowspan="1" colspan="1">236</td><td align="center" rowspan="1" colspan="1">39%</td></tr><tr><td align="left" rowspan="1" colspan="1">Abdullah, 12 [<xref rid="pone.0135281.ref047" ref-type="bibr">47</xref>]</td><td colspan="2" align="center" rowspan="1">2005&#x02013;07</td><td align="center" rowspan="1" colspan="1">Dialysis unit</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Hemodialysis patients</td><td align="center" rowspan="1" colspan="1">80</td><td align="center" rowspan="1" colspan="1">28.7%</td></tr><tr><td align="left" rowspan="1" colspan="1">Abed, 10 [<xref rid="pone.0135281.ref150" ref-type="bibr">150</xref>]</td><td colspan="2" align="center" rowspan="1">2008</td><td align="center" rowspan="1" colspan="1">Thalassemia center</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Thalassemic patients</td><td align="center" rowspan="1" colspan="1">111</td><td align="center" rowspan="1" colspan="1">46%</td></tr><tr><td align="left" rowspan="1" colspan="1">Albahadle, 13 [<xref rid="pone.0135281.ref151" ref-type="bibr">151</xref>]</td><td colspan="2" align="center" rowspan="1">2011</td><td align="center" rowspan="1" colspan="1">Thalassemia center</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Thalassemic patients (0&#x02013;18 years)</td><td align="center" rowspan="1" colspan="1">206</td><td align="center" rowspan="1" colspan="1">19.9%</td></tr><tr><td align="left" rowspan="1" colspan="1">Al-Barzinji, 06 [<xref rid="pone.0135281.ref152" ref-type="bibr">152</xref>]</td><td colspan="2" align="center" rowspan="1">2004</td><td align="center" rowspan="1" colspan="1">Hospital</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Multi-transfused leukemia patients on chemotherapy (1&#x02013;12 years)</td><td align="center" rowspan="1" colspan="1">88</td><td align="center" rowspan="1" colspan="1">4.5%</td></tr><tr><td align="left" rowspan="1" colspan="1">Al-Beldawi, 10 [<xref rid="pone.0135281.ref056" ref-type="bibr">56</xref>]</td><td colspan="2" align="center" rowspan="1">2006</td><td align="center" rowspan="1" colspan="1">Hemophilia center</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Hemophilia patients (&#x0003c;20 years)</td><td align="center" rowspan="1" colspan="1">200</td><td align="center" rowspan="1" colspan="1">40%</td></tr><tr><td align="left" rowspan="1" colspan="1">Al-Dulaimi, 12 [<xref rid="pone.0135281.ref049" ref-type="bibr">49</xref>]</td><td colspan="2" align="center" rowspan="1">2010&#x02013;11</td><td align="center" rowspan="1" colspan="1">Hospital</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Hemodialysis patients</td><td align="center" rowspan="1" colspan="1">84</td><td align="center" rowspan="1" colspan="1">14.3%</td></tr><tr><td align="left" rowspan="1" colspan="1">Al-Greti, 13 [<xref rid="pone.0135281.ref153" ref-type="bibr">153</xref>]</td><td colspan="2" align="center" rowspan="1">2011&#x02013;12</td><td align="center" rowspan="1" colspan="1">Thalassemia center</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Thalassemic patients</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">37%</td></tr><tr><td align="left" rowspan="1" colspan="1">Al-Juboori, 12 [<xref rid="pone.0135281.ref154" ref-type="bibr">154</xref>]</td><td colspan="2" align="center" rowspan="1">2010&#x02013;11</td><td align="center" rowspan="1" colspan="1">Thalassemia center</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Thalassemic patients (&#x0003c;20 years)</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">10%</td></tr><tr><td align="left" rowspan="1" colspan="1">Al Kubaisy, 06 [<xref rid="pone.0135281.ref045" ref-type="bibr">45</xref>]</td><td colspan="2" align="center" rowspan="1">1998</td><td align="center" rowspan="1" colspan="1">Hospital</td><td align="center" rowspan="1" colspan="1">SRS</td><td align="center" rowspan="1" colspan="1">Thalassemic patients (2&#x02013;10 years)</td><td align="center" rowspan="1" colspan="1">559</td><td align="center" rowspan="1" colspan="1">67.3%</td></tr><tr><td align="left" rowspan="1" colspan="1">Al-Marzoqi, 09 [<xref rid="pone.0135281.ref066" ref-type="bibr">66</xref>]</td><td colspan="2" align="center" rowspan="1">2008</td><td align="center" rowspan="1" colspan="1">Thalassemia center</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Thalassemic patients (children)</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">38%</td></tr><tr><td align="left" rowspan="1" colspan="1">Al-Mashhadani, 07 [<xref rid="pone.0135281.ref050" ref-type="bibr">50</xref>]</td><td colspan="2" align="center" rowspan="1">2002</td><td align="center" rowspan="1" colspan="1">Hospital</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Hemodialysis patients</td><td align="center" rowspan="1" colspan="1">87</td><td align="center" rowspan="1" colspan="1">11.5%</td></tr><tr><td align="left" rowspan="1" colspan="1">Al-Thwani, 06 [<xref rid="pone.0135281.ref057" ref-type="bibr">57</xref>]</td><td colspan="2" align="center" rowspan="1">1997&#x02013;04</td><td align="center" rowspan="1" colspan="1">Blood trans center</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Hemophilia patients</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">25%</td></tr><tr><td align="left" rowspan="1" colspan="1">Al Wtaify, 00 [<xref rid="pone.0135281.ref155" ref-type="bibr">155</xref>]</td><td colspan="2" align="center" rowspan="1">1998&#x02013;99</td><td align="center" rowspan="1" colspan="1">Thalassemia center</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Thalassemic patients (children)</td><td align="center" rowspan="1" colspan="1">200</td><td align="center" rowspan="1" colspan="1">9.5%</td></tr><tr><td align="left" rowspan="1" colspan="1">Al-Zamili, 09 [<xref rid="pone.0135281.ref156" ref-type="bibr">156</xref>]</td><td colspan="2" align="center" rowspan="1">2007&#x02013;08</td><td align="center" rowspan="1" colspan="1">Hospital</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Thalassemic patients (&#x0003c;20 years)</td><td align="center" rowspan="1" colspan="1">325</td><td align="center" rowspan="1" colspan="1">4%</td></tr><tr><td align="left" rowspan="1" colspan="1">Easa, 09 [<xref rid="pone.0135281.ref157" ref-type="bibr">157</xref>]</td><td colspan="2" align="center" rowspan="1">2007&#x02013;08</td><td align="center" rowspan="1" colspan="1">Thalassemia center</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Thalassemic patients (5&#x02013;18 years)</td><td align="center" rowspan="1" colspan="1">140</td><td align="center" rowspan="1" colspan="1">26.4%</td></tr><tr><td align="left" rowspan="1" colspan="1">Fadhil, 12 [<xref rid="pone.0135281.ref158" ref-type="bibr">158</xref>]</td><td colspan="2" align="center" rowspan="1">2010&#x02013;11</td><td align="center" rowspan="1" colspan="1">Thalassemia center</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Thalassemic patients</td><td align="center" rowspan="1" colspan="1">200</td><td align="center" rowspan="1" colspan="1">21%</td></tr><tr><td align="left" rowspan="1" colspan="1">Hashem, 13 [<xref rid="pone.0135281.ref159" ref-type="bibr">159</xref>]</td><td colspan="2" align="center" rowspan="1">2011</td><td align="center" rowspan="1" colspan="1">Hereditary blood diseases center</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Thalassemic patients</td><td align="center" rowspan="1" colspan="1">284</td><td align="center" rowspan="1" colspan="1">19%</td></tr><tr><td align="left" rowspan="1" colspan="1">Hassan, 08 [<xref rid="pone.0135281.ref137" ref-type="bibr">137</xref>]</td><td colspan="2" align="center" rowspan="1">1996&#x02013;01</td><td align="center" rowspan="1" colspan="1">Central laboratory</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Thalassemic patients</td><td align="center" rowspan="1" colspan="1">136</td><td align="center" rowspan="1" colspan="1">16.9%</td></tr><tr><td align="left" rowspan="1" colspan="1">Khaled, 14 [<xref rid="pone.0135281.ref160" ref-type="bibr">160</xref>]</td><td colspan="2" align="center" rowspan="1">2012</td><td align="center" rowspan="1" colspan="1">Thalassemia center</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Thalassemic patients</td><td align="center" rowspan="1" colspan="1">480</td><td align="center" rowspan="1" colspan="1">10.4%</td></tr><tr><td align="left" rowspan="1" colspan="1">Khalid, 12 [<xref rid="pone.0135281.ref161" ref-type="bibr">161</xref>]</td><td colspan="2" align="center" rowspan="1"/><td align="center" rowspan="1" colspan="1">Thalassemia center</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Thalassemic patients</td><td align="center" rowspan="1" colspan="1">200</td><td align="center" rowspan="1" colspan="1">17.5%</td></tr><tr><td align="left" rowspan="1" colspan="1">Khattab, 08 [<xref rid="pone.0135281.ref051" ref-type="bibr">51</xref>]</td><td colspan="2" align="center" rowspan="1">2003&#x02013;05</td><td align="center" rowspan="1" colspan="1">Renal transplant center</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Hemodialysis patients</td><td align="center" rowspan="1" colspan="1">169</td><td align="center" rowspan="1" colspan="1">7.1%</td></tr><tr><td align="left" rowspan="1" colspan="1">Khattab, 10 [<xref rid="pone.0135281.ref052" ref-type="bibr">52</xref>]</td><td colspan="2" align="center" rowspan="1">2003&#x02013;08</td><td align="center" rowspan="1" colspan="1">Renal transplant center</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Hemodialysis patients</td><td align="center" rowspan="1" colspan="1">244</td><td align="center" rowspan="1" colspan="1">4.9%</td></tr><tr><td align="left" rowspan="1" colspan="1">Mnuti, 11 [<xref rid="pone.0135281.ref053" ref-type="bibr">53</xref>]</td><td colspan="2" align="center" rowspan="1">2008&#x02013;10</td><td align="center" rowspan="1" colspan="1">Hemodialysis unit</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Hemodialysis patients</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">41%</td></tr><tr><td align="left" rowspan="1" colspan="1">Muhsin, 13 [<xref rid="pone.0135281.ref058" ref-type="bibr">58</xref>]</td><td colspan="2" align="center" rowspan="1">2011&#x02013;12</td><td align="center" rowspan="1" colspan="1">Hospital</td><td align="center" rowspan="1" colspan="1">SRS</td><td align="center" rowspan="1" colspan="1">Hemophilia patients</td><td align="center" rowspan="1" colspan="1">60</td><td align="center" rowspan="1" colspan="1">6.7%</td></tr><tr><td align="left" rowspan="1" colspan="1">Muhsin, 13 [<xref rid="pone.0135281.ref058" ref-type="bibr">58</xref>]</td><td colspan="2" align="center" rowspan="1">2011&#x02013;12</td><td align="center" rowspan="1" colspan="1">Hospital</td><td align="center" rowspan="1" colspan="1">SRS</td><td align="center" rowspan="1" colspan="1">Thalassemic patients</td><td align="center" rowspan="1" colspan="1">56</td><td align="center" rowspan="1" colspan="1">25%</td></tr><tr><td align="left" rowspan="1" colspan="1">Mustafa, 10 [<xref rid="pone.0135281.ref162" ref-type="bibr">162</xref>]</td><td colspan="2" align="center" rowspan="1">2003&#x02013;04</td><td align="center" rowspan="1" colspan="1">Thalassemia center</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Thalassemic patients (&#x0003c;20 years)</td><td align="center" rowspan="1" colspan="1">626</td><td align="center" rowspan="1" colspan="1">28.1%</td></tr><tr><td align="left" rowspan="1" colspan="1">Omer, 11 [<xref rid="pone.0135281.ref163" ref-type="bibr">163</xref>]</td><td colspan="2" align="center" rowspan="1">2006&#x02013;08</td><td align="center" rowspan="1" colspan="1">Hospital</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Multi-transfused leukemia patients</td><td align="center" rowspan="1" colspan="1">291</td><td align="center" rowspan="1" colspan="1">3.4%</td></tr><tr><td align="left" rowspan="1" colspan="1">Omer, 11 [<xref rid="pone.0135281.ref164" ref-type="bibr">164</xref>]</td><td colspan="2" align="center" rowspan="1">2010</td><td align="center" rowspan="1" colspan="1">Thalassemia center</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Thalassemic patients</td><td align="center" rowspan="1" colspan="1">54</td><td align="center" rowspan="1" colspan="1">7.4%</td></tr><tr><td align="left" rowspan="1" colspan="1">Raham, 11 [<xref rid="pone.0135281.ref165" ref-type="bibr">165</xref>]</td><td colspan="2" align="center" rowspan="1">1999&#x02013;00</td><td align="center" rowspan="1" colspan="1">Thalassemia center</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Thalassemic patients</td><td align="center" rowspan="1" colspan="1">110</td><td align="center" rowspan="1" colspan="1">26.4%</td></tr><tr><td align="left" rowspan="1" colspan="1">Ramzi, 10 [<xref rid="pone.0135281.ref054" ref-type="bibr">54</xref>]</td><td colspan="2" align="center" rowspan="1">2009</td><td align="center" rowspan="1" colspan="1">Dialysis center</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Hemodialysis patients</td><td align="center" rowspan="1" colspan="1">101</td><td align="center" rowspan="1" colspan="1">26.7%</td></tr><tr><td align="left" rowspan="1" colspan="1">Saadoon, 12 [<xref rid="pone.0135281.ref064" ref-type="bibr">64</xref>]</td><td colspan="2" align="center" rowspan="1"/><td align="center" rowspan="1" colspan="1">Blood trans center</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Thalassemic patients</td><td align="center" rowspan="1" colspan="1">162</td><td align="center" rowspan="1" colspan="1">34.6%</td></tr><tr><td align="left" rowspan="1" colspan="1">Shihab, 14 [<xref rid="pone.0135281.ref055" ref-type="bibr">55</xref>]</td><td colspan="2" align="center" rowspan="1">2012&#x02013;13</td><td align="center" rowspan="1" colspan="1">Hospital</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Hemodialysis patients</td><td align="center" rowspan="1" colspan="1">122</td><td align="center" rowspan="1" colspan="1">42.6%</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Jordan (n = 7)</bold>
</td><td colspan="2" align="center" rowspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Al-Jamal, 09 [<xref rid="pone.0135281.ref166" ref-type="bibr">166</xref>]</td><td colspan="2" align="center" rowspan="1">2007&#x02013;08</td><td align="center" rowspan="1" colspan="1">Hospitals</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Hemodialysis patients</td><td align="center" rowspan="1" colspan="1">120</td><td align="center" rowspan="1" colspan="1">28%</td></tr><tr><td align="left" rowspan="1" colspan="1">Al-Sweedan, 11 [<xref rid="pone.0135281.ref068" ref-type="bibr">68</xref>]</td><td colspan="2" align="center" rowspan="1">2008</td><td align="center" rowspan="1" colspan="1">Thalassemia unit</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Thalassemic patients</td><td align="center" rowspan="1" colspan="1">122</td><td align="center" rowspan="1" colspan="1">32.8%</td></tr><tr><td align="left" rowspan="1" colspan="1">Batchoun, 11 [<xref rid="pone.0135281.ref167" ref-type="bibr">167</xref>]</td><td colspan="2" align="center" rowspan="1"/><td align="center" rowspan="1" colspan="1">Hospitals</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Hemodialysis patients</td><td align="center" rowspan="1" colspan="1">134</td><td align="center" rowspan="1" colspan="1">47.7%</td></tr><tr><td align="left" rowspan="1" colspan="1">Batieha, 07 [<xref rid="pone.0135281.ref039" ref-type="bibr">39</xref>]</td><td colspan="2" align="center" rowspan="1">2003</td><td align="center" rowspan="1" colspan="1">Hemodialysis units</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Hemodialysis patients</td><td align="center" rowspan="1" colspan="1">1711</td><td align="center" rowspan="1" colspan="1">21%</td></tr><tr><td align="left" rowspan="1" colspan="1">Bdour, 02 [<xref rid="pone.0135281.ref111" ref-type="bibr">111</xref>]</td><td colspan="2" align="center" rowspan="1"/><td align="center" rowspan="1" colspan="1">Hemodialysis units</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Hemodialysis patients</td><td align="center" rowspan="1" colspan="1">283</td><td align="center" rowspan="1" colspan="1">32.5%</td></tr><tr><td align="left" rowspan="1" colspan="1">Ghunaimat, 07 [<xref rid="pone.0135281.ref168" ref-type="bibr">168</xref>]</td><td colspan="2" align="center" rowspan="1"/><td align="center" rowspan="1" colspan="1">Hemodialysis unit</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Hemodialysis patients</td><td align="center" rowspan="1" colspan="1">209</td><td align="center" rowspan="1" colspan="1">49.8%</td></tr><tr><td align="left" rowspan="1" colspan="1">Said, 95 [<xref rid="pone.0135281.ref169" ref-type="bibr">169</xref>]</td><td colspan="2" align="center" rowspan="1">1994</td><td align="center" rowspan="1" colspan="1">Hemodialysis centers</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Hemodialysis patients</td><td align="center" rowspan="1" colspan="1">273</td><td align="center" rowspan="1" colspan="1">24.5%</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Lebanon (n = 6)</bold>
</td><td colspan="2" align="center" rowspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Abdelnour, 97 [<xref rid="pone.0135281.ref072" ref-type="bibr">72</xref>]</td><td colspan="2" align="center" rowspan="1"/><td align="center" rowspan="1" colspan="1">Hospitals</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Hemodialysis patients</td><td align="center" rowspan="1" colspan="1">108</td><td align="center" rowspan="1" colspan="1">16%</td></tr><tr><td align="left" rowspan="1" colspan="1">Inati, 09 [<xref rid="pone.0135281.ref074" ref-type="bibr">74</xref>]</td><td colspan="2" align="center" rowspan="1"/><td align="center" rowspan="1" colspan="1">Thalassemia center</td><td align="center" rowspan="1" colspan="1">SRS</td><td align="center" rowspan="1" colspan="1">Thalassemic patients</td><td align="center" rowspan="1" colspan="1">200</td><td align="center" rowspan="1" colspan="1">0%</td></tr><tr><td align="left" rowspan="1" colspan="1">Mahfoud, 10 [<xref rid="pone.0135281.ref071" ref-type="bibr">71</xref>]</td><td colspan="2" align="center" rowspan="1">2007&#x02013;08</td><td align="center" rowspan="1" colspan="1">Not applicable</td><td align="center" rowspan="1" colspan="1">RDS</td><td align="center" rowspan="1" colspan="1">People who inject drugs</td><td align="center" rowspan="1" colspan="1">106</td><td align="center" rowspan="1" colspan="1">52.8%</td></tr><tr><td align="left" rowspan="1" colspan="1">Naman, 96 [<xref rid="pone.0135281.ref073" ref-type="bibr">73</xref>]</td><td colspan="2" align="center" rowspan="1"/><td align="center" rowspan="1" colspan="1">Hemodialysis centers</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Hemodialysis patients</td><td align="center" rowspan="1" colspan="1">317</td><td align="center" rowspan="1" colspan="1">27%</td></tr><tr><td align="left" rowspan="1" colspan="1">Ramia, 02 [<xref rid="pone.0135281.ref075" ref-type="bibr">75</xref>]</td><td colspan="2" align="center" rowspan="1">1999&#x02013;00</td><td align="center" rowspan="1" colspan="1">Thalassemia center</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Thalassemic patients</td><td align="center" rowspan="1" colspan="1">395</td><td align="center" rowspan="1" colspan="1">14.0%</td></tr><tr><td align="left" rowspan="1" colspan="1">Ramia, 03 [<xref rid="pone.0135281.ref076" ref-type="bibr">76</xref>]</td><td colspan="2" align="center" rowspan="1"/><td align="center" rowspan="1" colspan="1">Hospital</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Multi-transfused cancer patients</td><td align="center" rowspan="1" colspan="1">65</td><td align="center" rowspan="1" colspan="1">4.6%</td></tr><tr><td colspan="2" align="left" rowspan="1">
<bold>Palestine (n = 3)</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td colspan="2" align="left" rowspan="1">Dumaidi, 14 [<xref rid="pone.0135281.ref087" ref-type="bibr">87</xref>]</td><td align="center" rowspan="1" colspan="1">2012&#x02013;13</td><td align="center" rowspan="1" colspan="1">Hemodialysis units</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Hemodialysis patients</td><td align="center" rowspan="1" colspan="1">146</td><td align="center" rowspan="1" colspan="1">27.4%</td></tr><tr><td colspan="2" align="left" rowspan="1">El-Kader, 10 [<xref rid="pone.0135281.ref088" ref-type="bibr">88</xref>]</td><td align="center" rowspan="1" colspan="1">2007</td><td align="center" rowspan="1" colspan="1">Hospital</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Hemodialysis patients</td><td align="center" rowspan="1" colspan="1">246</td><td align="center" rowspan="1" colspan="1">17.9%</td></tr><tr><td colspan="2" align="left" rowspan="1">Stulhofer, 12 [<xref rid="pone.0135281.ref089" ref-type="bibr">89</xref>]</td><td align="center" rowspan="1" colspan="1">2010</td><td align="center" rowspan="1" colspan="1">Different localities</td><td align="center" rowspan="1" colspan="1">RDS</td><td align="center" rowspan="1" colspan="1">People who inject drugs</td><td align="center" rowspan="1" colspan="1">199</td><td align="center" rowspan="1" colspan="1">45.2%</td></tr><tr><td colspan="2" align="left" rowspan="1">
<bold>Syria (n = 5)</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td colspan="2" align="left" rowspan="1">Abdulkarim, 98 [<xref rid="pone.0135281.ref092" ref-type="bibr">92</xref>]</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Dialysis unit</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Hemodialysis patients</td><td align="center" rowspan="1" colspan="1">120</td><td align="center" rowspan="1" colspan="1">75%</td></tr><tr><td colspan="2" align="left" rowspan="1">Ali, 12 [<xref rid="pone.0135281.ref096" ref-type="bibr">96</xref>]</td><td align="center" rowspan="1" colspan="1">2007&#x02013;11</td><td align="center" rowspan="1" colspan="1">Hospital</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Hemophilia patients</td><td align="center" rowspan="1" colspan="1">375</td><td align="center" rowspan="1" colspan="1">20.5%</td></tr><tr><td colspan="2" align="left" rowspan="1">Syrian MOH, 08 [<xref rid="pone.0135281.ref095" ref-type="bibr">95</xref>]</td><td align="center" rowspan="1" colspan="1">2006</td><td align="center" rowspan="1" colspan="1">Not applicable</td><td align="center" rowspan="1" colspan="1">Snowball</td><td align="center" rowspan="1" colspan="1">Drug users including people who inject drugs</td><td align="center" rowspan="1" colspan="1">336</td><td align="center" rowspan="1" colspan="1">21%</td></tr><tr><td colspan="2" align="left" rowspan="1">Moukeh, 09 [<xref rid="pone.0135281.ref093" ref-type="bibr">93</xref>]</td><td align="center" rowspan="1" colspan="1">2006</td><td align="center" rowspan="1" colspan="1">Hospital</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Hemodialysis patients</td><td align="center" rowspan="1" colspan="1">550</td><td align="center" rowspan="1" colspan="1">54.4%</td></tr><tr><td colspan="2" align="left" rowspan="1">Othman, 01 [<xref rid="pone.0135281.ref170" ref-type="bibr">170</xref>]</td><td align="center" rowspan="1" colspan="1">1996</td><td align="center" rowspan="1" colspan="1">Hospital</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Hemodialysis patients</td><td align="center" rowspan="1" colspan="1">139</td><td align="center" rowspan="1" colspan="1">48.9%</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>MENA HIV/AIDS ESP, Middle East and North Africa HIV/AIDS Epidemiology Synthesis Project database; MOH, Ministry of Health; Prev, prevalence; RDS, respondent driven sampling; SRS, simple random sampling; Trans, transfusion.</p></fn><fn id="t002fn002"><p>*The table reports only studies whose sample size is greater or equal to 50 participants. For space considerations, the table shows the overall HCV measure of each study rather than stratifications within population subgroups.</p></fn><fn id="t002fn003"><p>**The decimal places of the prevalence figures are as reported in the original report, but prevalence figures with more than one decimal places were rounded to one decimal place.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone.0135281.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0135281.t003</object-id><label>Table 3</label><caption><title>Studies reporting hepatitis C virus (HCV) prevalence among the general population (populations at low risk) in countries of the Fertile Crescent.</title></caption><alternatives><graphic id="pone.0135281.t003g" xlink:href="pone.0135281.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">First author, year of publication [citation]</th><th align="center" rowspan="1" colspan="1">Years of data collection</th><th align="center" rowspan="1" colspan="1">Study site</th><th align="center" rowspan="1" colspan="1">Study sampling procedure</th><th align="center" rowspan="1" colspan="1">Population</th><th align="center" rowspan="1" colspan="1">Sample size<xref rid="t003fn002" ref-type="table-fn">*</xref>
</th><th align="left" rowspan="1" colspan="1">HCV prev<xref rid="t003fn003" ref-type="table-fn">**</xref>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Iraq (n = 45)</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Abdul-Aziz, 01 [<xref rid="pone.0135281.ref046" ref-type="bibr">46</xref>]</td><td align="center" rowspan="1" colspan="1">1999&#x02013;01</td><td align="center" rowspan="1" colspan="1">Central laboratory</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">20108</td><td align="center" rowspan="1" colspan="1">0.8%</td></tr><tr><td align="left" rowspan="1" colspan="1">Abdul-Aziz, 01 [<xref rid="pone.0135281.ref046" ref-type="bibr">46</xref>]</td><td align="center" rowspan="1" colspan="1">1999&#x02013;01</td><td align="center" rowspan="1" colspan="1">Central laboratory</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">New employees</td><td align="center" rowspan="1" colspan="1">257</td><td align="center" rowspan="1" colspan="1">0.4%</td></tr><tr><td align="left" rowspan="1" colspan="1">Abdullah, 12 [<xref rid="pone.0135281.ref047" ref-type="bibr">47</xref>]</td><td align="center" rowspan="1" colspan="1">2005&#x02013;07</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">1%</td></tr><tr><td align="left" rowspan="1" colspan="1">Al-Ani, 11 [<xref rid="pone.0135281.ref043" ref-type="bibr">43</xref>]</td><td align="center" rowspan="1" colspan="1">2007&#x02013;09</td><td align="center" rowspan="1" colspan="1">Hospital</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Children</td><td align="center" rowspan="1" colspan="1">60</td><td align="center" rowspan="1" colspan="1">0%</td></tr><tr><td align="left" rowspan="1" colspan="1">Al-Azzawi, 06 [<xref rid="pone.0135281.ref171" ref-type="bibr">171</xref>]</td><td align="center" rowspan="1" colspan="1">2004</td><td align="center" rowspan="1" colspan="1">Primary health centers</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Pregnant women</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">1%</td></tr><tr><td align="left" rowspan="1" colspan="1">Al-Doori, 06 [<xref rid="pone.0135281.ref172" ref-type="bibr">172</xref>]</td><td align="center" rowspan="1" colspan="1">2004&#x02013;05</td><td align="center" rowspan="1" colspan="1">Central laboratory</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">1978</td><td align="center" rowspan="1" colspan="1">0.4%</td></tr><tr><td align="left" rowspan="1" colspan="1">Al-Duliami, 12 [<xref rid="pone.0135281.ref173" ref-type="bibr">173</xref>]</td><td align="center" rowspan="1" colspan="1">2010&#x02013;11</td><td align="center" rowspan="1" colspan="1">Central laboratory</td><td align="center" rowspan="1" colspan="1">SRS</td><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">90</td><td align="center" rowspan="1" colspan="1">0%</td></tr><tr><td align="left" rowspan="1" colspan="1">Al-Greti, 13 [<xref rid="pone.0135281.ref153" ref-type="bibr">153</xref>]</td><td align="center" rowspan="1" colspan="1">2011&#x02013;12</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">General population</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">4%</td></tr><tr><td align="left" rowspan="1" colspan="1">Al-Hamdani, 12 [<xref rid="pone.0135281.ref174" ref-type="bibr">174</xref>]</td><td align="center" rowspan="1" colspan="1">2003&#x02013;04, 06, 08&#x02013;09</td><td align="center" rowspan="1" colspan="1">Hospital</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">New employees</td><td align="center" rowspan="1" colspan="1">4162</td><td align="center" rowspan="1" colspan="1">2.6%</td></tr><tr><td align="left" rowspan="1" colspan="1">Ali, 09 [<xref rid="pone.0135281.ref175" ref-type="bibr">175</xref>]</td><td align="center" rowspan="1" colspan="1">2007&#x02013;08</td><td align="center" rowspan="1" colspan="1">Blood bank</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">600</td><td align="center" rowspan="1" colspan="1">1.7%</td></tr><tr><td align="left" rowspan="1" colspan="1">Al-Jebori, 10 [<xref rid="pone.0135281.ref176" ref-type="bibr">176</xref>]</td><td align="center" rowspan="1" colspan="1">2003&#x02013;09</td><td align="center" rowspan="1" colspan="1">Central laboratory</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Mixed general population</td><td align="center" rowspan="1" colspan="1">120460</td><td align="center" rowspan="1" colspan="1">0.2%</td></tr><tr><td align="left" rowspan="1" colspan="1">Aljooani, 12 [<xref rid="pone.0135281.ref177" ref-type="bibr">177</xref>]</td><td align="center" rowspan="1" colspan="1">2005&#x02013;07</td><td align="center" rowspan="1" colspan="1">Hospital</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">430</td><td align="center" rowspan="1" colspan="1">2.8%</td></tr><tr><td align="left" rowspan="1" colspan="1">Al-Juboury, 10 [<xref rid="pone.0135281.ref178" ref-type="bibr">178</xref>]</td><td align="center" rowspan="1" colspan="1">2007&#x02013;08</td><td align="center" rowspan="1" colspan="1">Blood bank</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">23336</td><td align="center" rowspan="1" colspan="1">0.5%</td></tr><tr><td align="left" rowspan="1" colspan="1">Al-Kamil, 11 [<xref rid="pone.0135281.ref179" ref-type="bibr">179</xref>]</td><td align="center" rowspan="1" colspan="1">2006&#x02013;08</td><td align="center" rowspan="1" colspan="1">Central blood bank</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">161987</td><td align="center" rowspan="1" colspan="1">0.1%</td></tr><tr><td align="left" rowspan="1" colspan="1">Al-Kubaisy, 02 [<xref rid="pone.0135281.ref102" ref-type="bibr">102</xref>]</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Hospitals &#x00026; health care centers</td><td align="center" rowspan="1" colspan="1">SRS</td><td align="center" rowspan="1" colspan="1">Pregnant women</td><td align="center" rowspan="1" colspan="1">3491</td><td align="center" rowspan="1" colspan="1">3.2%</td></tr><tr><td align="left" rowspan="1" colspan="1">Al-Saad, 09 [<xref rid="pone.0135281.ref061" ref-type="bibr">61</xref>]</td><td align="center" rowspan="1" colspan="1">2008</td><td align="center" rowspan="1" colspan="1">Hospital</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">General population</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">0%</td></tr><tr><td align="left" rowspan="1" colspan="1">Al Wtaify, 00 [<xref rid="pone.0135281.ref155" ref-type="bibr">155</xref>]</td><td align="center" rowspan="1" colspan="1">1998&#x02013;99</td><td align="center" rowspan="1" colspan="1">Hospital</td><td align="center" rowspan="1" colspan="1">SRS</td><td align="center" rowspan="1" colspan="1">Outpatient hospital attendees (children)</td><td align="center" rowspan="1" colspan="1">200</td><td align="center" rowspan="1" colspan="1">0.5%</td></tr><tr><td align="left" rowspan="1" colspan="1">Al-Zamili, 09 [<xref rid="pone.0135281.ref156" ref-type="bibr">156</xref>]</td><td align="center" rowspan="1" colspan="1">2007&#x02013;08</td><td align="center" rowspan="1" colspan="1">Hospital</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Children</td><td align="center" rowspan="1" colspan="1">325</td><td align="center" rowspan="1" colspan="1">0%</td></tr><tr><td align="left" rowspan="1" colspan="1">Amin, 12 [<xref rid="pone.0135281.ref180" ref-type="bibr">180</xref>]</td><td align="center" rowspan="1" colspan="1">2008&#x02013;09</td><td align="center" rowspan="1" colspan="1">Blood bank</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">35540</td><td align="center" rowspan="1" colspan="1">0.1%</td></tr><tr><td align="left" rowspan="1" colspan="1">Ataallah, 11 [<xref rid="pone.0135281.ref181" ref-type="bibr">181</xref>]</td><td align="center" rowspan="1" colspan="1">2006&#x02013;09</td><td align="center" rowspan="1" colspan="1">National blood trans center</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">495648</td><td align="center" rowspan="1" colspan="1">0.3%</td></tr><tr><td align="left" rowspan="1" colspan="1">Chiad, 09 [<xref rid="pone.0135281.ref182" ref-type="bibr">182</xref>]</td><td align="center" rowspan="1" colspan="1">2003&#x02013;04</td><td align="center" rowspan="1" colspan="1">National blood trans center</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">1000</td><td align="center" rowspan="1" colspan="1">1%</td></tr><tr><td align="left" rowspan="1" colspan="1">Chironna, 03 [<xref rid="pone.0135281.ref105" ref-type="bibr">105</xref>]</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Refugee camp</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Refugees</td><td align="center" rowspan="1" colspan="1">637</td><td align="center" rowspan="1" colspan="1">0.1%</td></tr><tr><td align="left" rowspan="1" colspan="1">Fadhil, 12 [<xref rid="pone.0135281.ref158" ref-type="bibr">158</xref>]</td><td align="center" rowspan="1" colspan="1">2010&#x02013;11</td><td align="center" rowspan="1" colspan="1">Hospital</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Outpatient hospital attendees</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">0%</td></tr><tr><td align="left" rowspan="1" colspan="1">Fawzi, 11 [<xref rid="pone.0135281.ref183" ref-type="bibr">183</xref>]</td><td align="center" rowspan="1" colspan="1">2010</td><td align="center" rowspan="1" colspan="1">Hospital &#x00026; health centers</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Pregnant women</td><td align="center" rowspan="1" colspan="1">520</td><td align="center" rowspan="1" colspan="1">1.1%</td></tr><tr><td align="left" rowspan="1" colspan="1">Hamim, 12 [<xref rid="pone.0135281.ref184" ref-type="bibr">184</xref>]</td><td align="center" rowspan="1" colspan="1">2006&#x02013;10</td><td align="center" rowspan="1" colspan="1">Main blood trans center</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Outpatient hospital attendees</td><td align="center" rowspan="1" colspan="1">4886</td><td align="center" rowspan="1" colspan="1">0.9%</td></tr><tr><td align="left" rowspan="1" colspan="1">Hamim, 12 [<xref rid="pone.0135281.ref185" ref-type="bibr">185</xref>]</td><td align="center" rowspan="1" colspan="1">2008&#x02013;09</td><td align="center" rowspan="1" colspan="1">Blood trans centers</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">871973</td><td align="center" rowspan="1" colspan="1">0.4%</td></tr><tr><td align="left" rowspan="1" colspan="1">Hassan, 08 [<xref rid="pone.0135281.ref137" ref-type="bibr">137</xref>]</td><td align="center" rowspan="1" colspan="1">1996&#x02013;01</td><td align="center" rowspan="1" colspan="1">Central laboratory</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">42140</td><td align="center" rowspan="1" colspan="1">0.1%</td></tr><tr><td align="left" rowspan="1" colspan="1">Hussain, 08 [<xref rid="pone.0135281.ref186" ref-type="bibr">186</xref>]</td><td align="center" rowspan="1" colspan="1">2004&#x02013;05</td><td align="center" rowspan="1" colspan="1">Hospital</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">General population</td><td align="center" rowspan="1" colspan="1">108</td><td align="center" rowspan="1" colspan="1">0%</td></tr><tr><td align="left" rowspan="1" colspan="1">Hussein, 10 [<xref rid="pone.0135281.ref187" ref-type="bibr">187</xref>]</td><td align="center" rowspan="1" colspan="1">2006&#x02013;07</td><td align="center" rowspan="1" colspan="1">Central blood bank</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">31574</td><td align="center" rowspan="1" colspan="1">0.1%</td></tr><tr><td align="left" rowspan="1" colspan="1">Hussain, 10 [<xref rid="pone.0135281.ref188" ref-type="bibr">188</xref>]</td><td align="center" rowspan="1" colspan="1">2008&#x02013;09</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">117</td><td align="center" rowspan="1" colspan="1">0.8%</td></tr><tr><td align="left" rowspan="1" colspan="1">Jassim, 11 [<xref rid="pone.0135281.ref189" ref-type="bibr">189</xref>]</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">170</td><td align="center" rowspan="1" colspan="1">0%</td></tr><tr><td align="left" rowspan="1" colspan="1">Khalid, 12 [<xref rid="pone.0135281.ref161" ref-type="bibr">161</xref>]</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Central blood bank</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">2%</td></tr><tr><td align="left" rowspan="1" colspan="1">Naji, 13 [<xref rid="pone.0135281.ref190" ref-type="bibr">190</xref>]</td><td align="center" rowspan="1" colspan="1">2011&#x02013;12</td><td align="center" rowspan="1" colspan="1">Central laboratory</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Newly married individuals</td><td align="center" rowspan="1" colspan="1">200</td><td align="center" rowspan="1" colspan="1">1.5%</td></tr><tr><td align="left" rowspan="1" colspan="1">Noaman, 12 [<xref rid="pone.0135281.ref063" ref-type="bibr">63</xref>]</td><td align="center" rowspan="1" colspan="1">2009&#x02013;10</td><td align="center" rowspan="1" colspan="1">Blood bank</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">93</td><td align="center" rowspan="1" colspan="1">1.1%</td></tr><tr><td align="left" rowspan="1" colspan="1">Obied, 14 [<xref rid="pone.0135281.ref100" ref-type="bibr">100</xref>]</td><td align="center" rowspan="1" colspan="1">2012&#x02013;13</td><td align="center" rowspan="1" colspan="1">Central blood bank</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">5179</td><td align="center" rowspan="1" colspan="1">0.4%</td></tr><tr><td align="left" rowspan="1" colspan="1">Omer, 11 [<xref rid="pone.0135281.ref163" ref-type="bibr">163</xref>]</td><td align="center" rowspan="1" colspan="1">2006&#x02013;08</td><td align="center" rowspan="1" colspan="1">Hospital</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">General population</td><td align="center" rowspan="1" colspan="1">350</td><td align="center" rowspan="1" colspan="1">0.3%</td></tr><tr><td align="left" rowspan="1" colspan="1">Richter, 14 [<xref rid="pone.0135281.ref191" ref-type="bibr">191</xref>]</td><td align="center" rowspan="1" colspan="1">2011</td><td align="center" rowspan="1" colspan="1">Community</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">First generation immigrants</td><td align="center" rowspan="1" colspan="1">290</td><td align="center" rowspan="1" colspan="1">0.3%</td></tr><tr><td align="left" rowspan="1" colspan="1">Saadoon, 08 [<xref rid="pone.0135281.ref192" ref-type="bibr">192</xref>]</td><td align="center" rowspan="1" colspan="1">2007</td><td align="center" rowspan="1" colspan="1">Hospitals</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Pregnant women</td><td align="center" rowspan="1" colspan="1">875</td><td align="center" rowspan="1" colspan="1">5.1%</td></tr><tr><td align="left" rowspan="1" colspan="1">Saadoon, 12 [<xref rid="pone.0135281.ref064" ref-type="bibr">64</xref>]</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Blood bank</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">1128</td><td align="center" rowspan="1" colspan="1">0.6%</td></tr><tr><td align="left" rowspan="1" colspan="1">Salih, 07 [<xref rid="pone.0135281.ref193" ref-type="bibr">193</xref>]</td><td align="center" rowspan="1" colspan="1">2007</td><td align="center" rowspan="1" colspan="1">Hospital</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">95</td><td align="center" rowspan="1" colspan="1">2.1%</td></tr><tr><td align="left" rowspan="1" colspan="1">Salman, 07 [<xref rid="pone.0135281.ref194" ref-type="bibr">194</xref>]</td><td align="center" rowspan="1" colspan="1">2006&#x02013;07</td><td align="center" rowspan="1" colspan="1">Antenatal clinics</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Pregnant women</td><td align="center" rowspan="1" colspan="1">60</td><td align="center" rowspan="1" colspan="1">0%</td></tr><tr><td align="left" rowspan="1" colspan="1">Tarky, 13 [<xref rid="pone.0135281.ref059" ref-type="bibr">59</xref>]</td><td align="center" rowspan="1" colspan="1">2005&#x02013;06</td><td align="center" rowspan="1" colspan="1">Households</td><td align="center" rowspan="1" colspan="1">StRS</td><td align="center" rowspan="1" colspan="1">General population</td><td align="center" rowspan="1" colspan="1">9610</td><td align="center" rowspan="1" colspan="1">0.4%</td></tr><tr><td align="left" rowspan="1" colspan="1">Tawfeeq, 13 [<xref rid="pone.0135281.ref101" ref-type="bibr">101</xref>]</td><td align="center" rowspan="1" colspan="1">2011&#x02013;12</td><td align="center" rowspan="1" colspan="1">Blood bank</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">15560</td><td align="center" rowspan="1" colspan="1">0.3%</td></tr><tr><td align="left" rowspan="1" colspan="1">Toffik, 06 [<xref rid="pone.0135281.ref195" ref-type="bibr">195</xref>]</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Hospital</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Outpatient clinic attendees</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">0%</td></tr><tr><td align="left" rowspan="1" colspan="1">Toffik, 06 [<xref rid="pone.0135281.ref195" ref-type="bibr">195</xref>]</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">200</td><td align="center" rowspan="1" colspan="1">0.5%</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Jordan (n = 5)</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Al Abbadi, 14 [<xref rid="pone.0135281.ref196" ref-type="bibr">196</xref>]</td><td align="center" rowspan="1" colspan="1">2009&#x02013;11</td><td align="center" rowspan="1" colspan="1">Blood bank</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">94270</td><td align="center" rowspan="1" colspan="1">0.1%</td></tr><tr><td align="left" rowspan="1" colspan="1">Al-Gani, 11 [<xref rid="pone.0135281.ref197" ref-type="bibr">197</xref>]</td><td align="center" rowspan="1" colspan="1">2006&#x02013;09</td><td align="center" rowspan="1" colspan="1">Blood bank</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">8190</td><td align="center" rowspan="1" colspan="1">0.9%</td></tr><tr><td align="left" rowspan="1" colspan="1">Hamoudi, 13 [<xref rid="pone.0135281.ref112" ref-type="bibr">112</xref>]</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Health centers</td><td align="center" rowspan="1" colspan="1">SRS</td><td align="center" rowspan="1" colspan="1">Health centers&#x02019; attendees</td><td align="center" rowspan="1" colspan="1">706</td><td align="center" rowspan="1" colspan="1">0.4%</td></tr><tr><td align="left" rowspan="1" colspan="1">Jbara, 06 [<xref rid="pone.0135281.ref198" ref-type="bibr">198</xref>]</td><td align="center" rowspan="1" colspan="1">2003&#x02013;05</td><td align="center" rowspan="1" colspan="1">Blood bank</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">8750</td><td align="center" rowspan="1" colspan="1">0.8%</td></tr><tr><td align="left" rowspan="1" colspan="1">Rashdan, 08 [<xref rid="pone.0135281.ref103" ref-type="bibr">103</xref>]</td><td align="center" rowspan="1" colspan="1">2004&#x02013;06</td><td align="center" rowspan="1" colspan="1">Blood bank</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">14236</td><td align="center" rowspan="1" colspan="1">0.2%</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Lebanon (n = 13)</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Araj, 95 [<xref rid="pone.0135281.ref077" ref-type="bibr">77</xref>]</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">SRS</td><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">4179</td><td align="center" rowspan="1" colspan="1">0.1%</td></tr><tr><td align="left" rowspan="1" colspan="1">Baddoura, 02 [<xref rid="pone.0135281.ref084" ref-type="bibr">84</xref>]</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Laboratories (nation-wide)</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">General population (Lebanese)</td><td align="center" rowspan="1" colspan="1">2879</td><td align="center" rowspan="1" colspan="1">0.6%</td></tr><tr><td align="left" rowspan="1" colspan="1">Baddoura, 02 [<xref rid="pone.0135281.ref084" ref-type="bibr">84</xref>]</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Laboratories (nation-wide)</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">General population (immigrants)</td><td align="center" rowspan="1" colspan="1">103</td><td align="center" rowspan="1" colspan="1">2.9%</td></tr><tr><td align="left" rowspan="1" colspan="1">Irani-Hakime, 01 [<xref rid="pone.0135281.ref199" ref-type="bibr">199</xref>]</td><td align="center" rowspan="1" colspan="1">1999</td><td align="center" rowspan="1" colspan="1">Blood bank</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">600</td><td align="center" rowspan="1" colspan="1">0.2%</td></tr><tr><td align="left" rowspan="1" colspan="1">Irani-Hakime, 06 [<xref rid="pone.0135281.ref078" ref-type="bibr">78</xref>]</td><td align="center" rowspan="1" colspan="1">1997&#x02013;03</td><td align="center" rowspan="1" colspan="1">Blood bank</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">16084</td><td align="center" rowspan="1" colspan="1">0.4%</td></tr><tr><td align="left" rowspan="1" colspan="1">Nabulsi, 97 [<xref rid="pone.0135281.ref080" ref-type="bibr">80</xref>]</td><td align="center" rowspan="1" colspan="1">1993&#x02013;95</td><td align="center" rowspan="1" colspan="1">Antenatal clinics</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Pregnant women</td><td align="center" rowspan="1" colspan="1">558</td><td align="center" rowspan="1" colspan="1">0%</td></tr><tr><td align="left" rowspan="1" colspan="1">Naman, 96 [<xref rid="pone.0135281.ref073" ref-type="bibr">73</xref>]</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">7771</td><td align="center" rowspan="1" colspan="1">0.4%</td></tr><tr><td align="left" rowspan="1" colspan="1">Ramia, 03 [<xref rid="pone.0135281.ref076" ref-type="bibr">76</xref>]</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Hospital</td><td align="center" rowspan="1" colspan="1">SRS</td><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">500</td><td align="center" rowspan="1" colspan="1">0.2%</td></tr><tr><td align="left" rowspan="1" colspan="1">Ramia, 05 [<xref rid="pone.0135281.ref081" ref-type="bibr">81</xref>]</td><td align="center" rowspan="1" colspan="1">2002&#x02013;03</td><td align="center" rowspan="1" colspan="1">Blood bank</td><td align="center" rowspan="1" colspan="1">SRS</td><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">56</td><td align="center" rowspan="1" colspan="1">0%</td></tr><tr><td align="left" rowspan="1" colspan="1">Salem, 03 [<xref rid="pone.0135281.ref082" ref-type="bibr">82</xref>]</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Hospital</td><td align="center" rowspan="1" colspan="1">SRS</td><td align="center" rowspan="1" colspan="1">Outpatient hospital attendees</td><td align="center" rowspan="1" colspan="1">70</td><td align="center" rowspan="1" colspan="1">0%</td></tr><tr><td align="left" rowspan="1" colspan="1">Salem, 03 [<xref rid="pone.0135281.ref082" ref-type="bibr">82</xref>]</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Hospital</td><td align="center" rowspan="1" colspan="1">SRS</td><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">150</td><td align="center" rowspan="1" colspan="1">0%</td></tr><tr><td align="left" rowspan="1" colspan="1">Tamim, 01 [<xref rid="pone.0135281.ref083" ref-type="bibr">83</xref>]</td><td align="center" rowspan="1" colspan="1">1998&#x02013;00</td><td align="center" rowspan="1" colspan="1">Blood bank</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Blood donors (Lebanese)</td><td align="center" rowspan="1" colspan="1">5027</td><td align="center" rowspan="1" colspan="1">0.3%</td></tr><tr><td align="left" rowspan="1" colspan="1">Tamim, 01 [<xref rid="pone.0135281.ref083" ref-type="bibr">83</xref>]</td><td align="center" rowspan="1" colspan="1">1998&#x02013;00</td><td align="center" rowspan="1" colspan="1">Blood bank</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Blood donors (non-Lebanese)</td><td align="center" rowspan="1" colspan="1">88</td><td align="center" rowspan="1" colspan="1">3.4%</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Palestine (n = 11)</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">PHIC, 14 [<xref rid="pone.0135281.ref033" ref-type="bibr">33</xref>]</td><td align="center" rowspan="1" colspan="1">2013</td><td align="center" rowspan="1" colspan="1">Blood banks (hospitals)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">19571</td><td align="center" rowspan="1" colspan="1">0.2%</td></tr><tr><td align="left" rowspan="1" colspan="1">PHIC, 14 [<xref rid="pone.0135281.ref033" ref-type="bibr">33</xref>]</td><td align="center" rowspan="1" colspan="1">2013</td><td align="center" rowspan="1" colspan="1">National blood bank</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">9643</td><td align="center" rowspan="1" colspan="1">0.3%</td></tr><tr><td align="left" rowspan="1" colspan="1">MENA HIV ESP, 11 [<xref rid="pone.0135281.ref018" ref-type="bibr">18</xref>, <xref rid="pone.0135281.ref032" ref-type="bibr">32</xref>]</td><td align="center" rowspan="1" colspan="1">2011</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">63477</td><td align="center" rowspan="1" colspan="1">0.2%</td></tr><tr><td align="left" rowspan="1" colspan="1">PHIC, 10 [<xref rid="pone.0135281.ref034" ref-type="bibr">34</xref>]</td><td align="center" rowspan="1" colspan="1">2009</td><td align="center" rowspan="1" colspan="1">Blood banks (hospitals)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">48001</td><td align="center" rowspan="1" colspan="1">0.2%</td></tr><tr><td align="left" rowspan="1" colspan="1">PHIC, 08 [<xref rid="pone.0135281.ref035" ref-type="bibr">35</xref>]</td><td align="center" rowspan="1" colspan="1">2007</td><td align="center" rowspan="1" colspan="1">Blood banks (hospitals)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">49105</td><td align="center" rowspan="1" colspan="1">0.3%</td></tr><tr><td align="left" rowspan="1" colspan="1">PHIC, 07 [<xref rid="pone.0135281.ref036" ref-type="bibr">36</xref>]</td><td align="center" rowspan="1" colspan="1">2006</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">53151</td><td align="center" rowspan="1" colspan="1">0.2%</td></tr><tr><td align="left" rowspan="1" colspan="1">PHIC, 06 [<xref rid="pone.0135281.ref037" ref-type="bibr">37</xref>]</td><td align="center" rowspan="1" colspan="1">2005</td><td align="center" rowspan="1" colspan="1">Blood bank</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">45029</td><td align="center" rowspan="1" colspan="1">0.2%</td></tr><tr><td align="left" rowspan="1" colspan="1">PHIC, 04 [<xref rid="pone.0135281.ref038" ref-type="bibr">38</xref>]</td><td align="center" rowspan="1" colspan="1">2003</td><td align="center" rowspan="1" colspan="1">Blood bank</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">44990</td><td align="center" rowspan="1" colspan="1">0.3%</td></tr><tr><td align="left" rowspan="1" colspan="1">Novack, 07 [<xref rid="pone.0135281.ref091" ref-type="bibr">91</xref>]</td><td align="center" rowspan="1" colspan="1">1999&#x02013;02</td><td align="center" rowspan="1" colspan="1">Blood bank</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">2784</td><td align="center" rowspan="1" colspan="1">3.9%</td></tr><tr><td align="left" rowspan="1" colspan="1">Shemer-Avni, 98 [<xref rid="pone.0135281.ref090" ref-type="bibr">90</xref>]</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Blood bank</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">1509</td><td align="center" rowspan="1" colspan="1">2.2%</td></tr><tr><td align="left" rowspan="1" colspan="1">Shemer-Avni, 98 [<xref rid="pone.0135281.ref090" ref-type="bibr">90</xref>]</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Hospital</td><td align="center" rowspan="1" colspan="1">SRS</td><td align="center" rowspan="1" colspan="1">Outpatient hospital attendees</td><td align="center" rowspan="1" colspan="1">124</td><td align="center" rowspan="1" colspan="1">9%</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Syria (n = 10)</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Ali, 10 [<xref rid="pone.0135281.ref200" ref-type="bibr">200</xref>]</td><td align="center" rowspan="1" colspan="1">2000&#x02013;07</td><td align="center" rowspan="1" colspan="1">Blood trans center</td><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">131403</td><td align="center" rowspan="1" colspan="1">0.4%</td></tr><tr><td align="left" rowspan="1" colspan="1">MENA HIV ESP, 10 [<xref rid="pone.0135281.ref018" ref-type="bibr">18</xref>, <xref rid="pone.0135281.ref032" ref-type="bibr">32</xref>]</td><td align="center" rowspan="1" colspan="1">Q 1, 2006</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">55549</td><td align="center" rowspan="1" colspan="1">0.3%</td></tr><tr><td align="left" rowspan="1" colspan="1">MENA HIV ESP, 10 [<xref rid="pone.0135281.ref018" ref-type="bibr">18</xref>, <xref rid="pone.0135281.ref032" ref-type="bibr">32</xref>]</td><td align="center" rowspan="1" colspan="1">Q 2, 2006</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">87920</td><td align="center" rowspan="1" colspan="1">0.4%</td></tr><tr><td align="left" rowspan="1" colspan="1">MENA HIV ESP, 10 [<xref rid="pone.0135281.ref018" ref-type="bibr">18</xref>, <xref rid="pone.0135281.ref032" ref-type="bibr">32</xref>]</td><td align="center" rowspan="1" colspan="1">Q 3, 2006</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">77734</td><td align="center" rowspan="1" colspan="1">0.6%</td></tr><tr><td align="left" rowspan="1" colspan="1">MENA HIV ESP, 10 [<xref rid="pone.0135281.ref018" ref-type="bibr">18</xref>, <xref rid="pone.0135281.ref032" ref-type="bibr">32</xref>]</td><td align="center" rowspan="1" colspan="1">Q 4, 2006</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">83347</td><td align="center" rowspan="1" colspan="1">0.5%</td></tr><tr><td align="left" rowspan="1" colspan="1">MENA HIV ESP, 10 [<xref rid="pone.0135281.ref018" ref-type="bibr">18</xref>, <xref rid="pone.0135281.ref032" ref-type="bibr">32</xref>]</td><td align="center" rowspan="1" colspan="1">Q 1, 2007</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">83501</td><td align="center" rowspan="1" colspan="1">0.4%</td></tr><tr><td align="left" rowspan="1" colspan="1">MENA HIV ESP, 10 [<xref rid="pone.0135281.ref018" ref-type="bibr">18</xref>, <xref rid="pone.0135281.ref032" ref-type="bibr">32</xref>]</td><td align="center" rowspan="1" colspan="1">Q 2, 2007</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">92452</td><td align="center" rowspan="1" colspan="1">0.4%</td></tr><tr><td align="left" rowspan="1" colspan="1">MENA HIV ESP, 10 [<xref rid="pone.0135281.ref018" ref-type="bibr">18</xref>, <xref rid="pone.0135281.ref032" ref-type="bibr">32</xref>]</td><td align="center" rowspan="1" colspan="1">Q 3, 2007</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">83560</td><td align="center" rowspan="1" colspan="1">0.5%</td></tr><tr><td align="left" rowspan="1" colspan="1">MENA HIV ESP, 10 [<xref rid="pone.0135281.ref018" ref-type="bibr">18</xref>, <xref rid="pone.0135281.ref032" ref-type="bibr">32</xref>]</td><td align="center" rowspan="1" colspan="1">2011</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">416984</td><td align="center" rowspan="1" colspan="1">0.6%</td></tr><tr><td align="left" rowspan="1" colspan="1">Othman, 02 [<xref rid="pone.0135281.ref097" ref-type="bibr">97</xref>]</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Convenience</td><td align="center" rowspan="1" colspan="1">Blood donors</td><td align="center" rowspan="1" colspan="1">2100</td><td align="center" rowspan="1" colspan="1">0.9%</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t003fn001"><p>MENA HIV ESP, Middle East and North Africa HIV/AIDS Epidemiology Synthesis Project database; PHIC, Palestinian Health Information Center; Prev, prevalence; Q, quarter; RDS, respondent driven sampling; SRS, simple random sampling; StRS, stratified random sampling; Trans, transfusion.</p></fn><fn id="t003fn002"><p>*The table reports only studies whose sample size is greater or equal to 50 participants. For space considerations, the table shows the overall HCV measure of each study rather than stratifications within population subgroups.</p></fn><fn id="t003fn003"><p>**The decimal places of the prevalence figures are as reported in the original report, but prevalence figures with more than one decimal places were rounded to one decimal place.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec008"><title>Study selection</title><p>The search results were imported into a reference manager, Endnote, where duplicate publications were identified and excluded. The titles and abstracts of remaining records were screened for relevance, and full-texts of articles deemed relevant or potentially relevant were retrieved for further screening. The references of all articles and all reviews of literature were also checked to identify additional articles that could have been potentially missed. Any document reporting a measure of HCV incidence and/or prevalence based on primary data was considered for the review (<xref rid="pone.0135281.g001" ref-type="fig">Fig 1</xref>). Case reports, case series, editorials, letters to editors, commentaries, studies referring to hepatitis C as non-A non-B hepatitis, and records of HCV among military personnel who were stationed in this region for some time, but are from countries outside the region, were excluded from our review. A secondary independent screening for articles reporting HCV genotype information, irrespective of their inclusion of HCV incidence and/or prevalence measures, was also performed (<xref rid="pone.0135281.s003" ref-type="supplementary-material">S3 Fig</xref>).</p><fig id="pone.0135281.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0135281.g001</object-id><label>Fig 1</label><caption><title>Flow chart of article selection for the systematic review of hepatitis C virus (HCV) incidence and prevalence in the Fertile Crescent countries, adapted from the PRISMA 2009 guidelines [<xref rid="pone.0135281.ref016" ref-type="bibr">16</xref>].</title></caption><graphic xlink:href="pone.0135281.g001"/></fig><p>In this work, a &#x0201c;report&#x0201d; refers to a document containing outcome measures of interest, while a &#x0201c;study&#x0201d; refers to all details pertaining to a specific outcome measure. Accordingly, one report could contribute multiple studies, and multiple reports of the same study, after being identified as duplicates, are considered as one study.</p></sec><sec id="sec009"><title>Data extraction and data synthesis</title><p>Data from relevant reports were extracted by HC. To check for consistency, 10% of the reports were double extracted by another co-author (KC). The list of extracted information can be found in <xref rid="pone.0135281.s010" ref-type="supplementary-material">S1 Table</xref>. The extracted data were then synthesized by country and by populations&#x02019; risk of acquiring HCV (high, intermediate, and low risk). Our classification of risk was informed by HCV epidemiology literature [<xref rid="pone.0135281.ref002" ref-type="bibr">2</xref>, <xref rid="pone.0135281.ref022" ref-type="bibr">22</xref>, <xref rid="pone.0135281.ref023" ref-type="bibr">23</xref>] and a previously published classification [<xref rid="pone.0135281.ref012" ref-type="bibr">12</xref>]. In events where the level of exposure to HCV in certain populations was uncertain, and hence difficult to classify within the three pre-determined levels of risk, we followed a conservative approach that grouped such populations into a distinct risk category. We labeled this category as &#x02018;special clinical populations&#x02019; since all of these populations were clinical populations. Details pertaining to the definitions and risk classification of identified populations can be found in <xref rid="pone.0135281.s004" ref-type="supplementary-material">S4 Fig</xref>.</p><p>The quality of HCV incidence and prevalence measures identified through our review was determined by assessing the risk of bias (ROB) for each study using the Cochrane approach [<xref rid="pone.0135281.ref024" ref-type="bibr">24</xref>], and by evaluating the precision of the reported measures. A description of the quality assessment criteria and studies&#x02019; ROB appraisal can be found in <xref rid="pone.0135281.s005" ref-type="supplementary-material">S5 Fig</xref>.</p></sec><sec id="sec010"><title>Quantitative analysis</title><p>For each country, HCV antibody and RNA prevalence data in studies comprising at least 50 participants were stratified by population risk and summarized using reported ranges (Tables <xref rid="pone.0135281.t002" ref-type="table">2</xref> and <xref rid="pone.0135281.t003" ref-type="table">3</xref>, and S2 and <xref rid="pone.0135281.s012" ref-type="supplementary-material">S3</xref> Tables). Meta-analyses of HCV prevalence measures were conducted, for each country, for the various populations at risk whenever at least five HCV measures were available. Studies comprising a minimum of 25 participants were considered eligible for inclusion in the meta-analysis. HCV prevalence for the total sample was replaced with stratified measures whenever the sample size requirement was fulfilled at the level of each stratum. For each study, one final stratification was considered based on a pre-defined sequential order that prioritizes nationality followed by population, sex, year, region, and age.</p><p>The variance of the prevalence measures was stabilized using the Freeman-Tukey type arcsine square-root transformation [<xref rid="pone.0135281.ref025" ref-type="bibr">25</xref>]. Estimates for HCV prevalence were weighed using the inverse variance method and then pooled using a DerSimonian-Laird random effects model [<xref rid="pone.0135281.ref026" ref-type="bibr">26</xref>]. This model assumes a normal distribution of true effect sizes across studies, and therefore accounts for the sampling variation as well as the heterogeneity in effect size [<xref rid="pone.0135281.ref027" ref-type="bibr">27</xref>]. Heterogeneity measures were also calculated (<xref rid="pone.0135281.t004" ref-type="table">Table 4</xref>) [<xref rid="pone.0135281.ref027" ref-type="bibr">27</xref>, <xref rid="pone.0135281.ref028" ref-type="bibr">28</xref>].</p><table-wrap id="pone.0135281.t004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0135281.t004</object-id><label>Table 4</label><caption><title>Pooled mean estimates for hepatitis C virus (HCV) prevalence stratified by populations&#x02019; risk of infection across countries of the Fertile Crescent.</title></caption><alternatives><graphic id="pone.0135281.t004g" xlink:href="pone.0135281.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Studies</th><th align="center" rowspan="1" colspan="1">Samples</th><th align="center" rowspan="1" colspan="1">Prevalence</th><th colspan="2" align="center" rowspan="1">Effect size</th><th colspan="4" align="center" rowspan="1">Heterogeneity measures</th></tr><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Total N</th><th align="center" rowspan="1" colspan="1">Total N</th><th align="center" rowspan="1" colspan="1">Range (%)</th><th align="center" rowspan="1" colspan="1">Mean (%)</th><th align="center" rowspan="1" colspan="1">95% CI</th><th align="center" rowspan="1" colspan="1">Q (p-value)<xref rid="t004fn001" ref-type="table-fn">*</xref>
</th><th align="center" rowspan="1" colspan="1">
<italic>&#x003c4;</italic>
<sup>2</sup>
<xref rid="t004fn002" ref-type="table-fn">**</xref>
</th><th align="center" rowspan="1" colspan="1">I<sup>2</sup> (confidence limits)<xref rid="t004fn003" ref-type="table-fn">
<sup>&#x02020;</sup>
</xref>
</th><th align="center" rowspan="1" colspan="1">Prediction interval (%)<xref rid="t004fn004" ref-type="table-fn">
<sup>&#x02021;</sup>
</xref>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Iraq</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">General population</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">1859563</td><td align="center" rowspan="1" colspan="1">0.0&#x02013;7.2</td><td align="center" rowspan="1" colspan="1">0.2</td><td align="center" rowspan="1" colspan="1">0.1&#x02013;0.3</td><td align="center" rowspan="1" colspan="1">2355.9 (p&#x0003c;0.0001)</td><td align="center" rowspan="1" colspan="1">0.0014</td><td align="center" rowspan="1" colspan="1">95.8% (95.3&#x02013;96.3%)</td><td align="center" rowspan="1" colspan="1">0.0&#x02013;0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">Populations at high risk</td><td align="center" rowspan="1" colspan="1">58</td><td align="center" rowspan="1" colspan="1">6707</td><td align="center" rowspan="1" colspan="1">0.0&#x02013;67.3</td><td align="center" rowspan="1" colspan="1">19.5</td><td align="center" rowspan="1" colspan="1">14.9&#x02013;24.5</td><td align="center" rowspan="1" colspan="1">1345.8 (p&#x0003c;0.0001)</td><td align="center" rowspan="1" colspan="1">0.1982</td><td align="center" rowspan="1" colspan="1">95.8% (95.1&#x02013;96.4%)</td><td align="center" rowspan="1" colspan="1">0.0&#x02013;62.8</td></tr><tr><td align="left" rowspan="1" colspan="1">Populations at intermediate risk</td><td align="center" rowspan="1" colspan="1">28</td><td align="center" rowspan="1" colspan="1">8398</td><td align="center" rowspan="1" colspan="1">0.0&#x02013;35.1</td><td align="center" rowspan="1" colspan="1">1.5</td><td align="center" rowspan="1" colspan="1">0.7&#x02013;2.5</td><td align="center" rowspan="1" colspan="1">205.2 (p&#x0003c;0.0001)</td><td align="center" rowspan="1" colspan="1">0.0227</td><td align="center" rowspan="1" colspan="1">86.8% (82.1&#x02013;90.3%)</td><td align="center" rowspan="1" colspan="1">0.0&#x02013;8.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Special clinical populations</td><td align="center" rowspan="1" colspan="1">45</td><td align="center" rowspan="1" colspan="1">18845</td><td align="center" rowspan="1" colspan="1">0.0&#x02013;76.2</td><td align="center" rowspan="1" colspan="1">5.0</td><td align="center" rowspan="1" colspan="1">3.4&#x02013;6.9</td><td align="center" rowspan="1" colspan="1">1146.5 (p&#x0003c;0.0001)</td><td align="center" rowspan="1" colspan="1">0.0631</td><td align="center" rowspan="1" colspan="1">96.2% (95.5&#x02013;96.7%)</td><td align="center" rowspan="1" colspan="1">0.0&#x02013;22.1</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Jordan</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">General population</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">126152</td><td align="center" rowspan="1" colspan="1">0.0&#x02013;2.0</td><td align="center" rowspan="1" colspan="1">0.3</td><td align="center" rowspan="1" colspan="1">0.1&#x02013;0.5</td><td align="center" rowspan="1" colspan="1">170.7 (p&#x0003c;0.0001)</td><td align="center" rowspan="1" colspan="1">0.0016</td><td align="center" rowspan="1" colspan="1">93.6% (90.5&#x02013;95.6%)</td><td align="center" rowspan="1" colspan="1">0.0&#x02013;1.1</td></tr><tr><td align="left" rowspan="1" colspan="1">Populations at high risk</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">2888</td><td align="center" rowspan="1" colspan="1">21.0&#x02013;59.5</td><td align="center" rowspan="1" colspan="1">37.0</td><td align="center" rowspan="1" colspan="1">29.3&#x02013;45.0</td><td align="center" rowspan="1" colspan="1">137.8 (p&#x0003c;0.0001)</td><td align="center" rowspan="1" colspan="1">0.07</td><td align="center" rowspan="1" colspan="1">92.0% (87.9&#x02013;94.7%)</td><td align="center" rowspan="1" colspan="1">11.1&#x02013;67.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Populations at intermediate risk</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">152</td><td align="center" rowspan="1" colspan="1">0.65</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Special clinical populations</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">143</td><td align="center" rowspan="1" colspan="1">40.5</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Mixed populations</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">426</td><td align="center" rowspan="1" colspan="1">4.5</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Lebanon</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">General population</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">38059</td><td align="center" rowspan="1" colspan="1">0.0&#x02013;3.4</td><td align="center" rowspan="1" colspan="1">0.2</td><td align="center" rowspan="1" colspan="1">0.1&#x02013;0.3</td><td align="center" rowspan="1" colspan="1">38.2 (p&#x0003c;0.0008)</td><td align="center" rowspan="1" colspan="1">0.0008</td><td align="center" rowspan="1" colspan="1">60.8% (32.3&#x02013;77.3%)</td><td align="center" rowspan="1" colspan="1">0.0&#x02013;0.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Populations at high risk</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">1309</td><td align="center" rowspan="1" colspan="1">0.0&#x02013;52.8</td><td align="center" rowspan="1" colspan="1">14.5</td><td align="center" rowspan="1" colspan="1">5.6&#x02013;26.5</td><td align="center" rowspan="1" colspan="1">223 (p&#x0003c;0.0001)</td><td align="center" rowspan="1" colspan="1">0.2011</td><td align="center" rowspan="1" colspan="1">96.0% (94.2&#x02013;97.2%)</td><td align="center" rowspan="1" colspan="1">0.0&#x02013;66.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Populations at intermediate risk</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">1050</td><td align="center" rowspan="1" colspan="1">0.0&#x02013;7.7</td><td align="center" rowspan="1" colspan="1">1.2</td><td align="center" rowspan="1" colspan="1">0.1&#x02013;3.3</td><td align="center" rowspan="1" colspan="1">24.9 (p&#x0003c;0.0003)</td><td align="center" rowspan="1" colspan="1">0.0224</td><td align="center" rowspan="1" colspan="1">76.0% (49.3&#x02013;88.6%)</td><td align="center" rowspan="1" colspan="1">0.0&#x02013;10.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Special clinical populations</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">312</td><td align="center" rowspan="1" colspan="1">0.0&#x02013;19.6</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Palestine</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">General population</td><td align="center" rowspan="1" colspan="1">53</td><td align="center" rowspan="1" colspan="1">337384</td><td align="center" rowspan="1" colspan="1">0.0&#x02013;9.0</td><td align="center" rowspan="1" colspan="1">0.2</td><td align="center" rowspan="1" colspan="1">0.2&#x02013;0.3</td><td align="center" rowspan="1" colspan="1">637.8 (p&#x0003c;0.0001)</td><td align="center" rowspan="1" colspan="1">0.0019</td><td align="center" rowspan="1" colspan="1">91.8% (90.1&#x02013;93.3%)</td><td align="center" rowspan="1" colspan="1">0.0&#x02013;0.9</td></tr><tr><td align="left" rowspan="1" colspan="1">Populations at high risk</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">584</td><td align="center" rowspan="1" colspan="1">6.8&#x02013;45.2</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Populations at intermediate risk</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Special clinical populations</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Mixed populations</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">53363</td><td align="center" rowspan="1" colspan="1">0.3&#x02013;4.9</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Syria</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">General population</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">1114550</td><td align="center" rowspan="1" colspan="1">0.3&#x02013;0.9</td><td align="center" rowspan="1" colspan="1">0.4</td><td align="center" rowspan="1" colspan="1">0.4&#x02013;0.5</td><td align="center" rowspan="1" colspan="1">216.6 (p&#x0003c;0.0001)</td><td align="center" rowspan="1" colspan="1">0.0002</td><td align="center" rowspan="1" colspan="1">92.6% (89.7&#x02013;94.7%)</td><td align="center" rowspan="1" colspan="1">0.3&#x02013;0.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Populations at high risk</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">1279</td><td align="center" rowspan="1" colspan="1">21.0&#x02013;75.0</td><td align="center" rowspan="1" colspan="1">47.4</td><td align="center" rowspan="1" colspan="1">32.5&#x02013;62.5</td><td align="center" rowspan="1" colspan="1">190.6 (p&#x0003c;0.0001)</td><td align="center" rowspan="1" colspan="1">0.1779</td><td align="center" rowspan="1" colspan="1">96.3% (94.5&#x02013;97.6%)</td><td align="center" rowspan="1" colspan="1">3.8&#x02013;93.8</td></tr><tr><td align="left" rowspan="1" colspan="1">Populations at intermediate risk</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">725</td><td align="center" rowspan="1" colspan="1">2.0&#x02013;5.8</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Special clinical populations</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">218</td><td align="center" rowspan="1" colspan="1">1.0&#x02013;48.0</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>All countries</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">General population</td><td align="center" rowspan="1" colspan="1">197</td><td align="center" rowspan="1" colspan="1">3475708</td><td align="center" rowspan="1" colspan="1">0.0&#x02013;9.0</td><td align="center" rowspan="1" colspan="1">0.2</td><td align="center" rowspan="1" colspan="1">0.2&#x02013;0.3</td><td align="center" rowspan="1" colspan="1">4497.5 (p&#x0003c;0.0001)</td><td align="center" rowspan="1" colspan="1">0.0013</td><td align="center" rowspan="1" colspan="1">95.6% (95.3&#x02013;96.0%)</td><td align="center" rowspan="1" colspan="1">0.0&#x02013;0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">Populations at high risk</td><td align="center" rowspan="1" colspan="1">92</td><td align="center" rowspan="1" colspan="1">12767</td><td align="center" rowspan="1" colspan="1">0.0&#x02013;75.0</td><td align="center" rowspan="1" colspan="1">23.6</td><td align="center" rowspan="1" colspan="1">19.8&#x02013;27.5</td><td align="center" rowspan="1" colspan="1">2273.6 (p&#x0003c;0.0001)</td><td align="center" rowspan="1" colspan="1">0.1762</td><td align="center" rowspan="1" colspan="1">96.0% (95.5&#x02013;96.4%)</td><td align="center" rowspan="1" colspan="1">0.3&#x02013;64.5</td></tr><tr><td align="left" rowspan="1" colspan="1">Populations at intermediate risk</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">10325</td><td align="center" rowspan="1" colspan="1">0.0&#x02013;35.2</td><td align="center" rowspan="1" colspan="1">1.5</td><td align="center" rowspan="1" colspan="1">0.9&#x02013;2.3</td><td align="center" rowspan="1" colspan="1">243.5 (p&#x0003c;0.0001)</td><td align="center" rowspan="1" colspan="1">0.0208</td><td align="center" rowspan="1" colspan="1">84.0% (79.0&#x02013;87.8%)</td><td align="center" rowspan="1" colspan="1">0.0&#x02013;7.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Special clinical populations</td><td align="center" rowspan="1" colspan="1">52</td><td align="center" rowspan="1" colspan="1">19518</td><td align="center" rowspan="1" colspan="1">0.0&#x02013;76.2</td><td align="center" rowspan="1" colspan="1">5.4</td><td align="center" rowspan="1" colspan="1">3.7&#x02013;7.4</td><td align="center" rowspan="1" colspan="1">1377.9 (p&#x0003c;0.0001)</td><td align="center" rowspan="1" colspan="1">0.0729</td><td align="center" rowspan="1" colspan="1">96.3% (95.7&#x02013;96.8%)</td><td align="center" rowspan="1" colspan="1">0.0&#x02013;24.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Mixed populations</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">53789</td><td align="center" rowspan="1" colspan="1">0.3&#x02013;4.9</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="t004fn001"><p>*Q: the Cochran&#x02019;s Q statistic is a measure assessing the existence of heterogeneity in effect size.</p></fn><fn id="t004fn002"><p>**<italic>&#x003c4;</italic>
<sup>2</sup>: the estimated between-study variance in the double arcsine transformed proportions of the true effect sizes. The back-transformed <italic>&#x003c4;</italic>
<sup>2</sup> was not calculated as the methodology to do so is not currently available.</p></fn><fn id="t004fn003"><p>
<sup>&#x02020;</sup>I<sup>2</sup>: a measure assessing the magnitude of between-study variation that is due to differences in effect size across studies rather than chance.</p></fn><fn id="t004fn004"><p>
<sup>&#x02021;</sup>Prediction interval: estimates the 95% interval in which the true effect size in a new HCV study will lie.</p></fn></table-wrap-foot></table-wrap><p>For each country, we calculated the frequency of occurrence of each genotype relative to all identified genotypes (<xref rid="pone.0135281.t005" ref-type="table">Table 5</xref>). Here, individuals testing positive for multiple genotypes contributed separately to the quantification of each of the identified genotypes. Shannon Diversity Index [<xref rid="pone.0135281.ref029" ref-type="bibr">29</xref>] was applied to the resulting distributions to assess the diversity of genotypes across countries, with a higher score indicating more diversity (<xref rid="pone.0135281.t005" ref-type="table">Table 5</xref>). The country-specific distributions of HCV genotypes among HCV RNA positive individuals were also described (<xref rid="pone.0135281.s006" ref-type="supplementary-material">S6 Fig</xref>).</p><table-wrap id="pone.0135281.t005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0135281.t005</object-id><label>Table 5</label><caption><title>Frequency, distribution and Shannon Diversity Index of identified hepatitis C virus (HCV) genotypes across countries of the Fertile Crescent.</title></caption><alternatives><graphic id="pone.0135281.t005g" xlink:href="pone.0135281.t005"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th rowspan="2" align="left" colspan="1">Country</th><th align="center" rowspan="1" colspan="1">Iraq</th><th align="center" rowspan="1" colspan="1">Jordan</th><th align="center" rowspan="1" colspan="1">Lebanon</th><th align="center" rowspan="1" colspan="1">Palestine</th><th align="center" rowspan="1" colspan="1">Syria</th></tr><tr><th align="center" rowspan="1" colspan="1">n (%)</th><th align="center" rowspan="1" colspan="1">n (%)</th><th align="center" rowspan="1" colspan="1">n (%)</th><th align="center" rowspan="1" colspan="1">n (%)</th><th align="center" rowspan="1" colspan="1">n (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Genotype 1</bold>
</td><td align="center" rowspan="1" colspan="1">212 (33.2%)</td><td align="center" rowspan="1" colspan="1">30 (42.3%)</td><td align="center" rowspan="1" colspan="1">134 (39.9%)</td><td align="center" rowspan="1" colspan="1">38 (28.6%)</td><td align="center" rowspan="1" colspan="1">199 (29.5%)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Genotype 2</bold>
</td><td align="center" rowspan="1" colspan="1">3 (0.5%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">53 (15.8%)</td><td align="center" rowspan="1" colspan="1">1 (0.8%)</td><td align="center" rowspan="1" colspan="1">5 (0.7%)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Genotype 3</bold>
</td><td align="center" rowspan="1" colspan="1">24 (3.8%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">40 (11.9%)</td><td align="center" rowspan="1" colspan="1">2 (1.5%)</td><td align="center" rowspan="1" colspan="1">11 (1.6%)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Genotype 4</bold>
</td><td align="center" rowspan="1" colspan="1">399 (62.5%)</td><td align="center" rowspan="1" colspan="1">41 (57.7%)</td><td align="center" rowspan="1" colspan="1">108 (32.1%)</td><td align="center" rowspan="1" colspan="1">92 (69.2%)</td><td align="center" rowspan="1" colspan="1">392 (58.2%)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Genotype 5</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1 (0.3%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">67 (9.9%)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Genotype 6</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Genotype 7</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold><italic>Shannon Diversity Index (H)</italic></bold>
</td><td align="center" rowspan="1" colspan="1">0.81</td><td align="center" rowspan="1" colspan="1">0.68</td><td align="center" rowspan="1" colspan="1">1.29</td><td align="center" rowspan="1" colspan="1">0.71</td><td align="center" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold><italic>Index relative to total possible diversity</italic></bold>
</td><td align="center" rowspan="1" colspan="1">41.5%</td><td align="center" rowspan="1" colspan="1">35.0%</td><td align="center" rowspan="1" colspan="1">66.5%</td><td align="center" rowspan="1" colspan="1">36.6%</td><td align="center" rowspan="1" colspan="1">51.8%</td></tr></tbody></table></alternatives></table-wrap><p>Analyses were performed using SPSS 22.0 [<xref rid="pone.0135281.ref030" ref-type="bibr">30</xref>] and R 3.1.2. [<xref rid="pone.0135281.ref031" ref-type="bibr">31</xref>].</p></sec></sec><sec sec-type="results" id="sec011"><title>Results</title><sec id="sec012"><title>Search results</title><p>
<xref rid="pone.0135281.g001" ref-type="fig">Fig 1</xref> describes the process of study selection based on PRISMA guidelines [<xref rid="pone.0135281.ref016" ref-type="bibr">16</xref>]. We identified a total of 465 citations (92 through PubMed, 153 through Embase, and 220 through regional databases). A total of 166 records were identified as relevant or potentially relevant after removing duplicates and screening the titles and abstracts of remaining records. Out of these, 115 records were eligible for inclusion in the systematic review during the full-text screening stage. Twenty additional records were identified through screening the bibliographies of studies and reviews. Twenty one HCV prevalence measures from country-level data were also identified through the MENA HIV/AIDS Epidemiology Synthesis Project database [<xref rid="pone.0135281.ref018" ref-type="bibr">18</xref>, <xref rid="pone.0135281.ref032" ref-type="bibr">32</xref>&#x02013;<xref rid="pone.0135281.ref038" ref-type="bibr">38</xref>]. To sum, a total of 135 eligible reports and 21 HCV prevalence measures from county-level data were included in the systematic review. These yielded 8 HCV incidence/sero-conversion and 240 HCV prevalence measures.</p><p>All 465 citations identified through our search underwent an independent secondary screening for HCV genotype studies (<xref rid="pone.0135281.s003" ref-type="supplementary-material">S3 Fig</xref>). A total of 163 records were identified as relevant or potentially relevant after removing duplicates and screening the titles and abstracts of remaining records. Out of these, 29 records were eligible for inclusion in this secondary systematic review during the full-text screening stage yielding 47 HCV genotype study measures.</p></sec><sec id="sec013"><title>HCV incidence overview</title><p>Out of all countries being analyzed (Iraq, Jordan, Lebanon, Palestine, and Syria), data on HCV incidence was only available for Iraq and Jordan. There were no studies reporting strictly HCV incidence rate per person-year. All eight identified incidence measures were based on risk of sero-conversion over a specified time frame (<xref rid="pone.0135281.t001" ref-type="table">Table 1</xref>). One study conducted across all dialysis units in Jordan reported a sero-conversion risk of 9.2% over one year [<xref rid="pone.0135281.ref039" ref-type="bibr">39</xref>]. The rest of the studies were conducted in Iraq. In one study among hemodialysis patients, a sero-conversion risk of 40.3% over one year was reported [<xref rid="pone.0135281.ref040" ref-type="bibr">40</xref>]. Lower HCV sero-conversion risks ranging from 0&#x02013;3.5% were observed among pediatric cancer patients [<xref rid="pone.0135281.ref041" ref-type="bibr">41</xref>&#x02013;<xref rid="pone.0135281.ref043" ref-type="bibr">43</xref>]. A study among newborns to HCV infected mothers reported 100% clearance of maternal antibodies by six months of age [<xref rid="pone.0135281.ref044" ref-type="bibr">44</xref>].</p></sec><sec id="sec014"><title>HCV prevalence overview</title><p>We present here an overview of HCV prevalence studies identified in Iraq, Jordan, Lebanon, Palestine, and Syria. For the purpose of this analysis, we excluded HCV prevalence studies that were based on samples of less than 50 participants (37 studies). Accordingly, we report on a total of 203 HCV prevalence studies including 125 studies from Iraq, 15 from Jordan, 27 from Lebanon, 17 from Palestine, and 19 from Syria.</p><sec id="sec015"><title>Iraq</title><p>Among populations at high risk (<xref rid="pone.0135281.t002" ref-type="table">Table 2</xref>), high HCV prevalence levels ranging from 4% to 67.3% were reported among thalassemic patients, with the highest prevalence being observed among the 2 to 10 year-olds [<xref rid="pone.0135281.ref045" ref-type="bibr">45</xref>]. High HCV prevalence levels were also found among hemodialysis patients (range: 0&#x02013;42.6%) [<xref rid="pone.0135281.ref046" ref-type="bibr">46</xref>&#x02013;<xref rid="pone.0135281.ref055" ref-type="bibr">55</xref>] and hemophilia patients (range: 6.7&#x02013;40%) [<xref rid="pone.0135281.ref056" ref-type="bibr">56</xref>&#x02013;<xref rid="pone.0135281.ref058" ref-type="bibr">58</xref>].</p><p>For the general population (<xref rid="pone.0135281.t003" ref-type="table">Table 3</xref>), HCV prevalence varied between 0% and 5.1%, and ranged between 0% and 2.8% among blood donors, 0% and 5.1% among pregnant women, and was 0.4% in a national household-based survey [<xref rid="pone.0135281.ref059" ref-type="bibr">59</xref>] and overall less than 1% among other general population groups.</p><p>Among populations at intermediate risk (<xref rid="pone.0135281.s011" ref-type="supplementary-material">S2 Table</xref>), HCV prevalence ranged from 0% to 3.3% among health care workers [<xref rid="pone.0135281.ref046" ref-type="bibr">46</xref>, <xref rid="pone.0135281.ref050" ref-type="bibr">50</xref>, <xref rid="pone.0135281.ref060" ref-type="bibr">60</xref>&#x02013;<xref rid="pone.0135281.ref064" ref-type="bibr">64</xref>], and was higher among dental providers (9.1%) [<xref rid="pone.0135281.ref065" ref-type="bibr">65</xref>], hospitalized patients (14%) [<xref rid="pone.0135281.ref066" ref-type="bibr">66</xref>], and type I diabetes mellitus patients (35.1%) [<xref rid="pone.0135281.ref067" ref-type="bibr">67</xref>]. HCV prevalence also varied widely among special clinical populations ranging from 0% among patients with malignancies or liver-related problems to 71.9% among acute viral hepatitis patients (<xref rid="pone.0135281.s011" ref-type="supplementary-material">S2 Table</xref>).</p></sec><sec id="sec016"><title>Jordan</title><p>Among populations at high risk (<xref rid="pone.0135281.t002" ref-type="table">Table 2</xref>), high HCV prevalence levels ranging from 21% to 49.8% were observed among hemodialysis patients. A prevalence of 32.8% was also observed among thalassemic patients [<xref rid="pone.0135281.ref068" ref-type="bibr">68</xref>].</p><p>For the general population (<xref rid="pone.0135281.t003" ref-type="table">Table 3</xref>), low HCV prevalence levels of less than 1% were observed among blood donors and people attending health centers (range: 0.1&#x02013;0.9%). Among populations at intermediate risk and special clinical populations (<xref rid="pone.0135281.s011" ref-type="supplementary-material">S2 Table</xref>), low HCV prevalence of 0.6% was reported among health care workers [<xref rid="pone.0135281.ref069" ref-type="bibr">69</xref>] and high prevalence of 40.5% was reported among patients with hemolytic anemia [<xref rid="pone.0135281.ref070" ref-type="bibr">70</xref>].</p></sec><sec id="sec017"><title>Lebanon</title><p>Among populations at high risk (<xref rid="pone.0135281.t002" ref-type="table">Table 2</xref>), high HCV prevalence of 52.8% was reported among PWID [<xref rid="pone.0135281.ref071" ref-type="bibr">71</xref>]. Overall high HCV prevalence was also reported among other populations at high risk (<xref rid="pone.0135281.t002" ref-type="table">Table 2</xref>) such as hemodialysis patients (16% [<xref rid="pone.0135281.ref072" ref-type="bibr">72</xref>] and 27% [<xref rid="pone.0135281.ref073" ref-type="bibr">73</xref>]), thalassemia patients (0% [<xref rid="pone.0135281.ref074" ref-type="bibr">74</xref>] and 14% [<xref rid="pone.0135281.ref075" ref-type="bibr">75</xref>]), and multi-transfused cancer patients (4.6% [<xref rid="pone.0135281.ref076" ref-type="bibr">76</xref>]).</p><p>For the general population (<xref rid="pone.0135281.t003" ref-type="table">Table 3</xref>), HCV prevalence was measured at less than 0.6% among Lebanese nationals [<xref rid="pone.0135281.ref073" ref-type="bibr">73</xref>, <xref rid="pone.0135281.ref076" ref-type="bibr">76</xref>&#x02013;<xref rid="pone.0135281.ref084" ref-type="bibr">84</xref>] and at about 3% among non-Lebanese nationals residing in Lebanon [<xref rid="pone.0135281.ref083" ref-type="bibr">83</xref>, <xref rid="pone.0135281.ref084" ref-type="bibr">84</xref>].</p><p>Rather low HCV prevalence was observed among populations at intermediate risk ranging from 0% among female sex workers and men who have sex with men to 7.7% among HIV patients infected apparently via the sexual route (<xref rid="pone.0135281.s011" ref-type="supplementary-material">S2 Table</xref>). Among special clinical populations (<xref rid="pone.0135281.s011" ref-type="supplementary-material">S2 Table</xref>), HCV prevalence was 19.6% [<xref rid="pone.0135281.ref085" ref-type="bibr">85</xref>] among hepatocellular carcinoma patients and 0% [<xref rid="pone.0135281.ref082" ref-type="bibr">82</xref>, <xref rid="pone.0135281.ref086" ref-type="bibr">86</xref>] among patients with other malignancies.</p></sec><sec id="sec018"><title>Palestine</title><p>Among populations at high risk (<xref rid="pone.0135281.t002" ref-type="table">Table 2</xref>), HCV prevalence was measured at 27.4% among hemodialysis patients in the West Bank [<xref rid="pone.0135281.ref087" ref-type="bibr">87</xref>], and at 17.9% among hemodialysis patients in the Gaza strip [<xref rid="pone.0135281.ref088" ref-type="bibr">88</xref>]. A prevalence of 45.2% was reported among PWID in East Jerusalem [<xref rid="pone.0135281.ref089" ref-type="bibr">89</xref>].</p><p>For the general population (<xref rid="pone.0135281.t003" ref-type="table">Table 3</xref>), HCV prevalence among blood donors from different parts of Palestine ranged between 0.2% and 0.3% [<xref rid="pone.0135281.ref018" ref-type="bibr">18</xref>, <xref rid="pone.0135281.ref032" ref-type="bibr">32</xref>&#x02013;<xref rid="pone.0135281.ref038" ref-type="bibr">38</xref>]. In older studies, all of which were in the Gaza strip, HCV prevalence was reported at 2.2% and 3.9% among blood donors [<xref rid="pone.0135281.ref090" ref-type="bibr">90</xref>, <xref rid="pone.0135281.ref091" ref-type="bibr">91</xref>] and at 9% among outpatient hospital attendees [<xref rid="pone.0135281.ref090" ref-type="bibr">90</xref>].</p></sec><sec id="sec019"><title>Syria</title><p>Among populations at high risk (<xref rid="pone.0135281.t002" ref-type="table">Table 2</xref>), high HCV prevalence ranging from 48.9% to 75% was reported among hemodialysis patients [<xref rid="pone.0135281.ref092" ref-type="bibr">92</xref>&#x02013;<xref rid="pone.0135281.ref094" ref-type="bibr">94</xref>]. Meanwhile, HCV prevalence among drug users (injecting and non-injecting) and among hemophilia patients was measured at 21% [<xref rid="pone.0135281.ref095" ref-type="bibr">95</xref>] and 20.5% [<xref rid="pone.0135281.ref096" ref-type="bibr">96</xref>], respectively.</p><p>For the general population (<xref rid="pone.0135281.t003" ref-type="table">Table 3</xref>), HCV prevalence ranged between 0.3% and 0.9% among blood donors. Among populations at intermediate risk (<xref rid="pone.0135281.s011" ref-type="supplementary-material">S2 Table</xref>), HCV prevalence ranged between 2% among female sex workers [<xref rid="pone.0135281.ref097" ref-type="bibr">97</xref>] and up to 3.8% among health care workers [<xref rid="pone.0135281.ref098" ref-type="bibr">98</xref>]. The only study among special clinical populations (<xref rid="pone.0135281.s011" ref-type="supplementary-material">S2 Table</xref>) was among acute viral hepatitis patients and reported a prevalence of 1.0% [<xref rid="pone.0135281.ref099" ref-type="bibr">99</xref>].</p></sec><sec id="sec020"><title>Overall HCV prevalence ranges and medians</title><p>For all countries, HCV prevalence ranged from 0&#x02013;75% among populations at high risk with a median of 25.0%, from 0&#x02013;9% among populations at low risk with a median of 0.4%, from 0&#x02013;35.1% among populations at intermediate risk with a median of 1.2%, and from 0&#x02013;71.9% among special clinical populations with a median of 3.4%.</p></sec></sec><sec id="sec021"><title>Pooled mean HCV prevalence estimates</title><p>Our pooled country-specific estimates for the national population-level HCV prevalence, based on pooling the general population measures, were: 0.2% (95% CI: 0.1&#x02013;0.3%) in Iraq, 0.3% (95% CI: 0.1&#x02013;0.5%) in Jordan, 0.2% (95% CI: 0.1&#x02013;0.3%) in Lebanon, 0.2% (95% CI: 0.2&#x02013;0.3%) in Palestine, 0.4% (95% CI: 0.4&#x02013;0.5%) in Syria, and 0.2% (95% CI: 0.2&#x02013;0.3%) in FC countries as a whole (<xref rid="pone.0135281.t004" ref-type="table">Table 4</xref>). The prediction interval for each of these pooled means, that is the estimated 95% interval range for the true effect size (HCV prevalence) across studies, also rarely exceeded 1% (<xref rid="pone.0135281.t004" ref-type="table">Table 4</xref>). The forest plots of the country-specific meta-analyses can be found in <xref rid="pone.0135281.s007" ref-type="supplementary-material">S7</xref>&#x02013;<xref rid="pone.0135281.s009" ref-type="supplementary-material">S9</xref> Figs.</p><p>High pooled HCV prevalence levels were estimated for populations at high risk: 19.5% (95% CI: 14.9&#x02013;24.5%) in Iraq, 37.0% (95% CI: 29.3&#x02013;45.0%) in Jordan, 14.5% (95% CI: 5.6&#x02013;26.5%) in Lebanon, 47.4% (95% CI: 32.5&#x02013;62.5%) in Syria, and 23.6% (95% CI: 19.8&#x02013;27.5%) in FC countries as a whole (<xref rid="pone.0135281.t004" ref-type="table">Table 4</xref>). The prediction intervals for these measures were also wide across countries (<xref rid="pone.0135281.t004" ref-type="table">Table 4</xref>).</p><p>For populations at intermediate risk, the pooled HCV prevalence was 1.5% (95% CI: 0.7&#x02013;2.5%) in Iraq, 1.2% (95% CI: 0.1&#x02013;3.3%) in Lebanon, and 1.5% (95% CI: 0.9&#x02013;2.3%) in FC countries as a whole (<xref rid="pone.0135281.t004" ref-type="table">Table 4</xref>). For special clinical populations, the pooled HCV prevalence was 5.0% (95% CI: 3.4&#x02013;6.9%) in Iraq and 5.4% (95% CI: 3.7&#x02013;7.4%) in FC countries as a whole (<xref rid="pone.0135281.t004" ref-type="table">Table 4</xref>). The prediction intervals for these measures were also wide across countries (<xref rid="pone.0135281.t004" ref-type="table">Table 4</xref>).</p><p>There was significant evidence for heterogeneity in effect size in all meta-analyses, the p-value was always &#x0003c;0.001 (<xref rid="pone.0135281.t004" ref-type="table">Table 4</xref>). Most of the variation in all meta-analyses was attributed to variation in effect size across studies rather than chance (I<sup>2</sup> &#x0003e;60%; <xref rid="pone.0135281.t004" ref-type="table">Table 4</xref>).</p></sec><sec id="sec022"><title>HCV RNA prevalence</title><p>Our search identified a total of 34 HCV RNA measures (<xref rid="pone.0135281.s012" ref-type="supplementary-material">S3 Table</xref>). Generally high HCV RNA prevalence was found among HCV antibody positive individuals at high risk across all countries ranging from 26.1% among hemodialysis patients to 88% among thalassemia patients. HCV RNA prevalence was also substantial among HCV antibody negative individuals at high risk ranging from 3.5% among hemodialysis patients to 16.7% among thalassemic children.</p><p>For the general population (<xref rid="pone.0135281.s012" ref-type="supplementary-material">S3 Table</xref>), the prevalence of HCV RNA among HCV antibody positive individuals in Iraq and Palestine hovered around 65% in different samples of blood donors [<xref rid="pone.0135281.ref090" ref-type="bibr">90</xref>, <xref rid="pone.0135281.ref100" ref-type="bibr">100</xref>, <xref rid="pone.0135281.ref101" ref-type="bibr">101</xref>], pregnant women [<xref rid="pone.0135281.ref102" ref-type="bibr">102</xref>], and outpatients [<xref rid="pone.0135281.ref090" ref-type="bibr">90</xref>], but was at 89.7% among blood donors in Jordan [<xref rid="pone.0135281.ref103" ref-type="bibr">103</xref>].</p></sec><sec id="sec023"><title>HCV genotypes</title><p>Information on HCV genotypes was available in 47 studies including a total of 1749 HCV RNA positive individuals (<xref rid="pone.0135281.t005" ref-type="table">Table 5</xref> and <xref rid="pone.0135281.s006" ref-type="supplementary-material">S6 Fig</xref>).</p><p>In Iraq, the majority of participants were infected by a single strain, only 11.3% had multiple genotypes isolated from their plasma (<xref rid="pone.0135281.s006" ref-type="supplementary-material">S6A Fig</xref>) [<xref rid="pone.0135281.ref045" ref-type="bibr">45</xref>, <xref rid="pone.0135281.ref048" ref-type="bibr">48</xref>, <xref rid="pone.0135281.ref101" ref-type="bibr">101</xref>, <xref rid="pone.0135281.ref102" ref-type="bibr">102</xref>, <xref rid="pone.0135281.ref104" ref-type="bibr">104</xref>&#x02013;<xref rid="pone.0135281.ref110" ref-type="bibr">110</xref>]. The distribution of HCV genotypes showed a high prevalence for genotype 4 (62.5%) and genotype 1 (33.2%) followed by genotype 3 (3.8%) and genotype 2 (0.5%) (<xref rid="pone.0135281.t005" ref-type="table">Table 5</xref>). Subtypes 1a and 1b were isolated, respectively, from 33.2% and 66.8% of infected persons with genotype 1 (where subtype information was available). About two-third of the infections among populations at high risk and slightly more than half of those among general populations were attributed to genotype 4.</p><p>All HCV RNA positive individuals in Jordan were infected by a single strain (<xref rid="pone.0135281.s006" ref-type="supplementary-material">S6B Fig</xref>), with 57.7% carrying genotype 4 and 42.3% carrying genotype 1 (<xref rid="pone.0135281.t005" ref-type="table">Table 5</xref>) [<xref rid="pone.0135281.ref068" ref-type="bibr">68</xref>, <xref rid="pone.0135281.ref103" ref-type="bibr">103</xref>, <xref rid="pone.0135281.ref111" ref-type="bibr">111</xref>, <xref rid="pone.0135281.ref112" ref-type="bibr">112</xref>]. Subtypes 1a and 1b were isolated, respectively, from 54.5% and 45.5% of infected persons with genotype 1. The majority of genotype 1 samples were among hemodialysis and thalassemia patients, while samples with genotype 4 were equally distributed between populations at high risk and the general population.</p><p>In Lebanon, over 90% of participants were infected by a single strain (<xref rid="pone.0135281.s006" ref-type="supplementary-material">S6C Fig</xref>) [<xref rid="pone.0135281.ref071" ref-type="bibr">71</xref>, <xref rid="pone.0135281.ref072" ref-type="bibr">72</xref>, <xref rid="pone.0135281.ref075" ref-type="bibr">75</xref>, <xref rid="pone.0135281.ref076" ref-type="bibr">76</xref>, <xref rid="pone.0135281.ref113" ref-type="bibr">113</xref>&#x02013;<xref rid="pone.0135281.ref117" ref-type="bibr">117</xref>]. The distribution of genotypes indicated genotype 1 as the most common (39.9%), followed by genotype 4 (32.1%), genotype 2 (15.8%), genotype 3 (11.9%) and genotype 5 (0.3%) (<xref rid="pone.0135281.t005" ref-type="table">Table 5</xref>). Studies reporting subtype information for genotype 1 showed an equal distribution of subtypes 1a and 1b. About half of genotype 3 infections (47.5%) were collected among PWID; and an additional third were collected among hemodialysis and thalassemia patients. Genotype 3 was also identified in a prison setting [<xref rid="pone.0135281.ref113" ref-type="bibr">113</xref>]. Genotype 5 was reported in only one study among a sample of patients with symptomatic liver disease [<xref rid="pone.0135281.ref116" ref-type="bibr">116</xref>].</p><p>All HCV genotype studies in Palestine were conducted in the Gaza strip [<xref rid="pone.0135281.ref090" ref-type="bibr">90</xref>, <xref rid="pone.0135281.ref118" ref-type="bibr">118</xref>]. Almost all infections were single strained (<xref rid="pone.0135281.s006" ref-type="supplementary-material">S6D Fig</xref>). Genotype 4 was the most common (69.2%), followed by genotype 1 (28.6%), genotype 3 (1.5%) and genotype 2 (0.8%) (<xref rid="pone.0135281.t005" ref-type="table">Table 5</xref>). Subtypes 1a and 1b constituted, respectively, 69.0% and 31.0% of genotype 1 cases.</p><p>The distribution of HCV genotypes in Syria (<xref rid="pone.0135281.s006" ref-type="supplementary-material">S6E Fig</xref>) revealed genotype 4 as the most common (58.2%) followed by genotype 1 (29.5%), genotype 5 (9.9%), genotype 3 (1.6%) and genotype 2 (0.7%) (<xref rid="pone.0135281.t005" ref-type="table">Table 5</xref>) [<xref rid="pone.0135281.ref092" ref-type="bibr">92</xref>, <xref rid="pone.0135281.ref119" ref-type="bibr">119</xref>, <xref rid="pone.0135281.ref120" ref-type="bibr">120</xref>]. Subtypes 1a and 1b were isolated, respectively, from 44.4% and 55.6% of infected persons with genotype 1.</p><p>The largest possible value for the Shannon Diversity Index, assuming equal distribution of the seven known HCV genotypes [<xref rid="pone.0135281.ref121" ref-type="bibr">121</xref>], is 1.95 [<xref rid="pone.0135281.ref029" ref-type="bibr">29</xref>]. Lebanon scored highest on this index (H = 1.29 out of 1.95 or 66.5%) indicating high diversity in the types and frequency of isolated genotypes (<xref rid="pone.0135281.t005" ref-type="table">Table 5</xref>). The next most diverse genotype distributions were found in Syria (H = 1.00 out of 1.95 or 51.8%), and Iraq (H = 0.81 out of 1.95 or 41.5%), while the least diversity was observed in Palestine, more specifically in the Gaza strip (H = 0.71 out of 1.95 or 36.6%), and Jordan (H = 0.68 out of 1.95 or 35.0%).</p></sec><sec id="sec024"><title>Risk factors for HCV infection</title><p>Few studies (n = 5) investigated possible risk factors for HCV infection using multivariable logistic regression analyses. Common reported risk factors among hemodialysis patients included duration of dialysis and number of blood units transfused [<xref rid="pone.0135281.ref054" ref-type="bibr">54</xref>, <xref rid="pone.0135281.ref094" ref-type="bibr">94</xref>]. Among individuals presenting to laboratory units for diverse testing in Lebanon, hemodialysis was the main risk factor for HCV infection [<xref rid="pone.0135281.ref084" ref-type="bibr">84</xref>]. Meanwhile, maternal age and number of previous miscarriages were identified as the main risk factors for HCV infection among pregnant women in Iraq [<xref rid="pone.0135281.ref102" ref-type="bibr">102</xref>]. Among patients suspected of having acute viral hepatitis, blood transfusion, tattooing, and cupping were identified as risk factors for HCV infection in a study in Iraq [<xref rid="pone.0135281.ref122" ref-type="bibr">122</xref>].</p></sec><sec id="sec025"><title>Quality assessment of HCV incidence and prevalence measures</title><p>The results of the quality assessment conducted for the HCV incidence and prevalence measures are summarized in <xref rid="pone.0135281.s013" ref-type="supplementary-material">S4 Table</xref>. The study-specific quality assessment for each of these measures is found in <xref rid="pone.0135281.s014" ref-type="supplementary-material">S5</xref>&#x02013;<xref rid="pone.0135281.s017" ref-type="supplementary-material">S8</xref> Tables.</p><p>The majority of HCV incidence studies involved samples of less than 100 patients, and thus were classified as having low precision. All studies were based on convenience samples selected from clinical facilities and were characterized by a high response rate. The type and generation of the biological assays used to ascertain infection were specified in almost all studies, with more than half relying on the more recent, sensitive and specific 3<sup>rd</sup> and 4<sup>th</sup> generation ELISA tests.</p><p>The majority of HCV prevalence measures had high precision (81.3%). The ROB assessment was possible for 184 HCV prevalence measures, while 19 measures were judged to be of unknown quality as limited description of the samples was available and were excluded from further analyses. However, all studies with unknown ROB were based on testing among blood donors reported by ministries of health and blood banks. For the vast majority of measures (98.4%), HCV ascertainment was based on biological assays. Information about the generation of the used assay was missing for more than half of the studies. Among studies with information on the assay&#x02019;s generation, 85.2% reported the use of the more sensitive and specific 3<sup>rd</sup> and 4<sup>th</sup> generation assays. Most of the studies were drawn using convenience sampling. Half of the studies had low ROB in the response rate domain, while 3.8% had high ROB. Response rate information was missing for 46.2% of the measures.</p><p>Overall, HCV incidence and prevalence studies were of reasonable quality, but incidence studies were of lower precision. Nearly all studies had low ROB in at least one quality domain (99.0%), and 47.9% of all studies had low ROB in at least two of the three quality domains. Less than 3.6% of all studies had high ROB in two or three quality domains.</p></sec></sec><sec sec-type="conclusions" id="sec026"><title>Discussion</title><p>We presented to our knowledge the first systematic review and synthesis of HCV incidence and prevalence across countries of the FC subregion of MENA. We also provided estimates for HCV prevalence at the national level and for various at risk populations. Our results suggest that HCV prevalence is at less than 1% among the general population across these countries (<xref rid="pone.0135281.t004" ref-type="table">Table 4</xref>). Meanwhile, high prevalence levels were noted among hemodialysis, thalassemia and multi-transfused patients (<xref rid="pone.0135281.t002" ref-type="table">Table 2</xref>). Genotypes 4 and 1 seem to be the most common genotypes circulating in these countries (<xref rid="pone.0135281.t005" ref-type="table">Table 5</xref> and <xref rid="pone.0135281.s006" ref-type="supplementary-material">S6 Fig</xref>).</p><p>Our estimates for the national HCV prevalence of less than 1% suggest that HCV levels in these countries are comparable to those in developed and other developing countries, but are towards the lower end of the global range [<xref rid="pone.0135281.ref001" ref-type="bibr">1</xref>, <xref rid="pone.0135281.ref002" ref-type="bibr">2</xref>, <xref rid="pone.0135281.ref123" ref-type="bibr">123</xref>]. These estimates also suggest that this subregion appears to have the lowest HCV prevalence of all MENA subregions [<xref rid="pone.0135281.ref007" ref-type="bibr">7</xref>, <xref rid="pone.0135281.ref011" ref-type="bibr">11</xref>&#x02013;<xref rid="pone.0135281.ref015" ref-type="bibr">15</xref>]&#x02014;substantially lower than in other MENA countries namely Egypt [<xref rid="pone.0135281.ref006" ref-type="bibr">6</xref>, <xref rid="pone.0135281.ref007" ref-type="bibr">7</xref>] and Pakistan [<xref rid="pone.0135281.ref008" ref-type="bibr">8</xref>, <xref rid="pone.0135281.ref009" ref-type="bibr">9</xref>].</p><p>A large fraction of HCV prevalence measures in the general population were among blood donors, and HCV prevalence in this normally healthy population may underestimate HCV prevalence in the population at large. In the USA, for example, HCV prevalence among blood donors [<xref rid="pone.0135281.ref124" ref-type="bibr">124</xref>] is substantially lower than that estimated in nationally-representative population-based surveys [<xref rid="pone.0135281.ref125" ref-type="bibr">125</xref>]. We conducted sensitivity analyses (not shown) to examine the impact of excluding blood donor data on our pooled estimates for HCV prevalence. For Iraq, HCV prevalence increased substantially from 0.2% to 0.8% with the exclusion of blood donors. Meanwhile, there were minor changes to the prevalence in Jordan (0.3% versus 0.2%) and Lebanon (0.2% versus 0.3%). Sensitivity analyses were not possible for Palestine and Syria due to the small number of studies among other general population groups (1 study in Palestine and 0 studies in Syria).</p><p>Overall, these results support our conclusion that HCV prevalence is likely to be below 1% among the population at large in each of the FC countries. It bears notice that our estimate for HCV prevalence in Iraq is substantially lower than that estimated recently using a different methodology in a global study (0.2% in our study versus 3.2% in <italic>Gower et al</italic>. study [<xref rid="pone.0135281.ref022" ref-type="bibr">22</xref>]). The difference in estimates arises from <italic>Gower et al</italic>. [<xref rid="pone.0135281.ref022" ref-type="bibr">22</xref>] basing their estimate on a single study [<xref rid="pone.0135281.ref102" ref-type="bibr">102</xref>] while our pooled prevalence was based on 99 studies, a large fraction of which were identified through our expanded search of data in non-indexed journals.</p><p>Despite the lower prevalence among the population at large, our findings indicate on-going transmission in at least some medical facilities. Exposures to hemodialysis [<xref rid="pone.0135281.ref054" ref-type="bibr">54</xref>, <xref rid="pone.0135281.ref084" ref-type="bibr">84</xref>, <xref rid="pone.0135281.ref094" ref-type="bibr">94</xref>] or blood transfusion [<xref rid="pone.0135281.ref054" ref-type="bibr">54</xref>, <xref rid="pone.0135281.ref122" ref-type="bibr">122</xref>] were cited as risk factors for acquiring HCV. High HCV prevalence was generally observed among hemodialysis and thalassemia patients across countries (<xref rid="pone.0135281.t002" ref-type="table">Table 2</xref>). High sero-conversion risks of up to 40% were found among hemodialysis patients in prospective studies (<xref rid="pone.0135281.t001" ref-type="table">Table 1</xref>). Measurable HCV RNA prevalence among HCV antibody negative clinical populations were documented suggesting recent nosocomial HCV exposures (<xref rid="pone.0135281.s012" ref-type="supplementary-material">S3 Table</xref>). Higher HCV levels (compared to the general population) among health care workers, hospitalized populations, different clinical populations, diabetics, and dental providers were identified suggesting health care related HCV exposures (<xref rid="pone.0135281.s011" ref-type="supplementary-material">S2 Table</xref>). While some of the prevalent HCV exposures may date to times before the enforcement of more stringent blood screening and infection control protocols in these countries, the totality of the evidence supports the conclusion of ongoing transmission in some clinical settings and through medical procedures. These results emphasize the importance of reinforcing blood screening and infection control in health care facilities.</p><p>Other HCV risk factors identified in this review included exposure to infected needles and sharp objects during tattooing and cupping procedures [<xref rid="pone.0135281.ref122" ref-type="bibr">122</xref>]. The latter, also known as <italic>hijama</italic>, is a common practice by community healers in MENA [<xref rid="pone.0135281.ref018" ref-type="bibr">18</xref>, <xref rid="pone.0135281.ref126" ref-type="bibr">126</xref>]. There is also evidence elsewhere in MENA of a wider scope of community related HCV exposures as well as traditions of some professions, such as barbers, administering health care related procedures such as injections [<xref rid="pone.0135281.ref007" ref-type="bibr">7</xref>, <xref rid="pone.0135281.ref018" ref-type="bibr">18</xref>, <xref rid="pone.0135281.ref127" ref-type="bibr">127</xref>]. These findings highlight the relevance of controlling these exposures and insuring the safety of injections. This could be done, for example, by wide-scale replacement of current re-usable syringes with safety-engineered &#x0201c;smart&#x0201d; syringes [<xref rid="pone.0135281.ref128" ref-type="bibr">128</xref>, <xref rid="pone.0135281.ref129" ref-type="bibr">129</xref>].</p><p>The ongoing political and military conflicts in this subregion (Iraq, Palestine, and Syria) introduce more challenges and serious barriers to the implementation of stringent blood screening and infection control in medical facilities and in communities. Shortages of medical supplies and trained human capital in these countries are often exacerbated by intermittent electricity and water supplies making the provision of even basic medical care difficult [<xref rid="pone.0135281.ref042" ref-type="bibr">42</xref>, <xref rid="pone.0135281.ref130" ref-type="bibr">130</xref>&#x02013;<xref rid="pone.0135281.ref132" ref-type="bibr">132</xref>]. Implications of these emergencies on current HCV transmission are unknown.</p><p>Injecting drug use appears to be the dominant driver of HCV incidence in many developed countries [<xref rid="pone.0135281.ref133" ref-type="bibr">133</xref>&#x02013;<xref rid="pone.0135281.ref135" ref-type="bibr">135</xref>]. The estimated population proportion of injecting drug use among the adult population in FC ranges between 0.07% in Syria and 0.35% in Palestine [<xref rid="pone.0135281.ref136" ref-type="bibr">136</xref>]. The population proportion of injecting drug use in MENA as a whole is estimated at 0.24%; in the intermediate range compared to global levels [<xref rid="pone.0135281.ref136" ref-type="bibr">136</xref>]. Our search identified only few studies assessing the status of HCV infection among PWID and other drug users [<xref rid="pone.0135281.ref018" ref-type="bibr">18</xref>, <xref rid="pone.0135281.ref071" ref-type="bibr">71</xref>, <xref rid="pone.0135281.ref089" ref-type="bibr">89</xref>]. These showed HCV prevalence varying between 21% in Syria and 52.8% in Lebanon (<xref rid="pone.0135281.t002" ref-type="table">Table 2</xref>). Relatively low HCV prevalence has been observed among prisoners, a fraction of whom are often drug users, in Iraq (0.6%) [<xref rid="pone.0135281.ref137" ref-type="bibr">137</xref>] and in Lebanon (3.4%) [<xref rid="pone.0135281.ref113" ref-type="bibr">113</xref>]. HCV prevalence among PWID in FC seems thus somewhat lower than that observed in other MENA countries and globally [<xref rid="pone.0135281.ref023" ref-type="bibr">23</xref>, <xref rid="pone.0135281.ref136" ref-type="bibr">136</xref>]. With these overall limited data on HCV among PWID, it is difficult to judge the relative importance of injecting drug use as a driver of HCV incidence and prevalence in FC.</p><p>Migration dynamics within MENA may have played a role in HCV epidemiology in this subregion. This is specially so in relation to the epidemic in Egypt, the country with the largest HCV prevalence worldwide [<xref rid="pone.0135281.ref006" ref-type="bibr">6</xref>, <xref rid="pone.0135281.ref007" ref-type="bibr">7</xref>]. The epidemic in Egypt is almost exclusively dominated by genotype 4 (&#x0003e;90%) [<xref rid="pone.0135281.ref138" ref-type="bibr">138</xref>], which is also a highly prevalent genotype in FC (<xref rid="pone.0135281.t005" ref-type="table">Table 5</xref>). Genotype 4 in MENA appears to have a larger frequency in countries geographically close to Egypt and/or in countries that host or have hosted large migrant labor populations from Egypt [<xref rid="pone.0135281.ref011" ref-type="bibr">11</xref>, <xref rid="pone.0135281.ref012" ref-type="bibr">12</xref>]. Iraq in particular, but also Jordan and Lebanon, have hosted or are currently hosting millions of Egyptian migrant labor [<xref rid="pone.0135281.ref139" ref-type="bibr">139</xref>&#x02013;<xref rid="pone.0135281.ref142" ref-type="bibr">142</xref>]. A large fraction of the labor market in Iraq at some point consisted of Egyptian migrant workers who formed the backbone of the major infrastructure and developmental projects and agricultural sector in this country&#x02014;such as during the era of the Iraq-Iran war [<xref rid="pone.0135281.ref139" ref-type="bibr">139</xref>&#x02013;<xref rid="pone.0135281.ref141" ref-type="bibr">141</xref>]. Movement of Egyptian labor, who often came from rural areas most affected by HCV [<xref rid="pone.0135281.ref007" ref-type="bibr">7</xref>], may have contributed to higher circulation of genotype 4 in host countries, but has had a limited impact on HCV prevalence in these countries. FC countries appear to have some of the lowest HCV prevalence levels globally.</p><p>The Gaza strip, which borders Egypt, seems to be the part of FC most influenced by HCV dynamics in Egypt. The Gaza strip was under Egyptian rule prior to the 1967 Israeli occupation and shares strong historical, cultural, and economic ties with Egypt. With the protracted Israeli siege of Gaza, Egypt has become the main gateway for Gaza residents to the world and the country that provides essential services to the people of Gaza. Gazans often seek medical treatment in Egypt for conditions that cannot be treated in this largely impoverished district. It is probably not surprising therefore that genotype 4 appears to be the dominant genotype in Gaza, and specially so among those with a history of travel, or of receiving medical care, including blood transfusions or surgical operations, in Egypt [<xref rid="pone.0135281.ref118" ref-type="bibr">118</xref>].</p><p>A substantial fraction of genotype 3 infections in FC were observed among PWID, affirming a global link between this genotype and injecting drug use [<xref rid="pone.0135281.ref121" ref-type="bibr">121</xref>, <xref rid="pone.0135281.ref138" ref-type="bibr">138</xref>, <xref rid="pone.0135281.ref143" ref-type="bibr">143</xref>]. Apart from Lebanon, very limited number of genotype 3 infections were identified (<xref rid="pone.0135281.t005" ref-type="table">Table 5</xref>). One reason could be that PWID contribution to HCV incidence is not large in these countries, and/or that genotypes 4 and 1 are the dominant genotypes circulating among PWID. An alternative explanation, and possibly a more plausible one, is that existing studies of genotypes have not yet reached this largely hidden population whose contribution to HCV incidence and prevalence remains poorly understood.</p><p>Lebanon and Syria showed higher genotype diversity with genotype 5 only detected in these countries, and genotype 2 being more prevalent in Lebanon than in the rest of FC (<xref rid="pone.0135281.t005" ref-type="table">Table 5</xref>). These findings are consistent with the large scale emigration rates and diaspora populations of these two countries globally&#x02014;specifically so for Lebanon. Such population movements may provide avenues for genotypes that are prevalent in other parts of the world, say in West Africa and Latin America for genotype 2 [<xref rid="pone.0135281.ref121" ref-type="bibr">121</xref>, <xref rid="pone.0135281.ref141" ref-type="bibr">141</xref>] and South Africa for genotype 5 [<xref rid="pone.0135281.ref121" ref-type="bibr">121</xref>, <xref rid="pone.0135281.ref138" ref-type="bibr">138</xref>], to be introduced into circulation in some of these countries.</p><p>Our systematic review and meta-analyses are limited by the variability in quantity and quality of studies across countries. There were few studies that assessed HCV incidence and some countries did not have sufficient number of prevalence measures in some of the at risk populations to warrant conduct of meta-analyses. With the convenience sampling in most studies, and the country-specific variability in frequency, specific population and geographical location of available data, the estimates may not be representative of the true HCV population prevalence. Data was also limited for some of the specific populations that play an important role in HCV epidemiology, most notably PWID. HCV RNA measures were limited in quantity and were often based on relatively small samples.</p><p>The number of genotyped infections was not large in all countries and available genotype data may not have captured the diversity and true frequency of genotypes across the different at risk populations in each country. For example, there were some differences, though minor, between the genotype frequencies identified here compared to those of two recent studies of global genotype distribution [<xref rid="pone.0135281.ref022" ref-type="bibr">22</xref>, <xref rid="pone.0135281.ref121" ref-type="bibr">121</xref>]. The main source of differences appears to be the inclusion of more studies on HCV genotypes in our review, largely as a consequence of including regional and national databases in our search of non-indexed published literature (<xref rid="pone.0135281.s003" ref-type="supplementary-material">S3</xref> and <xref rid="pone.0135281.s006" ref-type="supplementary-material">S6</xref> Figs).</p><p>Our meta-analyses highlighted heterogeneity in effect size among included studies. This is not unexpected considering the differences in prevalence measures in terms of the specific population studied, sampling methodology and participant recruitment, age-group representation in the sample, year of study, location and assay used [<xref rid="pone.0135281.ref012" ref-type="bibr">12</xref>]. However, due to the relatively small number of outcome measures for each country, we were unable to conduct a meaningful multivariable meta-regression analysis to identify sources of heterogeneity in effect size.</p></sec><sec sec-type="conclusions" id="sec027"><title>Conclusions</title><p>HCV prevalence in the population at large in FC appears to be below 1%, and is tending towards the lower end of the global range. HCV prevalence among high risk populations, such as hemodialysis and thalassemia patients, is considerable and the evidence indicates ongoing HCV transmission in at least some medical facilities. Genotypes 4 and 1 appear to be the most prevalent, and genotype distributions suggest a role for recent migrations in the circulation of different genotypes across national borders. With the limitations in available data, infection levels among PWID and the contribution of this population to HCV incidence and prevalence remain uncertain. The implications of the ongoing military conflicts and ensuing emergencies in FC on current HCV transmission are unknown.</p><p>Further research is needed for a better understanding of the epidemiology of this infection in this MENA subregion. Elucidation of the role of key populations in HCV transmission, such as PWID, is needed. Conduct of nationally-representative population-based surveys to estimate HCV prevalence, delineate spatial variability in prevalence, identify modes of exposure, and assess HCV knowledge and attitudes, as has been done recently in Egypt [<xref rid="pone.0135281.ref006" ref-type="bibr">6</xref>, <xref rid="pone.0135281.ref144" ref-type="bibr">144</xref>&#x02013;<xref rid="pone.0135281.ref148" ref-type="bibr">148</xref>], will enhance our knowledge of the epidemiology of this infection in this part of the world.</p><p>Our findings inform planning of health service provision, articulation of HCV policy guidelines, and implementation of effective HCV programming to reduce HCV transmission and decrease the burden of its associated diseases. Since HCV exposures in FC are linked to specific settings, HCV prevention efforts should be targeted and focus on infection control in clinical settings and harm reduction among PWID. Adoption of the new World Health Organization guidelines for the use of safety-engineered syringes [<xref rid="pone.0135281.ref128" ref-type="bibr">128</xref>, <xref rid="pone.0135281.ref129" ref-type="bibr">129</xref>] can also minimize exposure to HCV and other blood-borne pathogens.</p></sec><sec sec-type="supplementary-material" id="sec028"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0135281.s001"><label>S1 Fig</label><caption><title>Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) checklist.</title><p>(TIF)</p></caption><media xlink:href="pone.0135281.s001.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0135281.s002"><label>S2 Fig</label><caption><title>Data sources and search criteria for systematically reviewing hepatitis C virus (HCV) incidence and prevalence in countries of the Fertile Crescent.</title><p>(TIF)</p></caption><media xlink:href="pone.0135281.s002.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0135281.s003"><label>S3 Fig</label><caption><title>Flow chart of article selection for the systematic review of hepatitis C virus (HCV) genotypes in the Fertile Crescent countries, adapted from the PRISMA 2009 guidelines.</title><p>(TIF)</p></caption><media xlink:href="pone.0135281.s003.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0135281.s004"><label>S4 Fig</label><caption><title>Definitions and risk classification of populations identified through the systematic review.</title><p>(TIF)</p></caption><media xlink:href="pone.0135281.s004.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0135281.s005"><label>S5 Fig</label><caption><title>Description of quality assessment criteria and studies&#x02019; risk of bias (ROB) appraisal.</title><p>(TIF)</p></caption><media xlink:href="pone.0135281.s005.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0135281.s006"><label>S6 Fig</label><caption><title>Distribution of hepatitis C virus (HCV) genotypes and subtypes among HCV RNA positive individuals across countries of the Fertile Crescent.</title><p>Data on individuals infected with multiple HCV genotypes was only available for Iraq, Lebanon and Palestine.</p><p>(TIF)</p></caption><media xlink:href="pone.0135281.s006.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0135281.s007"><label>S7 Fig</label><caption><title>Forest plot presenting the results of the meta-analysis of hepatitis C virus (HCV) prevalence measures among the general population in Iraq.</title><p>(TIF)</p></caption><media xlink:href="pone.0135281.s007.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0135281.s008"><label>S8 Fig</label><caption><title>Forest plots presenting the results of the meta-analyses of hepatitis C virus (HCV) prevalence measures among the general population in: A) Jordan, B) Lebanon, and C) Syria.</title><p>(TIF)</p></caption><media xlink:href="pone.0135281.s008.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0135281.s009"><label>S9 Fig</label><caption><title>Forest plot presenting the results of the meta-analysis of hepatitis C virus (HCV) prevalence measures among the general population in Palestine.</title><p>(TIF)</p></caption><media xlink:href="pone.0135281.s009.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0135281.s010"><label>S1 Table</label><caption><title>Lists of variables extracted from relevant reports with hepatitis C virus (HCV) incidence and/or prevalence information or with HCV genotype information.</title><p>(DOCX)</p></caption><media xlink:href="pone.0135281.s010.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0135281.s011"><label>S2 Table</label><caption><title>Studies reporting hepatitis C virus (HCV) prevalence among populations at intermediate risk, special clinical populations, and mixed populations in countries of the Fertile Crescent.</title><p>(DOCX)</p></caption><media xlink:href="pone.0135281.s011.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0135281.s012"><label>S3 Table</label><caption><title>Studies reporting hepatitis C virus (HCV) RNA prevalence in countries of the Fertile Crescent.</title><p>(DOCX)</p></caption><media xlink:href="pone.0135281.s012.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0135281.s013"><label>S4 Table</label><caption><title>Summary of precision and risk of bias assessment for hepatitis C virus (HCV) incidence and prevalence measures extracted from eligible reports.</title><p>(DOCX)</p></caption><media xlink:href="pone.0135281.s013.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0135281.s014"><label>S5 Table</label><caption><title>Precision and risk of bias (ROB) assessment for individual hepatitis C virus (HCV) incidence measures in countries of the Fertile Crescent.</title><p>(DOCX)</p></caption><media xlink:href="pone.0135281.s014.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0135281.s015"><label>S6 Table</label><caption><title>Precision and risk of bias (ROB) assessment for individual hepatitis C virus (HCV) prevalence measures among populations at high risk in countries of the Fertile Crescent.</title><p>(DOCX)</p></caption><media xlink:href="pone.0135281.s015.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0135281.s016"><label>S7 Table</label><caption><title>Precision and risk of bias (ROB) assessment for individual hepatitis C virus (HCV) prevalence measures among the general population in countries of the Fertile Crescent.</title><p>(DOCX)</p></caption><media xlink:href="pone.0135281.s016.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0135281.s017"><label>S8 Table</label><caption><title>Precision and risk of bias (ROB) assessment of individual hepatitis C virus (HCV) prevalence measures among populations at intermediate risk and among special clinical populations in countries of the Fertile Crescent.</title><p>(DOCX)</p></caption><media xlink:href="pone.0135281.s017.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>The authors would like to thank Dr. Jane Messina for providing us with information on HCV genotypes.</p></ack><ref-list><title>References</title><ref id="pone.0135281.ref001"><label>1</label><mixed-citation publication-type="journal">
<name><surname>Mohd</surname><given-names>Hanafiah K</given-names></name>, <name><surname>Groeger</surname><given-names>J</given-names></name>, <name><surname>Flaxman</surname><given-names>AD</given-names></name>, <name><surname>Wiersma</surname><given-names>ST</given-names></name>. <article-title>Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence</article-title>. <source>Hepatology</source>. <year>2013</year>;<volume>57</volume>(<issue>4</issue>):<fpage>1333</fpage>&#x02013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1002/hep.26141</pub-id>
.<?supplied-pmid 23172780?><pub-id pub-id-type="pmid">23172780</pub-id></mixed-citation></ref><ref id="pone.0135281.ref002"><label>2</label><mixed-citation publication-type="journal">
<name><surname>Lavanchy</surname><given-names>D</given-names></name>. <article-title>Evolving epidemiology of hepatitis C virus</article-title>. <source>Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases</source>. <year>2011</year>;<volume>17</volume>(<issue>2</issue>):<fpage>107</fpage>&#x02013;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1111/j.1469-0691.2010.03432.x</pub-id>
.<?supplied-pmid 21091831?><pub-id pub-id-type="pmid">21091831</pub-id></mixed-citation></ref><ref id="pone.0135281.ref003"><label>3</label><mixed-citation publication-type="other">World Health Organization. Hepatitis C: fact sheet Geneva, Switzerland [updated April 2014; cited 2015 02/02]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/mediacentre/factsheets/fs164/en/">http://www.who.int/mediacentre/factsheets/fs164/en/</ext-link>.</mixed-citation></ref><ref id="pone.0135281.ref004"><label>4</label><mixed-citation publication-type="other">Centers for Disease Control and Prevention. Hepatitis C Atlanta, USA [updated August 1, 2013; cited 2015 02/02]. Available from: <ext-link ext-link-type="uri" xlink:href="http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-3-infectious-diseases-related-to-travel/hepatitis-c">http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-3-infectious-diseases-related-to-travel/hepatitis-c</ext-link>.</mixed-citation></ref><ref id="pone.0135281.ref005"><label>5</label><mixed-citation publication-type="other">A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection from The Liver Meeting 2013: The 64th Annual Meeting of the American Association for the Study of Liver DiseasesNovember 1&#x02013;5, 2013 &#x02022; Washington DCSpecial Reporting on:&#x02022; Simeprevir plus Sofosbuvir with or without Ribavirin Produces High SVR Rates in Genotype 1 HCV Infection&#x02022; Novel Interferon- and Ribavirin-Free Regimen Results in SVR12 Rates of Over 90% in HCV Genotype 1b Infection&#x02022; Studies Confirm Efficacy of Adjunctive Simeprevir in Difficult-to-Treat HCV Genotype 1 Subpopulations&#x02022; All-Oral Therapy with Sofosbuvir Plus Ribavirin Produces High SVR Rates in Patients Coinfected with HCV and HIV&#x02022; Faldaprevir Combined with Pegylated Interferon and Ribavirin Demonstrates High Efficacy in DifficuIt-to-Treat HCV Infection&#x02022; Once Daily Sofosbuvir/Ledipasvir Combination Elicits Rapid Decline in HCV RNA Gastroenterology &#x00026; Hepatology. 2014;10(1 Suppl 1):1&#x02013;19.</mixed-citation></ref><ref id="pone.0135281.ref006"><label>6</label><mixed-citation publication-type="book">
<name><surname>El-Zanaty</surname><given-names>F</given-names></name>, <name><surname>Way</surname><given-names>A</given-names></name>. <chapter-title>Egypt Demographic and Health Survey 2008</chapter-title>
<publisher-loc>Cairo</publisher-loc>: <publisher-name>Egyptian Ministry of Health</publisher-name>, <publisher-name>National Population Council</publisher-name>, <publisher-name>El-Zanaty and Associates</publisher-name>, and <publisher-name>ORC Macro</publisher-name>; <year>2009</year>. 431 p.</mixed-citation></ref><ref id="pone.0135281.ref007"><label>7</label><mixed-citation publication-type="journal">
<name><surname>Mohamoud</surname><given-names>YA</given-names></name>, <name><surname>Mumtaz</surname><given-names>GR</given-names></name>, <name><surname>Riome</surname><given-names>S</given-names></name>, <name><surname>Miller</surname><given-names>D</given-names></name>, <name><surname>Abu-Raddad</surname><given-names>LJ</given-names></name>. <article-title>The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis</article-title>. <source>BMC infectious diseases</source>. <year>2013</year>;<volume>13</volume>:<fpage>288</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2334-13-288</pub-id>
<?supplied-pmid 23799878?><pub-id pub-id-type="pmid">23799878</pub-id></mixed-citation></ref><ref id="pone.0135281.ref008"><label>8</label><mixed-citation publication-type="journal">
<name><surname>Qureshi</surname><given-names>H</given-names></name>, <name><surname>Bile</surname><given-names>KM</given-names></name>, <name><surname>Jooma</surname><given-names>R</given-names></name>, <name><surname>Alam</surname><given-names>SE</given-names></name>, <name><surname>Afridi</surname><given-names>HU</given-names></name>. <article-title>Prevalence of hepatitis B and C viral infections in Pakistan: findings of a national survey appealing for effective prevention and control measures</article-title>. <source>Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit</source>. <year>2010</year>;<volume>16</volume>
<issue>Suppl</issue>:<fpage>S15</fpage>&#x02013;<lpage>23</lpage>. .<?supplied-pmid 21495584?><pub-id pub-id-type="pmid">21495584</pub-id></mixed-citation></ref><ref id="pone.0135281.ref009"><label>9</label><mixed-citation publication-type="journal">
<name><surname>Umar</surname><given-names>M</given-names></name>, <name><surname>Bushra</surname><given-names>HT</given-names></name>, <name><surname>Ahmad</surname><given-names>M</given-names></name>, <name><surname>Data</surname><given-names>A</given-names></name>, <name><surname>Ahmad</surname><given-names>M</given-names></name>, <name><surname>Khurram</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Hepatitis C in Pakistan: a review of available data</article-title>. <source>Hepatitis monthly</source>. <year>2010</year>;<volume>10</volume>(<issue>3</issue>):<fpage>205</fpage>&#x02013;<lpage>14</lpage>. <?supplied-pmid 22308140?><pub-id pub-id-type="pmid">22308140</pub-id></mixed-citation></ref><ref id="pone.0135281.ref010"><label>10</label><mixed-citation publication-type="journal">
<name><surname>Chaabna</surname><given-names>K</given-names></name>, <name><surname>Mohamoud</surname><given-names>YA</given-names></name>, <name><surname>Chemaitelly</surname><given-names>H</given-names></name>, <name><surname>Mumtaz</surname><given-names>GR</given-names></name>, <name><surname>Abu-Raddad</surname><given-names>LJ</given-names></name>. <article-title>Protocol for a systematic review and meta-analysis of hepatitis C virus (HCV) prevalence and incidence in the Horn of Africa sub-region of the Middle East and North Africa</article-title>. <source>Systematic reviews</source>. <year>2014</year>;<volume>3</volume>:<fpage>146</fpage> Epub 2014/12/18. <pub-id pub-id-type="doi">10.1186/2046-4053-3-146</pub-id>
<?supplied-pmid 25516265?><pub-id pub-id-type="pmid">25516265</pub-id></mixed-citation></ref><ref id="pone.0135281.ref011"><label>11</label><mixed-citation publication-type="other">Mohamoud YA, Riome S, Abu-Raddad LJ. The epidemiology of hepatitis C virus in the Arabian Gulf countries: Systematic review and meta-analyses (under preparation). 2015.</mixed-citation></ref><ref id="pone.0135281.ref012"><label>12</label><mixed-citation publication-type="journal">
<name><surname>Fadlalla</surname><given-names>FA</given-names></name>, <name><surname>Mohamoud</surname><given-names>YA</given-names></name>, <name><surname>Mumtaz</surname><given-names>GR</given-names></name>, <name><surname>Abu-Raddad</surname><given-names>LJ</given-names></name>. <article-title>The epidemiology of hepatitis C virus in the maghreb region: systematic review and meta-analyses</article-title>. <source>PloS one</source>. <year>2015</year>;<volume>10</volume>(<issue>3</issue>):<fpage>e0121873</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0121873</pub-id>
<?supplied-pmid 25803848?><pub-id pub-id-type="pmid">25803848</pub-id></mixed-citation></ref><ref id="pone.0135281.ref013"><label>13</label><mixed-citation publication-type="other">Chaabna K., Kouyoumjian S., Abu-Raddad LJ. Hepatitis C virus prevalence and incidence in the Horn of Africa sub-region of the Middle East and North Africa: Systematic review and meta-analysis (under preparation). 2015.</mixed-citation></ref><ref id="pone.0135281.ref014"><label>14</label><mixed-citation publication-type="other">Chemaitelly H, Mahmud S, Abu-Raddad LJ. The epidemiology of hepatitis C in Afghanistan: Systematic review and meta-analyses (under preparation). 2015.</mixed-citation></ref><ref id="pone.0135281.ref015"><label>15</label><mixed-citation publication-type="other">Mahmud S, Akbarzadeh V, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Iran: Systematic review and meta-analyses (under preparation). 2015.</mixed-citation></ref><ref id="pone.0135281.ref016"><label>16</label><mixed-citation publication-type="journal">
<name><surname>Moher</surname><given-names>D</given-names></name>, <name><surname>Liberati</surname><given-names>A</given-names></name>, <name><surname>Tetzlaff</surname><given-names>J</given-names></name>, <name><surname>Altman</surname><given-names>DG</given-names></name>, <name><surname>Group</surname><given-names>P</given-names></name>. <article-title>Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement</article-title>. <source>PLoS medicine</source>. <year>2009</year>;<volume>6</volume>(<issue>7</issue>):<fpage>e1000097</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pmed.1000097</pub-id>
<?supplied-pmid 19621072?><pub-id pub-id-type="pmid">19621072</pub-id></mixed-citation></ref><ref id="pone.0135281.ref017"><label>17</label><mixed-citation publication-type="other">Chaabna K, Mohamoud YA, Chemaitelly H, Mumtaz GR, Abu-Raddad LJ. Protocol for a systematic review and meta-analysis of hepatitis C virus (HCV) prevalence and incidence in The Horn of Africa sub-region of the Middle East and North Africa. 2014. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.crd.york.ac.uk/NIHR_PROSPERO/display_record.asp?ID=CRD42014010318#.VRpKHuEQuCd">http://www.crd.york.ac.uk/NIHR_PROSPERO/display_record.asp?ID=CRD42014010318#.VRpKHuEQuCd</ext-link> 2014.</mixed-citation></ref><ref id="pone.0135281.ref018"><label>18</label><mixed-citation publication-type="book">
<name><surname>Abu-Raddad</surname><given-names>L</given-names></name>, <name><surname>Akala</surname><given-names>FA</given-names></name>, <name><surname>Semini</surname><given-names>I</given-names></name>, <name><surname>Riedner</surname><given-names>G</given-names></name>, <name><surname>Wilson</surname><given-names>D</given-names></name>, <name><surname>Tawil</surname><given-names>O</given-names></name>. <chapter-title>Characterizing the HIV/AIDS epidemic in the Middle East and North Africa: Time for strategic action</chapter-title> World Bank/UNAIDS/WHO Publication, editor. <publisher-loc>Washington DC</publisher-loc>: <publisher-name>The World Bank Press</publisher-name>; <year>2010</year>.</mixed-citation></ref><ref id="pone.0135281.ref019"><label>19</label><mixed-citation publication-type="journal">
<name><surname>Abu-Raddad</surname><given-names>LJ</given-names></name>, <name><surname>Hilmi</surname><given-names>N</given-names></name>, <name><surname>Mumtaz</surname><given-names>G</given-names></name>, <name><surname>Benkirane</surname><given-names>M</given-names></name>, <name><surname>Akala</surname><given-names>FA</given-names></name>, <name><surname>Riedner</surname><given-names>G</given-names></name>, <etal>et al</etal>
<article-title>Epidemiology of HIV infection in the Middle East and North Africa</article-title>. <source>AIDS (London, England)</source>. <year>2010</year>;<volume>24</volume>
<issue>Suppl 2</issue>:<fpage>S5</fpage>&#x02013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1097/01.aids.0000386729.56683.33</pub-id>
.<?supplied-pmid 20610949?><pub-id pub-id-type="pmid">20610949</pub-id></mixed-citation></ref><ref id="pone.0135281.ref020"><label>20</label><mixed-citation publication-type="journal">
<name><surname>Choo</surname><given-names>QL</given-names></name>, <name><surname>Kuo</surname><given-names>G</given-names></name>, <name><surname>Weiner</surname><given-names>AJ</given-names></name>, <name><surname>Overby</surname><given-names>LR</given-names></name>, <name><surname>Bradley</surname><given-names>DW</given-names></name>, <name><surname>Houghton</surname><given-names>M</given-names></name>. <article-title>Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome</article-title>. <source>Science</source>. <year>1989</year>;<volume>244</volume>(<issue>4902</issue>):<fpage>359</fpage>&#x02013;<lpage>62</lpage>. .<?supplied-pmid 2523562?><pub-id pub-id-type="pmid">2523562</pub-id></mixed-citation></ref><ref id="pone.0135281.ref021"><label>21</label><mixed-citation publication-type="journal">
<name><surname>Kuo</surname><given-names>G</given-names></name>, <name><surname>Choo</surname><given-names>QL</given-names></name>, <name><surname>Alter</surname><given-names>HJ</given-names></name>, <name><surname>Gitnick</surname><given-names>GL</given-names></name>, <name><surname>Redeker</surname><given-names>AG</given-names></name>, <name><surname>Purcell</surname><given-names>RH</given-names></name>, <etal>et al</etal>
<article-title>An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis</article-title>. <source>Science</source>. <year>1989</year>;<volume>244</volume>(<issue>4902</issue>):<fpage>362</fpage>&#x02013;<lpage>4</lpage>. .<?supplied-pmid 2496467?><pub-id pub-id-type="pmid">2496467</pub-id></mixed-citation></ref><ref id="pone.0135281.ref022"><label>22</label><mixed-citation publication-type="journal">
<name><surname>Gower</surname><given-names>E</given-names></name>, <name><surname>Estes</surname><given-names>C</given-names></name>, <name><surname>Blach</surname><given-names>S</given-names></name>, <name><surname>Razavi-Shearer</surname><given-names>K</given-names></name>, <name><surname>Razavi</surname><given-names>H</given-names></name>. <article-title>Global epidemiology and genotype distribution of the hepatitis C virus infection</article-title>. <source>J Hepatol</source>. <year>2014</year>;<volume>61</volume>(<issue>1</issue> Suppl):<fpage>S45</fpage>&#x02013;<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1016/j.jhep.2014.07.027</pub-id>
.<?supplied-pmid 25086286?><pub-id pub-id-type="pmid">25086286</pub-id></mixed-citation></ref><ref id="pone.0135281.ref023"><label>23</label><mixed-citation publication-type="journal">
<name><surname>Nelson</surname><given-names>PK</given-names></name>, <name><surname>Mathers</surname><given-names>BM</given-names></name>, <name><surname>Cowie</surname><given-names>B</given-names></name>, <name><surname>Hagan</surname><given-names>H</given-names></name>, <name><surname>Des Jarlais</surname><given-names>D</given-names></name>, <name><surname>Horyniak</surname><given-names>D</given-names></name>, <etal>et al</etal>
<article-title>Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews</article-title>. <source>Lancet</source>. <year>2011</year>;<volume>378</volume>(<issue>9791</issue>):<fpage>571</fpage>&#x02013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(11)61097-0</pub-id>
<?supplied-pmid 21802134?><pub-id pub-id-type="pmid">21802134</pub-id></mixed-citation></ref><ref id="pone.0135281.ref024"><label>24</label><mixed-citation publication-type="book">
<collab>The Cochrane collaboration</collab>. <chapter-title>Cochrane handbook for systematic reviews of interventions</chapter-title>
<publisher-loc>Hoboken (New Jersey)</publisher-loc>: <publisher-name>Wiley-Blackweill</publisher-name>; <year>2008</year>.</mixed-citation></ref><ref id="pone.0135281.ref025"><label>25</label><mixed-citation publication-type="journal">
<name><surname>Freeman</surname><given-names>MF</given-names></name>, <name><surname>Tukey</surname><given-names>JW</given-names></name>. <article-title>Transformations Related to the Angular and the Square Root</article-title>. <source>Ann Math Statist</source>. <year>1950</year>;<volume>21</volume>(<issue>4</issue>):<fpage>607</fpage>&#x02013;<lpage>11</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref026"><label>26</label><mixed-citation publication-type="journal">
<name><surname>Neyeloff</surname><given-names>JL</given-names></name>, <name><surname>Fuchs</surname><given-names>SC</given-names></name>, <name><surname>Moreira</surname><given-names>LB</given-names></name>. <article-title>Meta-analyses and Forest plots using a microsoft excel spreadsheet: step-by-step guide focusing on descriptive data analysis</article-title>. <source>BMC research notes</source>. <year>2012</year>;<volume>5</volume>:<fpage>52</fpage> Epub 2012/01/24. <pub-id pub-id-type="doi">10.1186/1756-0500-5-52</pub-id>
<?supplied-pmid 22264277?><pub-id pub-id-type="pmid">22264277</pub-id></mixed-citation></ref><ref id="pone.0135281.ref027"><label>27</label><mixed-citation publication-type="book">
<name><surname>Borenstein</surname><given-names>M</given-names></name>. <chapter-title>Introduction to meta-analysis</chapter-title>
<publisher-loc>Chichester, U.K.</publisher-loc>: <publisher-name>John Wiley &#x00026; Sons</publisher-name>; <year>2009</year>
<volume>xxviii</volume>, 421 p. p.</mixed-citation></ref><ref id="pone.0135281.ref028"><label>28</label><mixed-citation publication-type="journal">
<name><surname>Higgins</surname><given-names>J</given-names></name>, <name><surname>Thompson</surname><given-names>S</given-names></name>, <name><surname>Deeks</surname><given-names>J</given-names></name>, <name><surname>Altman</surname><given-names>D</given-names></name>. <article-title>Measuring inconsistency in meta-analyses</article-title>. <source>BMJ (Clinical research ed)</source>. <year>2003</year>;<volume>327</volume>:<fpage>557</fpage>&#x02013;<lpage>60</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref029"><label>29</label><mixed-citation publication-type="journal">
<name><surname>Shannon</surname><given-names>CE</given-names></name>. <article-title>The mathematical theory of communication. 1963</article-title>. <source>MD computing: computers in medical practice</source>. <year>1997</year>;<volume>14</volume>(<issue>4</issue>):<fpage>306</fpage>&#x02013;<lpage>17</lpage>. .<?supplied-pmid 9230594?><pub-id pub-id-type="pmid">9230594</pub-id></mixed-citation></ref><ref id="pone.0135281.ref030"><label>30</label><mixed-citation publication-type="book">
<collab>IBM Corporation</collab>. <chapter-title>IBM SPSS Statistics for Windows, Version 22.0</chapter-title>
<publisher-loc>Armonk, New York</publisher-loc>: <publisher-name>IBM Corporation</publisher-name>; <year>2013</year>.</mixed-citation></ref><ref id="pone.0135281.ref031"><label>31</label><mixed-citation publication-type="other">R Core Team. R 3.1.2: A language and environment for statistical computing. Vienna, Austria2014.</mixed-citation></ref><ref id="pone.0135281.ref032"><label>32</label><mixed-citation publication-type="other">Additional country-level data provided through the MENA HIV/AIDS Epidemiology Synthesis Project database by the World Health Organization Regional Office for the Eastern Mediterranean. 2014.</mixed-citation></ref><ref id="pone.0135281.ref033"><label>33</label><mixed-citation publication-type="other">Palestinian Health Information Center. Health Annual Report 2013. URL: <ext-link ext-link-type="uri" xlink:href="http://www.moh.ps/?lang=1&#x00026;page=4&#x00026;id=939">http://www.moh.ps/?lang=1&#x00026;page=4&#x00026;id=939</ext-link>: 2014.</mixed-citation></ref><ref id="pone.0135281.ref034"><label>34</label><mixed-citation publication-type="other">Palestinian Health Information Center. Health Annual Report 2009. URL: <ext-link ext-link-type="uri" xlink:href="http://www.moh.ps/?lang=1&#x00026;page=4&#x00026;id=150">http://www.moh.ps/?lang=1&#x00026;page=4&#x00026;id=150</ext-link>: 2010.</mixed-citation></ref><ref id="pone.0135281.ref035"><label>35</label><mixed-citation publication-type="other">Palestinian Health Information Center. Health Annual Report 2007. URL: <ext-link ext-link-type="uri" xlink:href="http://www.moh.ps/?lang=1&#x00026;page=4&#x00026;id=139">http://www.moh.ps/?lang=1&#x00026;page=4&#x00026;id=139</ext-link>: 2008.</mixed-citation></ref><ref id="pone.0135281.ref036"><label>36</label><mixed-citation publication-type="other">Palestinian Health Information Center. Health Annual Report 2006. URL: <ext-link ext-link-type="uri" xlink:href="http://www.moh.ps/?lang=1&#x00026;page=4&#x00026;id=142">http://www.moh.ps/?lang=1&#x00026;page=4&#x00026;id=142</ext-link>: 2007.</mixed-citation></ref><ref id="pone.0135281.ref037"><label>37</label><mixed-citation publication-type="other">Palestinian Health Information Center. Health Annual Report 2005. URL: <ext-link ext-link-type="uri" xlink:href="http://www.moh.ps/?lang=1&#x00026;page=4&#x00026;id=9">http://www.moh.ps/?lang=1&#x00026;page=4&#x00026;id=9</ext-link>: 2006.</mixed-citation></ref><ref id="pone.0135281.ref038"><label>38</label><mixed-citation publication-type="other">Palestinian Health Information Center. Health Annual Report 2003. URL: <ext-link ext-link-type="uri" xlink:href="http://www.moh.ps/?lang=1&#x00026;page=4&#x00026;id=137">http://www.moh.ps/?lang=1&#x00026;page=4&#x00026;id=137</ext-link>: 2004.</mixed-citation></ref><ref id="pone.0135281.ref039"><label>39</label><mixed-citation publication-type="journal">
<name><surname>Batieha</surname><given-names>A</given-names></name>, <name><surname>Abdallah</surname><given-names>S</given-names></name>, <name><surname>Maghaireh</surname><given-names>M</given-names></name>, <name><surname>Awad</surname><given-names>Z</given-names></name>, <name><surname>Al-Akash</surname><given-names>N</given-names></name>, <name><surname>Batieneh</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Epidemiology and cost of haemodialysis in Jordan</article-title>. <source>Eastern Mediterranean Health Journal</source>. <year>2007</year>;<volume>13</volume>(<issue>3</issue>):<fpage>654</fpage>&#x02013;<lpage>63</lpage>. .<?supplied-pmid 2007356348?><pub-id pub-id-type="pmid">17687839</pub-id></mixed-citation></ref><ref id="pone.0135281.ref040"><label>40</label><mixed-citation publication-type="journal">
<name><surname>Al-Rubaie</surname><given-names>H</given-names></name>. <string-name>MH</string-name>., <name><surname>Malik</surname><given-names>A.S</given-names></name>. <article-title>Seroconversion rate of hepatitis C virus infection among haemodialysis patients in Al-Kadhimiya Teaching Hospital (dialysis unit)</article-title>. <source>Iraqi Journal of Medical Sciences</source>. <year>2011</year>;<volume>9</volume>(<issue>4</issue>):<fpage>343</fpage>&#x02013;<lpage>9</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref041"><label>41</label><mixed-citation publication-type="journal">
<name><surname>Al-Ali</surname><given-names>N</given-names></name>. <string-name>AA</string-name>., <name><surname>AL-Kayatt</surname><given-names>T. N</given-names></name>. <article-title>Seroprevalence of hepatitis B &#x00026; C in pediatric malignancies</article-title>. <source>Iraqi Postgraduate Medical Journal</source>. <year>2014</year>;<volume>13</volume>(<issue>2</issue>):<fpage>262</fpage>&#x02013;<lpage>7</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref042"><label>42</label><mixed-citation publication-type="journal">
<name><surname>Al-Jadiry</surname><given-names>M</given-names></name>. <article-title>Viral hepatitis markers screen in children with acute lymphoblastic leukemia experience of Children Welfare Teaching Hospital</article-title>. <source>Journal of the Faculty of Medicine of Baghdad</source>. <year>2008</year>;<volume>50</volume>(<issue>2</issue>):<fpage>223</fpage>&#x02013;<lpage>30</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref043"><label>43</label><mixed-citation publication-type="journal">
<name><surname>Al-Ani</surname><given-names>M. H.</given-names></name>, <name><surname>Rasul</surname><given-names>T. H</given-names></name>. <article-title>Hepatitis B and C viral infections in children with acute leukemia in Erbil city</article-title>. <source>Journal of the Arab Board of Health Specializations</source>. <year>2011</year>;<volume>12</volume>(<issue>1</issue>):<fpage>21</fpage>&#x02013;<lpage>9</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref044"><label>44</label><mixed-citation publication-type="journal">
<name><surname>Al-Kubaisy</surname><given-names>W. A.</given-names></name>, <name><surname>Niazi</surname><given-names>A.</given-names></name>, <name><surname>Kubba</surname><given-names>K</given-names></name>. <article-title>Lack of mother-to-newborn transmission of hepatitis C virus in Iraqi women: a prospective study with hepatitis C virus RNA testing</article-title>. <source>Journal of the Arab Board of Health Specializations</source>. <year>2000</year>;<volume>2</volume>(<issue>2</issue>).</mixed-citation></ref><ref id="pone.0135281.ref045"><label>45</label><mixed-citation publication-type="journal">
<name><surname>Al-Kubaisy</surname><given-names>WA</given-names></name>, <name><surname>Al-Naib</surname><given-names>KT</given-names></name>, <name><surname>Habib</surname><given-names>M</given-names></name>. <article-title>Seroprevalence of hepatitis C virus specific antibodies among Iraqi children with thalassaemia</article-title>. <source>Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit</source>. <year>2006</year>;<volume>12</volume>(<issue>1&#x02013;2</issue>):<fpage>204</fpage>&#x02013;<lpage>10</lpage>. Epub 2006/10/14. .<?supplied-pmid 17037239?><pub-id pub-id-type="pmid">17037239</pub-id></mixed-citation></ref><ref id="pone.0135281.ref046"><label>46</label><mixed-citation publication-type="journal">
<name><surname>Abdul-Aziz</surname><given-names>M</given-names></name>, <name><surname>Abdul-Karem</surname><given-names>K</given-names></name>, <name><surname>Shamse-El-Den</surname><given-names>S</given-names></name>, <name><surname>Al-Moula</surname><given-names>GA</given-names></name>. <article-title>Prevalence of hepatitis B &#x00026; C among people attending Kirkuk Public Health Laboratory</article-title>. <source>Al-Taqani</source>. <year>2001</year>;<volume>23</volume>(<issue>3</issue>):<fpage>6</fpage>&#x02013;<lpage>15</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref047"><label>47</label><mixed-citation publication-type="journal">
<name><surname>Abdullah</surname><given-names>B. A.</given-names></name>, <name><surname>Khaled</surname><given-names>M. D.</given-names></name>, <name><surname>Maarouf</surname><given-names>M. N</given-names></name>. <article-title>Detection of hepatitis C virus (HCV) by ELISA, RIBA and Reverse Transcriptase- Polymerase Chain Reaction (RT-PCR) technique among kidney dialysis patients in Nineveh governorate/Iraq</article-title>. <source>Science Journal of Thi-Qar</source>
<year>2012</year>;<volume>3</volume>(<issue>2</issue>):<fpage>55</fpage>&#x02013;<lpage>67</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref048"><label>48</label><mixed-citation publication-type="journal">
<name><surname>Abdullah</surname><given-names>AM</given-names></name>, <name><surname>Hardan</surname><given-names>A</given-names></name>, <name><surname>Latif</surname><given-names>II</given-names></name>. <article-title>Genotyping of hepatitis C virus isolates from Iraqi hemodialysis patients by reverse transcription-PCR and one step nested RT-PCR</article-title>. <source>Diyala Journal of Medicine</source>. <year>2012</year>;<volume>3</volume>(<issue>1</issue>):<fpage>9</fpage>&#x02013;<lpage>18</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref049"><label>49</label><mixed-citation publication-type="journal">
<name><surname>Al-Dulaimi</surname><given-names>S. B. K.</given-names></name>, <name><surname>Al-Ubadi</surname><given-names>A. E.</given-names></name>, <name><surname>Al-Ubadi</surname><given-names>A. E.</given-names></name>, <name><surname>Al-Bayatti</surname><given-names>E. N.</given-names></name>, <name><surname>Al-Saday</surname><given-names>S. D. K</given-names></name>. <article-title>Toxoplasma gondii, HCV, and HBV seroprevalence in Haemodialysis patients with chronic renal failure in Al-Kindy Hospital Baghdad, Iraqi</article-title>. <source>Al-Mustansiriyah Journal of Science</source>. <year>2012</year>;<volume>23</volume>(<issue>5</issue>):<fpage>33</fpage>&#x02013;<lpage>8</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref050"><label>50</label><mixed-citation publication-type="journal">
<name><surname>Al-Mashhadani</surname><given-names>JI</given-names></name>. <article-title>Hepatitis C virus infection among haemodialysis patients in Al-Anbar governorate</article-title>. <source>Iraqi Journal of Community Medicine</source>. <year>2007</year>;<volume>20</volume>(<issue>1</issue>):<fpage>20</fpage>&#x02013;<lpage>3</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref051"><label>51</label><mixed-citation publication-type="journal">
<name><surname>Khattab</surname><given-names>OS</given-names></name>. <article-title>Prevalence and risk factors for hepatitis C virus infection in hemodialysis patients in an Iraqi renal transplant center</article-title>. <source>Saudi journal of kidney diseases and transplantation: an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia</source>. <year>2008</year>;<volume>19</volume>(<issue>1</issue>):<fpage>110</fpage>&#x02013;<lpage>5</lpage>. Epub 2007/12/19. .<?supplied-pmid 18087139?><pub-id pub-id-type="pmid">18087139</pub-id></mixed-citation></ref><ref id="pone.0135281.ref052"><label>52</label><mixed-citation publication-type="journal">
<name><surname>Khattab</surname><given-names>O. S</given-names></name>. <article-title>How to decrease the prevalence of hepatitis C in Iraqi hemodialysis patients</article-title>. <source>The Iraqi Postgraduate Medical Journal</source>. <year>2010</year>;<volume>9</volume>(<issue>1</issue>):<fpage>31</fpage>&#x02013;<lpage>5</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref053"><label>53</label><mixed-citation publication-type="journal">
<name><surname>Mnuti</surname><given-names>J. K.</given-names></name>, <name><surname>Al-Abbudi</surname><given-names>F. A</given-names></name>. <article-title>Hepatitis C virus infection assessment among chronic hemodialysis patients in Al-Kadhmiya Teaching Hospital</article-title>. <source>Iraqi Postgraduate Medical Journal</source>. <year>2011</year>;<volume>10</volume>(<issue>4</issue>):<fpage>460</fpage>&#x02013;<lpage>4</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref054"><label>54</label><mixed-citation publication-type="journal">
<name><surname>Ramzi</surname><given-names>Z. S.</given-names></name>, <name><surname>Abdulla</surname><given-names>A. A.</given-names></name>, <name><surname>Al-Hadithi</surname><given-names>T.</given-names></name>, <name><surname>Al-Tawil</surname><given-names>N</given-names></name>. <article-title>Prevalence and risk factors for hepatitis C virus infection in hemodialysis patients in Sulaimani</article-title>. <source>Zanco Journal of Medical Sciences</source>. <year>2010</year>;<volume>14</volume>(<issue>1</issue>):<fpage>44</fpage>&#x02013;<lpage>50</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref055"><label>55</label><mixed-citation publication-type="journal">
<name><surname>Shihab</surname><given-names>SS</given-names></name>, <name><surname>Al-Hmudi</surname><given-names>HA</given-names></name>, <name><surname>Al-Edani</surname><given-names>HS</given-names></name>, <name><surname>Mahdi</surname><given-names>KH</given-names></name>. <article-title>Viral hepatitis infections in Basrah haemodialysis unit: serological diagnosis and viral loading</article-title>. <source>European Journal of Experimental Biology</source>. <year>2014</year>;<volume>4</volume>(<issue>2</issue>):<fpage>106</fpage>&#x02013;<lpage>12</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref056"><label>56</label><mixed-citation publication-type="journal">
<name><surname>Al-Beldawi</surname><given-names>D. H</given-names></name>. <article-title>The risk factors of inhibitor development and hepatitis C virus among hemophilic patients in Children Welfare Teaching Hospital</article-title>. <source>Journal of the Faculty of Medicine of Baghdad</source>. <year>2010</year>;<volume>52</volume>(<issue>1</issue>):<fpage>4</fpage>&#x02013;<lpage>8</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref057"><label>57</label><mixed-citation publication-type="journal">
<name><surname>Al-Thwani</surname><given-names>A. N.</given-names></name>, <name><surname>Al-Yassiri</surname><given-names>A. S</given-names></name>. <article-title>Using ELISA &#x00026; ELFA for diagnosis of infection with hepatitis C, B and HIV viruses among Iraqi haemophilic patients</article-title>. <source>Iraqi Journal of Biotechnology</source>. <year>2006</year>;<volume>5</volume>(<issue>1</issue>):<fpage>70</fpage>&#x02013;<lpage>84</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref058"><label>58</label><mixed-citation publication-type="journal">
<name><surname>Muhsin</surname><given-names>M. A.</given-names></name>, <name><surname>Abdul-Husin</surname><given-names>I. F</given-names></name>. <article-title>Seroprevalence of hepatitis B and C among thalassemic, haemophilic patients in Babylon Governorate-Iraq</article-title>. <source>Medical Journal of Babylon</source>. <year>2013</year>;<volume>10</volume>(<issue>2</issue>):<fpage>445</fpage>&#x02013;<lpage>54</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref059"><label>59</label><mixed-citation publication-type="journal">
<name><surname>Tarky</surname><given-names>A. M.</given-names></name>, <name><surname>Akram</surname><given-names>W.</given-names></name>, <name><surname>Al-Naaimi</surname><given-names>A. S.</given-names></name>, <name><surname>Omer</surname><given-names>A. R</given-names></name>. <article-title>Epidemiology of viral heaptitis B and C in iraq: a national survey 2005&#x02013;2006</article-title>. <source>Zanco Journal of Medical Sciences</source>. <year>2013</year>;<volume>17</volume>(<issue>1</issue>):<fpage>370</fpage>&#x02013;<lpage>80</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref060"><label>60</label><mixed-citation publication-type="journal">
<name><surname>Al-Mashhadani</surname><given-names>J. I.</given-names></name>, <name><surname>Al-Hadithi</surname><given-names>T. S.</given-names></name>, <name><surname>Al-Diwan</surname><given-names>J. K.</given-names></name>, <name><surname>Omer</surname><given-names>A. R</given-names></name>. <article-title>Sociodemographic characteristics and risk factors of hepatitis B and C among Iraqi health care workers</article-title>. <source>Journal of the Faculty of Medicine of Baghdad</source>. <year>2009</year>;<volume>51</volume>(<issue>3</issue>):<fpage>308</fpage>&#x02013;<lpage>11</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref061"><label>61</label><mixed-citation publication-type="journal">
<name><surname>Al-Saad</surname><given-names>T</given-names></name>, <name><surname>Al-Alousi</surname><given-names>BM</given-names></name>, <name><surname>Khalaf</surname><given-names>NM</given-names></name>, <name><surname>Abdul Razak</surname><given-names>W</given-names></name>. <article-title>Prevalence of hepatitis B and C viruses among medical staff in Ramadi General Hospital</article-title>. <source>Al-Anbar Medical Journal</source>. <year>2009</year>;<volume>7</volume>(<issue>1</issue>):<fpage>68</fpage>&#x02013;<lpage>75</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref062"><label>62</label><mixed-citation publication-type="journal">
<name><surname>Hassan</surname><given-names>ZM</given-names></name>, <name><surname>Wahsheh</surname><given-names>MA</given-names></name>, <name><surname>Shishani</surname><given-names>KR</given-names></name>, <name><surname>Pryor</surname><given-names>ER</given-names></name>. <article-title>Hepatitis needs assessment among Jordanian healthcare workers</article-title>. <source>International nursing review</source>. <year>2008</year>;<volume>55</volume>(<issue>2</issue>):<fpage>142</fpage>&#x02013;<lpage>7</lpage>. Epub 2008/05/15. <pub-id pub-id-type="doi">10.1111/j.1466-7657.2007.00583.x</pub-id>
.<?supplied-pmid 18477097?><pub-id pub-id-type="pmid">18477097</pub-id></mixed-citation></ref><ref id="pone.0135281.ref063"><label>63</label><mixed-citation publication-type="journal">
<name><surname>Noaman</surname><given-names>N.G</given-names></name>. <article-title>Prevalence of hepatitis C virus infection among blood donors and certain risky groups in Diyala Province</article-title>. <source>Diyala Journal of Medicine</source>. <year>2012</year>;<volume>2</volume>(<issue>1</issue>):<fpage>46</fpage>&#x02013;<lpage>52</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref064"><label>64</label><mixed-citation publication-type="journal">
<name><surname>Saadoon</surname><given-names>A. A</given-names></name>. <article-title>Prevalence of viral hepatitis B and C among selected group in Thi-Qar</article-title>. <source>Thi-Qar Medical Journal</source>. <year>2012</year>;<volume>6</volume>(<issue>1</issue>):<fpage>79</fpage>&#x02013;<lpage>89</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref065"><label>65</label><mixed-citation publication-type="journal">
<name><surname>Hussain</surname><given-names>AI</given-names></name>, <name><surname>Anizy</surname><given-names>HH</given-names></name>. <article-title>Prevalence of viral hepatitis B and C among dentistry professionals in Anbar province</article-title>. <source>Journal of Al-Anbar University for Pure Science</source>. <year>2008</year>;<volume>2</volume>(<issue>2</issue>):<fpage>18</fpage>&#x02013;<lpage>24</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref066"><label>66</label><mixed-citation publication-type="journal">
<name><surname>Al-Marzoqi</surname><given-names>A. H.</given-names></name>, <name><surname>Shemmran</surname><given-names>A. R.</given-names></name>, <name><surname>Al-Hindi</surname><given-names>Z.</given-names></name>, <name><surname>Al-Taee</surname><given-names>Z. M.</given-names></name>, <name><surname>Al-Nafee</surname><given-names>M. K</given-names></name>. <article-title>Bacterial and viral infections associated with thalassemia in Hillah city</article-title>. <source>Journal of Al-Qadisiyah for Pure Science</source>. <year>2009</year>;<volume>14</volume>(<issue>3</issue>):<fpage>1</fpage>&#x02013;<lpage>15</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref067"><label>67</label><mixed-citation publication-type="journal">
<name><surname>Albaitushi</surname><given-names>A.</given-names></name>, <name><surname>Tariq</surname><given-names>G.</given-names></name>, <name><surname>Mahmood</surname><given-names>M</given-names></name>. <article-title>Viral infections and diabetes mellitus</article-title>. <source>Journal of the Biotechnology Research Center</source>. <year>2011</year>;<volume>5</volume>(<issue>3</issue>):<fpage>29</fpage>&#x02013;<lpage>33</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref068"><label>68</label><mixed-citation publication-type="journal">
<name><surname>Al-Sweedan</surname><given-names>SA</given-names></name>, <name><surname>Jaradat</surname><given-names>S</given-names></name>, <name><surname>Amer</surname><given-names>K</given-names></name>, <name><surname>Hayajneh</surname><given-names>W</given-names></name>, <name><surname>Haddad</surname><given-names>H</given-names></name>. <article-title>Seroprevalence and genotyping of hepatitis C virus in multiple transfused Jordanian patients with beta-thalassemia major. [Turkish]. Multipl transfuzyon uygulanan beta-talasemi majorlu urdunlu hastalarda hepatit c virusunun seroprevalansi{dotless} ve genotiplemesi</article-title>. <source>Turkish Journal of Hematology</source>. <year>2011</year>;<volume>28</volume>(<issue>1</issue>):<fpage>47</fpage>&#x02013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.5152/tjh.2011.05</pub-id>
.<?supplied-pmid 2011173285?><pub-id pub-id-type="pmid">27263941</pub-id></mixed-citation></ref><ref id="pone.0135281.ref069"><label>69</label><mixed-citation publication-type="journal">
<name><surname>Quadan</surname><given-names>A</given-names></name>. <article-title>Prevalence of anti hepatitis C virus among the hospital populations in Jordan</article-title>. <source>The new microbiologica</source>. <year>2002</year>;<volume>25</volume>(<issue>3</issue>):<fpage>269</fpage>&#x02013;<lpage>73</lpage>. Epub 2002/08/14. .<?supplied-pmid 12173766?><pub-id pub-id-type="pmid">12173766</pub-id></mixed-citation></ref><ref id="pone.0135281.ref070"><label>70</label><mixed-citation publication-type="journal">
<name><surname>Al-Sheyyab</surname><given-names>M</given-names></name>, <name><surname>Batieha</surname><given-names>A</given-names></name>, <name><surname>El-Khateeb</surname><given-names>M</given-names></name>. <article-title>The prevalence of hepatitis B, hepatitis C and human immune deficiency virus markers in multi-transfused patients</article-title>. <source>Journal of tropical pediatrics</source>. <year>2001</year>;<volume>47</volume>(<issue>4</issue>):<fpage>239</fpage>&#x02013;<lpage>42</lpage>. Epub 2001/08/29. .<?supplied-pmid 11523766?><pub-id pub-id-type="pmid">11523766</pub-id></mixed-citation></ref><ref id="pone.0135281.ref071"><label>71</label><mixed-citation publication-type="journal">
<name><surname>Mahfoud</surname><given-names>Z</given-names></name>, <name><surname>Kassak</surname><given-names>K</given-names></name>, <name><surname>Kreidieh</surname><given-names>K</given-names></name>, <name><surname>Shamra</surname><given-names>S</given-names></name>, <name><surname>Ramia</surname><given-names>S</given-names></name>. <article-title>Distribution of hepatitis C virus genotypes among injecting drug users in Lebanon</article-title>. <source>Virology journal</source>. <year>2010</year>;<volume>7</volume>:<fpage>96</fpage> Epub 2010/05/15. <pub-id pub-id-type="doi">10.1186/1743-422x-7-96</pub-id>
<?supplied-pmid 20465784?><pub-id pub-id-type="pmid">20465784</pub-id></mixed-citation></ref><ref id="pone.0135281.ref072"><label>72</label><mixed-citation publication-type="journal">
<name><surname>Abdelnour</surname><given-names>GE</given-names></name>, <name><surname>Matar</surname><given-names>GM</given-names></name>, <name><surname>Sharara</surname><given-names>HM</given-names></name>, <name><surname>Abdelnoor</surname><given-names>AM</given-names></name>. <article-title>Detection of anti-hepatitis C-virus antibodies and hepatitis C-virus RNA in Lebanese hemodialysis patients</article-title>. <source>European journal of epidemiology</source>. <year>1997</year>;<volume>13</volume>(<issue>8</issue>):<fpage>863</fpage>&#x02013;<lpage>7</lpage>. Epub 1998/02/26. .<?supplied-pmid 9476813?><pub-id pub-id-type="pmid">9476813</pub-id></mixed-citation></ref><ref id="pone.0135281.ref073"><label>73</label><mixed-citation publication-type="journal">
<name><surname>Naman</surname><given-names>RE</given-names></name>, <name><surname>Mansour</surname><given-names>I</given-names></name>, <name><surname>Klayme</surname><given-names>S</given-names></name>, <name><surname>Khalil</surname><given-names>G</given-names></name>. [<article-title>Hepatitis C virus in hemodialysis patients and blood donors in Lebanon</article-title>]. <source>Le Journal medical libanais The Lebanese medical journal</source>. <year>1996</year>;<volume>44</volume>(<issue>1</issue>):<fpage>4</fpage>&#x02013;<lpage>9</lpage>. Epub 1996/01/01. .<?supplied-pmid 8965318?><pub-id pub-id-type="pmid">8965318</pub-id></mixed-citation></ref><ref id="pone.0135281.ref074"><label>74</label><mixed-citation publication-type="journal">
<name><surname>Inati</surname><given-names>A</given-names></name>, <name><surname>Musallam</surname><given-names>K</given-names></name>, <name><surname>Taha</surname><given-names>M</given-names></name>, <name><surname>Ziade</surname><given-names>F</given-names></name>, <name><surname>Taher</surname><given-names>A</given-names></name>. <article-title>Magnetic resonance imaging T2* in the evaluation of cardiac Iron overload in patients with sickle cell disease</article-title>. <source>Haematologica</source>. <year>2009</year>;<volume>94</volume>:<fpage>511</fpage>&#x02013;<lpage>2</lpage>. .<?supplied-pmid 70013481?></mixed-citation></ref><ref id="pone.0135281.ref075"><label>75</label><mixed-citation publication-type="journal">
<name><surname>Ramia</surname><given-names>S</given-names></name>, <name><surname>Koussa</surname><given-names>S</given-names></name>, <name><surname>Taher</surname><given-names>A</given-names></name>, <name><surname>Haraki</surname><given-names>S</given-names></name>, <name><surname>Klayme</surname><given-names>S</given-names></name>, <name><surname>Sarkis</surname><given-names>D</given-names></name>, <etal>et al</etal>
<article-title>Hepatitis-C-virus genotypes and hepatitis-G-virus infection in Lebanese thalassaemics</article-title>. <source>Annals of tropical medicine and parasitology</source>. <year>2002</year>;<volume>96</volume>(<issue>2</issue>):<fpage>197</fpage>&#x02013;<lpage>202</lpage>. Epub 2002/06/26. <pub-id pub-id-type="doi">10.1179/000349802125000439</pub-id>
.<?supplied-pmid 12080981?><pub-id pub-id-type="pmid">12080981</pub-id></mixed-citation></ref><ref id="pone.0135281.ref076"><label>76</label><mixed-citation publication-type="journal">
<name><surname>Ramia</surname><given-names>S</given-names></name>, <name><surname>Klayme</surname><given-names>S</given-names></name>, <name><surname>Naman</surname><given-names>R</given-names></name>. <article-title>Infection with hepatitis B and C viruses and human retroviruses (HTLV-I and HIV) among high-risk Lebanese patients</article-title>. <source>Annals of tropical medicine and parasitology</source>. <year>2003</year>;<volume>97</volume>(<issue>2</issue>):<fpage>187</fpage>&#x02013;<lpage>92</lpage>. Epub 2003/06/14. <pub-id pub-id-type="doi">10.1179/000349803235001363</pub-id>
.<?supplied-pmid 12803874?><pub-id pub-id-type="pmid">12803874</pub-id></mixed-citation></ref><ref id="pone.0135281.ref077"><label>77</label><mixed-citation publication-type="journal">
<name><surname>Araj</surname><given-names>GF</given-names></name>, <name><surname>Kfoury-Baz</surname><given-names>EE</given-names></name>, <name><surname>Barada</surname><given-names>KA</given-names></name>, <name><surname>Nassif</surname><given-names>RE</given-names></name>, <name><surname>Alami</surname><given-names>SY</given-names></name>. <article-title>Hepatitis C virus: prevalence in Lebanese blood donors and brief overview of the disease</article-title>. <source>Le Journal medical libanais The Lebanese medical journal</source>. <year>1995</year>;<volume>43</volume>(<issue>1</issue>):<fpage>11</fpage>&#x02013;<lpage>6</lpage>. Epub 1995/01/01. .<?supplied-pmid 8676356?><pub-id pub-id-type="pmid">8676356</pub-id></mixed-citation></ref><ref id="pone.0135281.ref078"><label>78</label><mixed-citation publication-type="journal">
<name><surname>Irani-Hakime</surname><given-names>N</given-names></name>, <name><surname>Musharrafieh</surname><given-names>U</given-names></name>, <name><surname>Samaha</surname><given-names>H</given-names></name>, <name><surname>Almawi</surname><given-names>WY</given-names></name>. <article-title>Prevalence of antibodies against hepatitis B virus and hepatitis C virus among blood donors in Lebanon, 1997&#x02013;2003</article-title>. <source>American journal of infection control</source>. <year>2006</year>;<volume>34</volume>(<issue>4</issue>):<fpage>241</fpage>&#x02013;<lpage>3</lpage>. Epub 2006/05/09. <pub-id pub-id-type="doi">10.1016/j.ajic.2005.06.009</pub-id>
.<?supplied-pmid 16679184?><pub-id pub-id-type="pmid">16679184</pub-id></mixed-citation></ref><ref id="pone.0135281.ref079"><label>79</label><mixed-citation publication-type="journal">
<name><surname>Irani-Hakime</surname><given-names>N</given-names></name>, <name><surname>Tamim</surname><given-names>H</given-names></name>, <name><surname>Samaha</surname><given-names>H</given-names></name>, <name><surname>Almawi</surname><given-names>WY</given-names></name>. <article-title>Prevalence of antibodies against hepatitis C virus among blood donors in Lebanon, 1997&#x02013;2000</article-title>. <source>Clinical and laboratory haematology</source>. <year>2001</year>;<volume>23</volume>(<issue>5</issue>):<fpage>317</fpage>&#x02013;<lpage>23</lpage>. Epub 2001/11/13. .<?supplied-pmid 11703415?><pub-id pub-id-type="pmid">11703415</pub-id></mixed-citation></ref><ref id="pone.0135281.ref080"><label>80</label><mixed-citation publication-type="journal">
<name><surname>Nabulsi</surname><given-names>MM</given-names></name>, <name><surname>Araj</surname><given-names>GF</given-names></name>, <name><surname>Farah</surname><given-names>AE</given-names></name>, <name><surname>Khalil</surname><given-names>AM</given-names></name>. <article-title>Hepatitis C virus antibodies in pregnant Lebanese women</article-title>. <source>Journal of obstetrics and gynaecology: the journal of the Institute of Obstetrics and Gynaecology</source>. <year>1997</year>;<volume>17</volume>(<issue>6</issue>):<fpage>548</fpage> Epub 1997/01/01. <pub-id pub-id-type="doi">10.1080/01443619768560</pub-id>
.<?supplied-pmid 15511954?><pub-id pub-id-type="pmid">15511954</pub-id></mixed-citation></ref><ref id="pone.0135281.ref081"><label>81</label><mixed-citation publication-type="journal">
<name><surname>Ramia</surname><given-names>S</given-names></name>, <name><surname>Ramlawi</surname><given-names>F</given-names></name>, <name><surname>Kanaan</surname><given-names>M</given-names></name>, <name><surname>Klayme</surname><given-names>S</given-names></name>, <name><surname>Naman</surname><given-names>R</given-names></name>. <article-title>Frequency and significance of antibodies against hepatitis B core (anti-HBc) antigen as the only serological marker for hepatitis B infection in Lebanese blood donors</article-title>. <source>Epidemiology and infection</source>. <year>2005</year>;<volume>133</volume>(<issue>4</issue>):<fpage>695</fpage>&#x02013;<lpage>9</lpage>. Epub 2005/07/30. <?supplied-pmid 16050516?><pub-id pub-id-type="pmid">16050516</pub-id></mixed-citation></ref><ref id="pone.0135281.ref082"><label>82</label><mixed-citation publication-type="journal">
<name><surname>Salem</surname><given-names>Z</given-names></name>, <name><surname>Nuwaiyri-Salti</surname><given-names>N</given-names></name>, <name><surname>Ramlawi</surname><given-names>F</given-names></name>, <name><surname>Ramia</surname><given-names>S</given-names></name>. <article-title>Hepatitis C virus infection in Lebanese patients with B-cell non-Hodgkin's lymphoma</article-title>. <source>European journal of epidemiology</source>. <year>2003</year>;<volume>18</volume>(<issue>3</issue>):<fpage>251</fpage>&#x02013;<lpage>3</lpage>. Epub 2003/06/13. <pub-id pub-id-type="doi">10.1023/a:1023380316098</pub-id>
.<?supplied-pmid 12800950?><pub-id pub-id-type="pmid">12800950</pub-id></mixed-citation></ref><ref id="pone.0135281.ref083"><label>83</label><mixed-citation publication-type="journal">
<name><surname>Tamim</surname><given-names>H</given-names></name>, <name><surname>Irani-Hakime</surname><given-names>N</given-names></name>, <name><surname>Aoun</surname><given-names>JP</given-names></name>, <name><surname>Khoury</surname><given-names>S</given-names></name>, <name><surname>Samaha</surname><given-names>H</given-names></name>, <name><surname>Almawi</surname><given-names>WY</given-names></name>. <article-title>Seroprevalence of hepatitis C virus (HCV) infection among blood donors: a hospital-based study</article-title>. <source>Transfusion and apheresis science: official journal of the World Apheresis Association: official journal of the European Society for Haemapheresis</source>. <year>2001</year>;<volume>24</volume>(<issue>1</issue>):<fpage>29</fpage>&#x02013;<lpage>35</lpage>. Epub 2001/08/23. .<?supplied-pmid 11515608?><pub-id pub-id-type="pmid">11515608</pub-id></mixed-citation></ref><ref id="pone.0135281.ref084"><label>84</label><mixed-citation publication-type="journal">
<name><surname>Baddoura</surname><given-names>R</given-names></name>, <name><surname>Haddad</surname><given-names>C</given-names></name>, <name><surname>Germanos</surname><given-names>M</given-names></name>. <article-title>Hepatitis B and C seroprevalence in the Lebanese population</article-title>. <source>Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit</source>. <year>2002</year>;<volume>8</volume>(<issue>1</issue>):<fpage>150</fpage>&#x02013;<lpage>6</lpage>. Epub 2004/08/28. .<?supplied-pmid 15330570?><pub-id pub-id-type="pmid">15330570</pub-id></mixed-citation></ref><ref id="pone.0135281.ref085"><label>85</label><mixed-citation publication-type="journal">
<name><surname>Yaghi</surname><given-names>C</given-names></name>, <name><surname>Sharara</surname><given-names>AI</given-names></name>, <name><surname>Rassam</surname><given-names>P</given-names></name>, <name><surname>Moucari</surname><given-names>R</given-names></name>, <name><surname>Honein</surname><given-names>K</given-names></name>, <name><surname>BouJaoude</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Hepatocellular carcinoma in Lebanon: Etiology and prognostic factors associated with short-term survival</article-title>. <source>World Journal of Gastroenterology</source>. <year>2006</year>;<volume>12</volume>(<issue>22</issue>):<fpage>3575</fpage>&#x02013;<lpage>80</lpage>. .<?supplied-pmid 2006318933?><pub-id pub-id-type="pmid">16773714</pub-id></mixed-citation></ref><ref id="pone.0135281.ref086"><label>86</label><mixed-citation publication-type="journal">
<name><surname>Otrock</surname><given-names>ZK</given-names></name>, <name><surname>Saab</surname><given-names>J</given-names></name>, <name><surname>Aftimos</surname><given-names>G</given-names></name>, <name><surname>Nasr</surname><given-names>F</given-names></name>, <name><surname>Farhat</surname><given-names>FS</given-names></name>, <name><surname>Khairallah</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>A collaborative nationwide lymphoma study in Lebanon: incidence of various subtypes and analysis of associations with viruses</article-title>. <source>Pathology oncology research: POR</source>. <year>2013</year>;<volume>19</volume>(<issue>4</issue>):<fpage>715</fpage>&#x02013;<lpage>22</lpage>. Epub 2013/05/09. <pub-id pub-id-type="doi">10.1007/s12253-013-9634-0</pub-id>
.<?supplied-pmid 23653112?><pub-id pub-id-type="pmid">23653112</pub-id></mixed-citation></ref><ref id="pone.0135281.ref087"><label>87</label><mixed-citation publication-type="journal">
<name><surname>Dumaidi</surname><given-names>K</given-names></name>, <name><surname>Al-Jawabreh</surname><given-names>A</given-names></name>. <article-title>Prevalence of occult HBV among hemodialysis patients in two districts in the northern part of the West Bank, Palestine</article-title>. <source>Journal of medical virology</source>. <year>2014</year>;<volume>86</volume>(<issue>10</issue>):<fpage>1694</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.24008</pub-id>
.<?supplied-pmid 24992542?><pub-id pub-id-type="pmid">24992542</pub-id></mixed-citation></ref><ref id="pone.0135281.ref088"><label>88</label><mixed-citation publication-type="journal">
<name><surname>El-kader</surname><given-names>YE-OA</given-names></name>, <name><surname>Elmanama</surname><given-names>AA</given-names></name>, <name><surname>Ayesh</surname><given-names>BM</given-names></name>. <article-title>Prevalence and risk factors of hepatitis B and C viruses among haemodialysis patients in Gaza strip, Palestine</article-title>. <source>Virology journal</source>. <year>2010</year>;<volume>7</volume>:<fpage>210</fpage> Epub 2010/09/03. <pub-id pub-id-type="doi">10.1186/1743-422x-7-210</pub-id>
<?supplied-pmid 20809985?><pub-id pub-id-type="pmid">20809985</pub-id></mixed-citation></ref><ref id="pone.0135281.ref089"><label>89</label><mixed-citation publication-type="journal">
<name><surname>Stulhofer</surname><given-names>A</given-names></name>, <name><surname>Chetty</surname><given-names>A</given-names></name>, <name><surname>Rabie</surname><given-names>RA</given-names></name>, <name><surname>Jwehan</surname><given-names>I</given-names></name>, <name><surname>Ramlawi</surname><given-names>A</given-names></name>. <article-title>The prevalence of HIV, HBV, HCV, and HIV-related risk-taking behaviors among Palestinian injecting drug users in the East Jerusalem Governorate</article-title>. <source>Journal of urban health: bulletin of the New York Academy of Medicine</source>. <year>2012</year>;<volume>89</volume>(<issue>4</issue>):<fpage>671</fpage>&#x02013;<lpage>6</lpage>. Epub 2012/06/08. <pub-id pub-id-type="doi">10.1007/s11524-012-9672-z</pub-id>
<?supplied-pmid 22674463?><pub-id pub-id-type="pmid">22674463</pub-id></mixed-citation></ref><ref id="pone.0135281.ref090"><label>90</label><mixed-citation publication-type="journal">
<name><surname>Shemer-Avni</surname><given-names>Y</given-names></name>, <name><surname>el Astal</surname><given-names>Z</given-names></name>, <name><surname>Kemper</surname><given-names>O</given-names></name>, <name><surname>el Najjar</surname><given-names>KJ</given-names></name>, <name><surname>Yaari</surname><given-names>A</given-names></name>, <name><surname>Hanuka</surname><given-names>N</given-names></name>, <etal>et al</etal>
<article-title>Hepatitis C virus infection and genotypes in Southern Israel and the Gaza Strip</article-title>. <source>Journal of medical virology</source>. <year>1998</year>;<volume>56</volume>(<issue>3</issue>):<fpage>230</fpage>&#x02013;<lpage>3</lpage>. Epub 1998/10/23. .<?supplied-pmid 9783690?><pub-id pub-id-type="pmid">9783690</pub-id></mixed-citation></ref><ref id="pone.0135281.ref091"><label>91</label><mixed-citation publication-type="journal">
<name><surname>Novack</surname><given-names>L</given-names></name>, <name><surname>Shinar</surname><given-names>E</given-names></name>, <name><surname>Safi</surname><given-names>J</given-names></name>, <name><surname>Soliman</surname><given-names>H</given-names></name>, <name><surname>Yaari</surname><given-names>A</given-names></name>, <name><surname>Galai</surname><given-names>N</given-names></name>, <etal>et al</etal>
<article-title>Evaluation of pooled screening for anti-HCV in two blood services set-ups</article-title>. <source>Tropical medicine &#x00026; international health: TM &#x00026; IH</source>. <year>2007</year>;<volume>12</volume>(<issue>3</issue>):<fpage>415</fpage>&#x02013;<lpage>21</lpage>. Epub 2007/02/23. <pub-id pub-id-type="doi">10.1111/j.1365-3156.2006.01810.x</pub-id>
.<?supplied-pmid 17313513?><pub-id pub-id-type="pmid">17313513</pub-id></mixed-citation></ref><ref id="pone.0135281.ref092"><label>92</label><mixed-citation publication-type="journal">
<name><surname>Abdulkarim</surname><given-names>AS</given-names></name>, <name><surname>Zein</surname><given-names>NN</given-names></name>, <name><surname>Germer</surname><given-names>JJ</given-names></name>, <name><surname>Kolbert</surname><given-names>CP</given-names></name>, <name><surname>Kabbani</surname><given-names>L</given-names></name>, <name><surname>Krajnik</surname><given-names>KL</given-names></name>, <etal>et al</etal>
<article-title>Hepatitis C virus genotypes and hepatitis G virus in hemodialysis patients from Syria: identification of two novel hepatitis C virus subtypes</article-title>. <source>The American journal of tropical medicine and hygiene</source>. <year>1998</year>;<volume>59</volume>(<issue>4</issue>):<fpage>571</fpage>&#x02013;<lpage>6</lpage>. Epub 1998/10/28. .<?supplied-pmid 9790432?><pub-id pub-id-type="pmid">9790432</pub-id></mixed-citation></ref><ref id="pone.0135281.ref093"><label>93</label><mixed-citation publication-type="journal">
<name><surname>Moukeh</surname><given-names>G</given-names></name>, <name><surname>Yacoub</surname><given-names>R</given-names></name>, <name><surname>Fahdi</surname><given-names>F</given-names></name>, <name><surname>Rastam</surname><given-names>S</given-names></name>, <name><surname>Albitar</surname><given-names>S</given-names></name>. <article-title>Epidemiology of hemodialysis patients in Aleppo city</article-title>. <source>Saudi journal of kidney diseases and transplantation: an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia</source>. <year>2009</year>;<volume>20</volume>(<issue>1</issue>):<fpage>140</fpage>&#x02013;<lpage>6</lpage>. Epub 2008/12/30. .<?supplied-pmid 19112237?><pub-id pub-id-type="pmid">19112237</pub-id></mixed-citation></ref><ref id="pone.0135281.ref094"><label>94</label><mixed-citation publication-type="journal">
<name><surname>Othman</surname><given-names>B</given-names></name>, <name><surname>Monem</surname><given-names>F</given-names></name>. <article-title>Prevalence of antibodies to hepatitis C virus among hemodialysis patients in Damascus, Syria</article-title>. <source>Infection</source>. <year>2001</year>;<volume>29</volume>(<issue>5</issue>):<fpage>262</fpage>&#x02013;<lpage>5</lpage>. Epub 2001/11/02. .<?supplied-pmid 11688903?><pub-id pub-id-type="pmid">11688903</pub-id></mixed-citation></ref><ref id="pone.0135281.ref095"><label>95</label><mixed-citation publication-type="book">
<collab>Syria Mental Health Directorate and National AIDS Programme (of Syrian Ministry of Health)</collab>. <chapter-title>Assessment of HIV risk and sero-prevalence among drug users in greater Damascus</chapter-title>
<publisher-name>Syrian Ministry of Health</publisher-name>, <publisher-name>United Nations Office on Drugs and Crime, and the Joint United Nations Programme on HIV/AIDS</publisher-name>, <year>2008</year>.</mixed-citation></ref><ref id="pone.0135281.ref096"><label>96</label><mixed-citation publication-type="journal">
<name><surname>Ali</surname><given-names>T</given-names></name>, <name><surname>Schved</surname><given-names>JF</given-names></name>. <article-title>Registry of hemophilia and other bleeding disorders in Syria</article-title>. <source>Haemophilia</source>. <year>2012</year>;<volume>18</volume>(<issue>6</issue>):<fpage>851</fpage>&#x02013;<lpage>4</lpage>. Epub 2012/06/08. <pub-id pub-id-type="doi">10.1111/j.1365-2516.2012.02862.x</pub-id>
.<?supplied-pmid 22672010?><pub-id pub-id-type="pmid">22672010</pub-id></mixed-citation></ref><ref id="pone.0135281.ref097"><label>97</label><mixed-citation publication-type="journal">
<name><surname>Othman</surname><given-names>BM</given-names></name>, <name><surname>Monem</surname><given-names>FS</given-names></name>. <article-title>Prevalence of hepatitis C virus antibodies among intravenous drug abusers and prostitutes in Damascus, Syria</article-title>. <source>Saudi medical journal</source>. <year>2002</year>;<volume>23</volume>(<issue>4</issue>):<fpage>393</fpage>&#x02013;<lpage>5</lpage>. Epub 2002/04/16. .<?supplied-pmid 11953762?><pub-id pub-id-type="pmid">11953762</pub-id></mixed-citation></ref><ref id="pone.0135281.ref098"><label>98</label><mixed-citation publication-type="book">
<collab>National AIDS Programme and Central Statistics Bureau (of Syrian Ministry of Health)</collab>. <chapter-title>Knowledge, attitude, and professional behavior of health care workers around certain blood-borne diseases including AIDS and hepatitis B and C</chapter-title>
<publisher-name>Syrian Ministry of Health</publisher-name>, <publisher-name>United Nations Development Programme, and the World Health Organization</publisher-name>, date unknown.</mixed-citation></ref><ref id="pone.0135281.ref099"><label>99</label><mixed-citation publication-type="journal">
<name><surname>al-Azmeh</surname><given-names>J</given-names></name>, <name><surname>Frosner</surname><given-names>G</given-names></name>, <name><surname>Darwish</surname><given-names>Z</given-names></name>, <name><surname>Bashour</surname><given-names>H</given-names></name>, <name><surname>Monem</surname><given-names>F</given-names></name>. <article-title>Hepatitis E in Damascus, Syria</article-title>. <source>Infection</source>. <year>1999</year>;<volume>27</volume>(<issue>3</issue>):<fpage>221</fpage>&#x02013;<lpage>3</lpage>. Epub 1999/06/23. .<?supplied-pmid 10378137?><pub-id pub-id-type="pmid">10378137</pub-id></mixed-citation></ref><ref id="pone.0135281.ref100"><label>100</label><mixed-citation publication-type="journal">
<name><surname>Obied</surname><given-names>H.M.</given-names></name>, <name><surname>Alrodhan</surname><given-names>M.A.</given-names></name>, <name><surname>Mallah</surname><given-names>M.O</given-names></name>. <article-title>Molecular and immunological detection of hepatitis C virus infection among blood donors in Al-Muthanna province-Iraq</article-title>. <source>International Journal of Advanced Research</source>. <year>2014</year>;<volume>2</volume>(<issue>6</issue>):<fpage>295</fpage>&#x02013;<lpage>315</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref101"><label>101</label><mixed-citation publication-type="journal">
<name><surname>Tawfeeq</surname><given-names>WF</given-names></name>. <article-title>Detection of hepatitis C virus infection and genotypes among seropositive blood donors by polymerase chain reaction in babylon Governorate, Iraq</article-title>. <source>Medical Journal of Babylon</source>. <year>2013</year>;<volume>10</volume>(<issue>1</issue>):<fpage>25</fpage>&#x02013;<lpage>37</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref102"><label>102</label><mixed-citation publication-type="journal">
<name><surname>Al-Kubaisy</surname><given-names>WA</given-names></name>, <name><surname>Niazi</surname><given-names>AD</given-names></name>, <name><surname>Kubba</surname><given-names>K</given-names></name>. <article-title>History of miscarriage as a risk factor for hepatitis C virus infection in pregnant Iraqi women</article-title>. <source>Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit</source>. <year>2002</year>;<volume>8</volume>(<issue>2&#x02013;3</issue>):<fpage>239</fpage>&#x02013;<lpage>44</lpage>. Epub 2004/09/02. .<?supplied-pmid 15339110?><pub-id pub-id-type="pmid">15339110</pub-id></mixed-citation></ref><ref id="pone.0135281.ref103"><label>103</label><mixed-citation publication-type="journal">
<name><surname>Rashdan</surname><given-names>A</given-names></name>, <name><surname>Hijjawi</surname><given-names>S</given-names></name>, <name><surname>Jadallah</surname><given-names>K</given-names></name>, <name><surname>Matalka</surname><given-names>I</given-names></name>. <article-title>Prevalence of hepatitis C virus antibodies among blood donors in Northern Jordan</article-title>. <source>Jordan Medical Journal</source>. <year>2008</year>;<volume>42</volume>(<issue>3</issue>):<fpage>179</fpage>&#x02013;<lpage>83</lpage>. .<?supplied-pmid 2009005380?></mixed-citation></ref><ref id="pone.0135281.ref104"><label>104</label><mixed-citation publication-type="journal">
<name><surname>Al-Kubaisy</surname><given-names>W. A.</given-names></name>, <name><surname>Obaid</surname><given-names>K. J.</given-names></name>, <name><surname>Noor</surname><given-names>N. M.</given-names></name>, <name><surname>Ibrahim</surname><given-names>N. S.</given-names></name>, <name><surname>Al-Azawi</surname><given-names>A. A</given-names></name>. <article-title>Hepatitis C virus prevalence and genotyping among hepatocellular carcinoma patients in Baghdad</article-title>. <source>Asian pacific Journal of Cancer Prevention</source>. <year>2014</year>;<volume>15</volume>(<issue>18</issue>):<fpage>7725</fpage>&#x02013;<lpage>30</lpage>.
<?supplied-pmid 25292053?><pub-id pub-id-type="pmid">25292053</pub-id></mixed-citation></ref><ref id="pone.0135281.ref105"><label>105</label><mixed-citation publication-type="journal">
<name><surname>Chironna</surname><given-names>M</given-names></name>, <name><surname>Germinario</surname><given-names>C</given-names></name>, <name><surname>Lopalco</surname><given-names>PL</given-names></name>, <name><surname>Carrozzini</surname><given-names>F</given-names></name>, <name><surname>Barbuti</surname><given-names>S</given-names></name>, <name><surname>Quarto</surname><given-names>M</given-names></name>. <article-title>Prevalence rates of viral hepatitis infections in refugee Kurds from Iraq and Turkey</article-title>. <source>Infection</source>. <year>2003</year>;<volume>31</volume>(<issue>2</issue>):<fpage>70</fpage>&#x02013;<lpage>4</lpage>. Epub 2003/04/12. <pub-id pub-id-type="doi">10.1007/s15010-002-3100-3</pub-id>
.<?supplied-pmid 12682810?><pub-id pub-id-type="pmid">12682810</pub-id></mixed-citation></ref><ref id="pone.0135281.ref106"><label>106</label><mixed-citation publication-type="journal">
<name><surname>Al-Kubaisy</surname><given-names>WA</given-names></name>, <name><surname>Al-Naib</surname><given-names>KT</given-names></name>, <name><surname>Habib</surname><given-names>MA</given-names></name>. <article-title>Prevalence of HCV/HIV co-infection among haemophilia patients in Baghdad</article-title>. <source>Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit</source>. <year>2006</year>;<volume>12</volume>(<issue>3&#x02013;4</issue>):<fpage>264</fpage>&#x02013;<lpage>9</lpage>. Epub 2006/10/14. .<?supplied-pmid 17037693?><pub-id pub-id-type="pmid">17037693</pub-id></mixed-citation></ref><ref id="pone.0135281.ref107"><label>107</label><mixed-citation publication-type="journal">
<name><surname>Othman</surname><given-names>AA</given-names></name>, <name><surname>Eissa</surname><given-names>AA</given-names></name>, <name><surname>Markous</surname><given-names>RD</given-names></name>, <name><surname>Ahmed</surname><given-names>BD</given-names></name>, <name><surname>Al-Allawi</surname><given-names>NA</given-names></name>. <article-title>Hepatitis C virus genotypes among multiply transfused hemoglobinopathy patients from Northern Iraq</article-title>. <source>Asian journal of transfusion science</source>. <year>2014</year>;<volume>8</volume>(<issue>1</issue>):<fpage>32</fpage>&#x02013;<lpage>4</lpage>. Epub 2014/03/29. <pub-id pub-id-type="doi">10.4103/0973-6247.126687</pub-id>
<?supplied-pmid 24678171?><pub-id pub-id-type="pmid">24678171</pub-id></mixed-citation></ref><ref id="pone.0135281.ref108"><label>108</label><mixed-citation publication-type="journal">
<name><surname>Abbas</surname><given-names>Y. A.</given-names></name>, <name><surname>Aubaid</surname><given-names>A. H.</given-names></name>, <name><surname>Hamad</surname><given-names>B. J</given-names></name>. <article-title>Determination of hepatitis C viral load and genotypes by Real-Time and RT-PCR at Thi-Qar province</article-title>. <source>Al-Qadisiah Medical Journal</source>. <year>2013</year>;<volume>9</volume>(<issue>15</issue>):<fpage>250</fpage>&#x02013;<lpage>64</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref109"><label>109</label><mixed-citation publication-type="journal">
<name><surname>Al-hemiary</surname><given-names>R. M</given-names></name>. <article-title>The diagnostic value of hepatitis C genotyping by Real time-PCR in Iraqi patients</article-title>. <source>Iraq Journal of Market Research and Consumer Protection</source>. <year>2012</year>;<volume>4</volume>(<issue>2</issue>):<fpage>159</fpage>&#x02013;<lpage>67</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref110"><label>110</label><mixed-citation publication-type="journal">
<name><surname>Khalid</surname><given-names>M.D.</given-names></name>, <name><surname>Abdullah</surname><given-names>B. A</given-names></name>. <article-title>Hepatitis C virus genotypes in Iraq</article-title>. <source>Iraqi Journal of Biotechnology</source>. <year>2012</year>;<volume>11</volume>(<issue>2</issue>):<fpage>475</fpage>&#x02013;<lpage>80</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref111"><label>111</label><mixed-citation publication-type="journal">
<name><surname>Bdour</surname><given-names>S</given-names></name>. <article-title>Hepatitis C virus infection in Jordanian haemodialysis units: serological diagnosis and genotyping</article-title>. <source>Journal of medical microbiology</source>. <year>2002</year>;<volume>51</volume>(<issue>8</issue>):<fpage>700</fpage>&#x02013;<lpage>4</lpage>. Epub 2002/08/13. .<?supplied-pmid 12171303?><pub-id pub-id-type="pmid">12171303</pub-id></mixed-citation></ref><ref id="pone.0135281.ref112"><label>112</label><mixed-citation publication-type="journal">
<name><surname>Hamoudi</surname><given-names>W</given-names></name>, <name><surname>Ali</surname><given-names>SA</given-names></name>, <name><surname>Abdallat</surname><given-names>M</given-names></name>, <name><surname>Estes</surname><given-names>CR</given-names></name>, <name><surname>Razavi</surname><given-names>HA</given-names></name>. <article-title>HCV infection prevalence in a population recruited at health centers in Jordan</article-title>. <source>Journal of epidemiology and global health</source>. <year>2013</year>;<volume>3</volume>(<issue>2</issue>):<fpage>67</fpage>&#x02013;<lpage>71</lpage>. Epub 2013/07/17. <pub-id pub-id-type="doi">10.1016/j.jegh.2013.02.003</pub-id>
.<?supplied-pmid 23856567?><pub-id pub-id-type="pmid">23856567</pub-id></mixed-citation></ref><ref id="pone.0135281.ref113"><label>113</label><mixed-citation publication-type="journal">
<name><surname>Mahfoud</surname><given-names>Z</given-names></name>, <name><surname>Kassak</surname><given-names>K</given-names></name>, <name><surname>Kreidieh</surname><given-names>K</given-names></name>, <name><surname>Shamra</surname><given-names>S</given-names></name>, <name><surname>Ramia</surname><given-names>S</given-names></name>. <article-title>Prevalence of antibodies to human immunodeficiency virus (HIV), hepatitis B and hepatitis C and risk factors in prisoners in Lebanon</article-title>. <source>Journal of infection in developing countries</source>. <year>2010</year>;<volume>4</volume>(<issue>3</issue>):<fpage>144</fpage>&#x02013;<lpage>9</lpage>. Epub 2010/03/31. .<?supplied-pmid 20351454?><pub-id pub-id-type="pmid">20351454</pub-id></mixed-citation></ref><ref id="pone.0135281.ref114"><label>114</label><mixed-citation publication-type="journal">
<name><surname>Matar</surname><given-names>GM</given-names></name>, <name><surname>Sharara</surname><given-names>HM</given-names></name>, <name><surname>Abdelnour</surname><given-names>GE</given-names></name>, <name><surname>Abdelnoor</surname><given-names>AM</given-names></name>. <article-title>Genotyping of hepatitis C virus isolates from Lebanese hemodialysis patients by reverse transcription-PCR and restriction fragment length polymorphism analysis of 5' noncoding region</article-title>. <source>Journal of clinical microbiology</source>. <year>1996</year>;<volume>34</volume>(<issue>10</issue>):<fpage>2623</fpage>&#x02013;<lpage>4</lpage>. Epub 1996/10/01. <?supplied-pmid 8880537?><pub-id pub-id-type="pmid">8880537</pub-id></mixed-citation></ref><ref id="pone.0135281.ref115"><label>115</label><mixed-citation publication-type="journal">
<name><surname>Irani-Hakime</surname><given-names>N</given-names></name>, <name><surname>Samaha</surname><given-names>H</given-names></name>, <name><surname>Almawi</surname><given-names>W</given-names></name>, <name><surname>Nasr</surname><given-names>E</given-names></name>, <name><surname>Mokhbat</surname><given-names>J</given-names></name>, <name><surname>Abou Jaoude</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Prevalence of hepatitis C virus isolate genotypes from chronically infected Lebanese patients: a hospital-based study</article-title>. <source>Le Journal medical libanais The Lebanese medical journal</source>. <year>2003</year>;<volume>51</volume>(<issue>3</issue>):<fpage>121</fpage>&#x02013;<lpage>6</lpage>. Epub 2005/02/15. .<?supplied-pmid 15707071?><pub-id pub-id-type="pmid">15707071</pub-id></mixed-citation></ref><ref id="pone.0135281.ref116"><label>116</label><mixed-citation publication-type="journal">
<name><surname>Sharara</surname><given-names>AI</given-names></name>, <name><surname>Ramia</surname><given-names>S</given-names></name>, <name><surname>Ramlawi</surname><given-names>F</given-names></name>, <name><surname>Fares</surname><given-names>JE</given-names></name>, <name><surname>Klayme</surname><given-names>S</given-names></name>, <name><surname>Naman</surname><given-names>R</given-names></name>. <article-title>Genotypes of hepatitis C virus (HCV) among positive Lebanese patients: comparison of data with that from other Middle Eastern countries</article-title>. <source>Epidemiology and infection</source>. <year>2007</year>;<volume>135</volume>(<issue>3</issue>):<fpage>427</fpage>&#x02013;<lpage>32</lpage>. Epub 2006/07/20. <pub-id pub-id-type="doi">10.1017/s0950268806006911</pub-id>
<?supplied-pmid 16848924?><pub-id pub-id-type="pmid">16848924</pub-id></mixed-citation></ref><ref id="pone.0135281.ref117"><label>117</label><mixed-citation publication-type="journal">
<name><surname>Inati</surname><given-names>A</given-names></name>, <name><surname>Taher</surname><given-names>A</given-names></name>, <name><surname>Ghorra</surname><given-names>S</given-names></name>, <name><surname>Koussa</surname><given-names>S</given-names></name>, <name><surname>Taha</surname><given-names>M</given-names></name>, <name><surname>Aoun</surname><given-names>E</given-names></name>, <etal>et al</etal>
<article-title>Efficacy and tolerability of peginterferon alpha-2a with or without ribavirin in thalassaemia major patients with chronic hepatitis C virus infection</article-title>. <source>British journal of haematology</source>. <year>2005</year>;<volume>130</volume>(<issue>4</issue>):<fpage>644</fpage>&#x02013;<lpage>6</lpage>. Epub 2005/08/16. <pub-id pub-id-type="doi">10.1111/j.1365-2141.2005.05645.x</pub-id>
.<?supplied-pmid 16098081?><pub-id pub-id-type="pmid">16098081</pub-id></mixed-citation></ref><ref id="pone.0135281.ref118"><label>118</label><mixed-citation publication-type="journal">
<name><surname>Ayesh</surname><given-names>BM</given-names></name>, <name><surname>Zourob</surname><given-names>SS</given-names></name>, <name><surname>Abu-Jadallah</surname><given-names>SY</given-names></name>, <name><surname>Shemer-Avni</surname><given-names>Y</given-names></name>. <article-title>Most common genotypes and risk factors for HCV in Gaza strip: a cross sectional study</article-title>. <source>Virology journal</source>. <year>2009</year>;<volume>6</volume>:<fpage>105</fpage> Epub 2009/07/18. <pub-id pub-id-type="doi">10.1186/1743-422x-6-105</pub-id>
<?supplied-pmid 19607718?><pub-id pub-id-type="pmid">19607718</pub-id></mixed-citation></ref><ref id="pone.0135281.ref119"><label>119</label><mixed-citation publication-type="journal">
<name><surname>Antaki</surname><given-names>N</given-names></name>, <name><surname>Haddad</surname><given-names>M</given-names></name>, <name><surname>Kebbewar</surname><given-names>K</given-names></name>, <name><surname>Abdelwahab</surname><given-names>J</given-names></name>, <name><surname>Hamed</surname><given-names>O</given-names></name>, <name><surname>Aaraj</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>The unexpected discovery of a focus of hepatitis C virus genotype 5 in a Syrian province</article-title>. <source>Epidemiology and infection</source>. <year>2009</year>;<volume>137</volume>(<issue>1</issue>):<fpage>79</fpage>&#x02013;<lpage>84</lpage>. Epub 2008/03/19. <pub-id pub-id-type="doi">10.1017/s095026880800054x</pub-id>
.<?supplied-pmid 18346288?><pub-id pub-id-type="pmid">18346288</pub-id></mixed-citation></ref><ref id="pone.0135281.ref120"><label>120</label><mixed-citation publication-type="journal">
<name><surname>Karadat</surname><given-names>A</given-names></name>. <article-title>Hepatitis C genotypes in Syrian refugee patient in Turkey</article-title>. <source>Hepatology International</source>. <year>2015</year>;<volume>9</volume>(<issue>1</issue> SUPPL. 1):<fpage>S276</fpage>
<pub-id pub-id-type="doi">10.1007/s12072-015-9609-1</pub-id>. .<?supplied-pmid 71806886?></mixed-citation></ref><ref id="pone.0135281.ref121"><label>121</label><mixed-citation publication-type="journal">
<name><surname>Messina</surname><given-names>JP</given-names></name>, <name><surname>Humphreys</surname><given-names>I</given-names></name>, <name><surname>Flaxman</surname><given-names>A</given-names></name>, <name><surname>Brown</surname><given-names>A</given-names></name>, <name><surname>Cooke</surname><given-names>GS</given-names></name>, <name><surname>Pybus</surname><given-names>OG</given-names></name>, <etal>et al</etal>
<article-title>Global distribution and prevalence of hepatitis C virus genotypes</article-title>. <source>Hepatology</source>. <year>2015</year>;<volume>61</volume>(<issue>1</issue>):<fpage>77</fpage>&#x02013;<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1002/hep.27259</pub-id>
<?supplied-pmid 25069599?><pub-id pub-id-type="pmid">25069599</pub-id></mixed-citation></ref><ref id="pone.0135281.ref122"><label>122</label><mixed-citation publication-type="journal">
<name><surname>Khaleel</surname><given-names>H. A.</given-names></name>, <name><surname>Turky</surname><given-names>A. M.</given-names></name>, <name><surname>Al-Naaimi</surname><given-names>A. S.</given-names></name>, <name><surname>Jalil</surname><given-names>R. W.</given-names></name>, <name><surname>Mekhlef</surname><given-names>O. A.</given-names></name>, <name><surname>Abdul Kareem</surname><given-names>S.</given-names></name>, <etal>et al</etal>
<article-title>Prevalence of HBsAg and anti HCV Ab among patients with suspected acute viral hepatitis in Baghdad, Iraq in 2010</article-title>. <source>Epidemiology Reports</source>. <year>2014</year>;<volume>1</volume>(<issue>1</issue>). <pub-id pub-id-type="doi">10.7243/2054-9911-1-1</pub-id>
</mixed-citation></ref><ref id="pone.0135281.ref123"><label>123</label><mixed-citation publication-type="journal">
<name><surname>Cornberg</surname><given-names>M</given-names></name>, <name><surname>Razavi</surname><given-names>HA</given-names></name>, <name><surname>Alberti</surname><given-names>A</given-names></name>, <name><surname>Bernasconi</surname><given-names>E</given-names></name>, <name><surname>Buti</surname><given-names>M</given-names></name>, <name><surname>Cooper</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel</article-title>. <source>Liver international: official journal of the International Association for the Study of the Liver</source>. <year>2011</year>;<volume>31</volume>
<issue>Suppl 2</issue>:<fpage>30</fpage>&#x02013;<lpage>60</lpage>. Epub 2011/06/18. <pub-id pub-id-type="doi">10.1111/j.1478-3231.2011.02539.x</pub-id>
.<?supplied-pmid 21651702?><pub-id pub-id-type="pmid">21651702</pub-id></mixed-citation></ref><ref id="pone.0135281.ref124"><label>124</label><mixed-citation publication-type="journal">
<name><surname>Zou</surname><given-names>S</given-names></name>, <name><surname>Dorsey</surname><given-names>KA</given-names></name>, <name><surname>Notari</surname><given-names>EP</given-names></name>, <name><surname>Foster</surname><given-names>GA</given-names></name>, <name><surname>Krysztof</surname><given-names>DE</given-names></name>, <name><surname>Musavi</surname><given-names>F</given-names></name>, <etal>et al</etal>
<article-title>Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing</article-title>. <source>Transfusion</source>. <year>2010</year>;<volume>50</volume>(<issue>7</issue>):<fpage>1495</fpage>&#x02013;<lpage>504</lpage>. <pub-id pub-id-type="doi">10.1111/j.1537-2995.2010.02622.x</pub-id>
.<?supplied-pmid 20345570?><pub-id pub-id-type="pmid">20345570</pub-id></mixed-citation></ref><ref id="pone.0135281.ref125"><label>125</label><mixed-citation publication-type="journal">
<name><surname>Denniston</surname><given-names>MM</given-names></name>, <name><surname>Jiles</surname><given-names>RB</given-names></name>, <name><surname>Drobeniuc</surname><given-names>J</given-names></name>, <name><surname>Klevens</surname><given-names>RM</given-names></name>, <name><surname>Ward</surname><given-names>JW</given-names></name>, <name><surname>McQuillan</surname><given-names>GM</given-names></name>, <etal>et al</etal>
<article-title>Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010</article-title>. <source>Annals of internal medicine</source>. <year>2014</year>;<volume>160</volume>(<issue>5</issue>):<fpage>293</fpage>&#x02013;<lpage>300</lpage>. <pub-id pub-id-type="doi">10.7326/M13-1133</pub-id>
.<?supplied-pmid 24737271?><pub-id pub-id-type="pmid">24737271</pub-id></mixed-citation></ref><ref id="pone.0135281.ref126"><label>126</label><mixed-citation publication-type="journal">
<name><surname>El-Ghitany</surname><given-names>EM</given-names></name>, <name><surname>Abdel Wahab</surname><given-names>MM</given-names></name>, <name><surname>Abd El-Wahab</surname><given-names>EW</given-names></name>, <name><surname>Hassouna</surname><given-names>S</given-names></name>, <name><surname>Farghaly</surname><given-names>AG</given-names></name>. <article-title>A comprehensive hepatitis C virus risk factors meta-analysis (1989&#x02013;2013); Do they differ in Egypt?</article-title>
<source>Liver international: official journal of the International Association for the Study of the Liver</source>. <year>2015</year>;<volume>35</volume>(<issue>2</issue>):<fpage>489</fpage>&#x02013;<lpage>501</lpage>. <pub-id pub-id-type="doi">10.1111/liv.12617</pub-id>
.<?supplied-pmid 24923487?><pub-id pub-id-type="pmid">24923487</pub-id></mixed-citation></ref><ref id="pone.0135281.ref127"><label>127</label><mixed-citation publication-type="journal">
<name><surname>Mohamoud</surname><given-names>YA</given-names></name>, <name><surname>Miller</surname><given-names>FD</given-names></name>, <name><surname>Abu-Raddad</surname><given-names>LJ</given-names></name>. <article-title>Potential for human immunodeficiency virus parenteral transmission in the Middle East and North Africa: an analysis using hepatitis C virus as a proxy biomarker</article-title>. <source>World journal of gastroenterology: WJG</source>. <year>2014</year>;<volume>20</volume>(<issue>36</issue>):<fpage>12734</fpage>&#x02013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.3748/wjg.v20.i36.12734</pub-id>
<?supplied-pmid 25278675?><pub-id pub-id-type="pmid">25278675</pub-id></mixed-citation></ref><ref id="pone.0135281.ref128"><label>128</label><mixed-citation publication-type="other">World Health Organization. WHO guideline on the use of safety-engineered syringes for intramuscular, intradermal and subcutaneous injections in health-care settings. 2015 WHO/HIS/SDS/2015.5.</mixed-citation></ref><ref id="pone.0135281.ref129"><label>129</label><mixed-citation publication-type="other">WHO calls for worldwide use of "smart" syringes [Internet]. 2015; February 23. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/mediacentre/news/releases/2015/injection-safety/en/">http://www.who.int/mediacentre/news/releases/2015/injection-safety/en/</ext-link>
</mixed-citation></ref><ref id="pone.0135281.ref130"><label>130</label><mixed-citation publication-type="book">
<collab>World Health Organization</collab>. <chapter-title>Conflict and humanitarian crisis in Iraq Geneva</chapter-title>, <publisher-loc>Switzerland</publisher-loc>: <publisher-name>World Health Organization</publisher-name>; <year>2014</year> [cited HQ/PEC/ERM/SCT/2014.4/PHRA 23/02/2015]. Available from: <ext-link ext-link-type="uri" xlink:href="http://who.int/hac/crises/irq/iraq_phra_24october2014.pdf">http://who.int/hac/crises/irq/iraq_phra_24october2014.pdf</ext-link>.</mixed-citation></ref><ref id="pone.0135281.ref131"><label>131</label><mixed-citation publication-type="book">World Health Organization. Annual report of the Regional Director 2013: Emergency preparedness and response Switzerland, Geneva2013 [23/02/2015]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.emro.who.int/annual-report/2013/emergency-preparedness-and-response.html">http://www.emro.who.int/annual-report/2013/emergency-preparedness-and-response.html</ext-link>.</mixed-citation></ref><ref id="pone.0135281.ref132"><label>132</label><mixed-citation publication-type="journal">
<collab>World Health Organization</collab>. <article-title>Health emergency highlights</article-title>. <source>Emergency Risk Management and Humanitarian Response</source>. <year>2014</year>;(<issue>19</issue>).</mixed-citation></ref><ref id="pone.0135281.ref133"><label>133</label><mixed-citation publication-type="journal">
<name><surname>Alter</surname><given-names>MJ</given-names></name>. <article-title>Epidemiology of hepatitis C virus infection</article-title>. <source>World journal of gastroenterology: WJG</source>. <year>2007</year>;<volume>13</volume>(<issue>17</issue>):<fpage>2436</fpage>&#x02013;<lpage>41</lpage>. <?supplied-pmid 17552026?><pub-id pub-id-type="pmid">17552026</pub-id></mixed-citation></ref><ref id="pone.0135281.ref134"><label>134</label><mixed-citation publication-type="journal">
<name><surname>Shepard</surname><given-names>CW</given-names></name>, <name><surname>Finelli</surname><given-names>L</given-names></name>, <name><surname>Alter</surname><given-names>MJ</given-names></name>. <article-title>Global epidemiology of hepatitis C virus infection</article-title>. <source>The Lancet Infectious diseases</source>. <year>2005</year>;<volume>5</volume>(<issue>9</issue>):<fpage>558</fpage>&#x02013;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(05)70216-4</pub-id>
.<?supplied-pmid 16122679?><pub-id pub-id-type="pmid">16122679</pub-id></mixed-citation></ref><ref id="pone.0135281.ref135"><label>135</label><mixed-citation publication-type="journal">
<name><surname>Armstrong</surname><given-names>GL</given-names></name>, <name><surname>Wasley</surname><given-names>A</given-names></name>, <name><surname>Simard</surname><given-names>EP</given-names></name>, <name><surname>McQuillan</surname><given-names>GM</given-names></name>, <name><surname>Kuhnert</surname><given-names>WL</given-names></name>, <name><surname>Alter</surname><given-names>MJ</given-names></name>. <article-title>The prevalence of hepatitis C virus infection in the United States, 1999 through 2002</article-title>. <source>Annals of internal medicine</source>. <year>2006</year>;<volume>144</volume>(<issue>10</issue>):<fpage>705</fpage>&#x02013;<lpage>14</lpage>. .<?supplied-pmid 16702586?><pub-id pub-id-type="pmid">16702586</pub-id></mixed-citation></ref><ref id="pone.0135281.ref136"><label>136</label><mixed-citation publication-type="journal">
<name><surname>Mumtaz</surname><given-names>GR</given-names></name>, <name><surname>Weiss</surname><given-names>HA</given-names></name>, <name><surname>Thomas</surname><given-names>SL</given-names></name>, <name><surname>Riome</surname><given-names>S</given-names></name>, <name><surname>Setayesh</surname><given-names>H</given-names></name>, <name><surname>Riedner</surname><given-names>G</given-names></name>, <etal>et al</etal>
<article-title>HIV among people who inject drugs in the Middle East and North Africa: systematic review and data synthesis</article-title>. <source>PLoS medicine</source>. <year>2014</year>;<volume>11</volume>(<issue>6</issue>):<fpage>e1001663</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pmed.1001663</pub-id>
<?supplied-pmid 24937136?><pub-id pub-id-type="pmid">24937136</pub-id></mixed-citation></ref><ref id="pone.0135281.ref137"><label>137</label><mixed-citation publication-type="journal">
<name><surname>Hassan</surname><given-names>A. S</given-names></name>. <article-title>Prevalence of anti-hepatitis C virus antibodies among blood donors and risky groups in Diyala</article-title>. <source>Journal of the Faculty of Medicine of Baghdad</source>. <year>2008</year>;<volume>50</volume>(<issue>4</issue>):<fpage>467</fpage>&#x02013;<lpage>70</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref138"><label>138</label><mixed-citation publication-type="journal">
<name><surname>Ramia</surname><given-names>S</given-names></name>, <name><surname>Eid-Fares</surname><given-names>J</given-names></name>. <article-title>Distribution of hepatitis C virus genotypes in the Middle East</article-title>. <source>International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases</source>. <year>2006</year>;<volume>10</volume>(<issue>4</issue>):<fpage>272</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijid.2005.07.008</pub-id>
.<?supplied-pmid 16564719?><pub-id pub-id-type="pmid">16564719</pub-id></mixed-citation></ref><ref id="pone.0135281.ref139"><label>139</label><mixed-citation publication-type="book">
<name><surname>Taylor</surname><given-names>E</given-names></name>. <source>Egyptian Migration and Peasant Wives Middle East Research and Information Project 124</source>. <publisher-loc>Washington</publisher-loc>: <publisher-name>Middle East Research and Information Project</publisher-name>
</mixed-citation></ref><ref id="pone.0135281.ref140"><label>140</label><mixed-citation publication-type="journal">
<name><surname>Feiler</surname><given-names>G</given-names></name>. <article-title>Migration and Recession&#x02014;Arab Labor Mobility in the Middle-East, 1982&#x02013;89</article-title>. <source>Popul Dev Rev</source>. <year>1991</year>;<volume>17</volume>(<issue>1</issue>):<fpage>134</fpage>&#x02013;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.2307/1972356</pub-id>
.<?supplied-pmid WOS:A1991FP82100007?></mixed-citation></ref><ref id="pone.0135281.ref141"><label>141</label><mixed-citation publication-type="journal">
<name><surname>Humphrey</surname><given-names>M</given-names></name>. <article-title>Migrants, workers and refugees: the political economy of population movements in the Middle East</article-title>. <source>Middle East report</source>. <year>1993</year>;(<issue>181</issue>):<fpage>2</fpage>&#x02013;<lpage>7</lpage>. .<?supplied-pmid 12179391?><pub-id pub-id-type="pmid">12179391</pub-id></mixed-citation></ref><ref id="pone.0135281.ref142"><label>142</label><mixed-citation publication-type="other">International Organization for Migration. Migration and development in Egypt. 2010.</mixed-citation></ref><ref id="pone.0135281.ref143"><label>143</label><mixed-citation publication-type="journal">
<name><surname>Pawlotsky</surname><given-names>JM</given-names></name>, <name><surname>Tsakiris</surname><given-names>L</given-names></name>, <name><surname>Roudot-Thoraval</surname><given-names>F</given-names></name>, <name><surname>Pellet</surname><given-names>C</given-names></name>, <name><surname>Stuyver</surname><given-names>L</given-names></name>, <name><surname>Duval</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C</article-title>. <source>The Journal of infectious diseases</source>. <year>1995</year>;<volume>171</volume>(<issue>6</issue>):<fpage>1607</fpage>&#x02013;<lpage>10</lpage>. .<?supplied-pmid 7769300?><pub-id pub-id-type="pmid">7769300</pub-id></mixed-citation></ref><ref id="pone.0135281.ref144"><label>144</label><mixed-citation publication-type="journal">
<name><surname>Cuadros</surname><given-names>DF</given-names></name>, <name><surname>Branscum</surname><given-names>AJ</given-names></name>, <name><surname>Miller</surname><given-names>FD</given-names></name>, <name><surname>Abu-Raddad</surname><given-names>LJ</given-names></name>. <article-title>Spatial epidemiology of hepatitis C virus infection in Egypt: analyses and implications</article-title>. <source>Hepatology</source>. <year>2014</year>;<volume>60</volume>(<issue>4</issue>):<fpage>1150</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1002/hep.27248</pub-id>
<?supplied-pmid 24913187?><pub-id pub-id-type="pmid">24913187</pub-id></mixed-citation></ref><ref id="pone.0135281.ref145"><label>145</label><mixed-citation publication-type="journal">
<name><surname>Miller</surname><given-names>FD</given-names></name>, <name><surname>Abu-Raddad</surname><given-names>LJ</given-names></name>. <article-title>Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt</article-title>. <source>Proceedings of the National Academy of Sciences of the United States of America</source>. <year>2010</year>;<volume>107</volume>(<issue>33</issue>):<fpage>14757</fpage>&#x02013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1008877107</pub-id>
<?supplied-pmid 20696911?><pub-id pub-id-type="pmid">20696911</pub-id></mixed-citation></ref><ref id="pone.0135281.ref146"><label>146</label><mixed-citation publication-type="journal">
<name><surname>Chemaitelly</surname><given-names>H</given-names></name>, <name><surname>Abu-Raddad</surname><given-names>LJ</given-names></name>, <name><surname>Miller</surname><given-names>FD</given-names></name>. <article-title>An apparent lack of epidemiologic association between hepatitis C virus knowledge and the prevalence of hepatitis C infection in a national survey in Egypt</article-title>. <source>PloS one</source>. <year>2013</year>;<volume>8</volume>(<issue>7</issue>):<fpage>e69803</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0069803</pub-id>
<?supplied-pmid 23922806?><pub-id pub-id-type="pmid">23922806</pub-id></mixed-citation></ref><ref id="pone.0135281.ref147"><label>147</label><mixed-citation publication-type="journal">
<name><surname>Benova</surname><given-names>L</given-names></name>, <name><surname>Awad</surname><given-names>SF</given-names></name>, <name><surname>Miller</surname><given-names>FD</given-names></name>, <name><surname>Abu-Raddad</surname><given-names>LJ</given-names></name>. <article-title>Estimation of hepatitis C virus infections resulting from vertical transmission in Egypt</article-title>. <source>Hepatology</source>. <year>2015</year>;<volume>61</volume>(<issue>3</issue>):<fpage>834</fpage>&#x02013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1002/hep.27596</pub-id>
<?supplied-pmid 25366418?><pub-id pub-id-type="pmid">25366418</pub-id></mixed-citation></ref><ref id="pone.0135281.ref148"><label>148</label><mixed-citation publication-type="journal">
<name><surname>Guerra</surname><given-names>J</given-names></name>, <name><surname>Garenne</surname><given-names>M</given-names></name>, <name><surname>Mohamed</surname><given-names>MK</given-names></name>, <name><surname>Fontanet</surname><given-names>A</given-names></name>. <article-title>HCV burden of infection in Egypt: results from a nationwide survey</article-title>. <source>Journal of viral hepatitis</source>. <year>2012</year>;<volume>19</volume>(<issue>8</issue>):<fpage>560</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2893.2011.01576.x</pub-id>
.<?supplied-pmid 22762140?><pub-id pub-id-type="pmid">22762140</pub-id></mixed-citation></ref><ref id="pone.0135281.ref149"><label>149</label><mixed-citation publication-type="journal">
<name><surname>Abdul-Karim</surname><given-names>E. T</given-names></name>. <article-title>The prevalence of hepatitis in patients with congenital coagulation disorders</article-title>. <source>Journal of the Arab Board of Health Specializations</source>. <year>2011</year>;<volume>12</volume>(<issue>3</issue>):<fpage>9</fpage>&#x02013;<lpage>14</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref150"><label>150</label><mixed-citation publication-type="journal">
<name><surname>Abed</surname><given-names>B. A</given-names></name>. <article-title>Prevalence of hepatitis C virus (HCV) among thalassemia patients in Ibn Al-Balady Hospital</article-title>. <source>Journal of Al-Nahrain University</source>. <year>2010</year>;<volume>13</volume>(<issue>1</issue>):<fpage>121</fpage>&#x02013;<lpage>6</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref151"><label>151</label><mixed-citation publication-type="journal">
<name><surname>Albahadle</surname><given-names>AK. J.</given-names></name>, <name><surname>Abdul-Abass</surname><given-names>A.</given-names></name>, <name><surname>Ali</surname><given-names>A. H</given-names></name>. <article-title>Prevalence of hepatitis C infection among mutlitransfused thalassemia major patients in Ibn-AlBalady center for thalassemia</article-title>. <source>Al-Qadisiah Medical Journal</source>. <year>2013</year>;<volume>9</volume>(<issue>15</issue>):<fpage>73</fpage>&#x02013;<lpage>84</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref152"><label>152</label><mixed-citation publication-type="journal">
<name><surname>Al-Barzinji</surname><given-names>R M</given-names></name>. <article-title>Patients with childhood leukemia are at high risk for transfusion-transmitted HBV and HCV infections</article-title>. <source>The Iraqi Postgraduate Medical Journal</source>. <year>2006</year>;<volume>5</volume>(<issue>4</issue>):<fpage>442</fpage>&#x02013;<lpage>6</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref153"><label>153</label><mixed-citation publication-type="journal">
<name><surname>Al-Greti</surname><given-names>S. H. H</given-names></name>. <article-title>Prevalence of hepatitis C virus in beta-thalassemia major patients at Karbala governorate</article-title>. <source>Journal of Babylon University for Pure and Applied Sciences</source>. <year>2013</year>;<volume>21</volume>(<issue>8</issue>):<fpage>2801</fpage>&#x02013;<lpage>5</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref154"><label>154</label><mixed-citation publication-type="journal">
<name><surname>Al-Juboori</surname><given-names>L.F</given-names></name>. <article-title>Hepatitis C virus in thalassemia patients in Tikrit</article-title>. <source>Medical Journal of Tikrit</source>. <year>2012</year>;<volume>1</volume>(<issue>181</issue>):<fpage>95</fpage>&#x02013;<lpage>100</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref155"><label>155</label><mixed-citation publication-type="journal">
<name><surname>Al Wtaify</surname><given-names>AS</given-names></name>, <name><surname>Hassan</surname><given-names>MK</given-names></name>. <article-title>Prevalence of hepatitis C virus infection among multitransfused thalassemic children in Basrah&#x02014;Iraq</article-title>. <source>Qatar Medical Journal</source>. <year>2000</year>;<volume>9</volume>(<issue>2</issue>):<fpage>58</fpage>&#x02013;<lpage>61</lpage>. .<?supplied-pmid 2001134222?></mixed-citation></ref><ref id="pone.0135281.ref156"><label>156</label><mixed-citation publication-type="journal">
<name><surname>Al-Zamili</surname><given-names>A. H.</given-names></name>, <name><surname>Al-Shebani</surname><given-names>A. M.</given-names></name>, <name><surname>Mohsin</surname><given-names>R. K</given-names></name>. <article-title>Prevalence of hepatitis C viral infection among multi-transfused thalassemic patients</article-title>. <source>Al-Qadisiah Medical Journal</source>. <year>2009</year>;<volume>5</volume>(<issue>7</issue>):<fpage>89</fpage>&#x02013;<lpage>99</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref157"><label>157</label><mixed-citation publication-type="journal">
<name><surname>Easa</surname><given-names>Z. O</given-names></name>. <article-title>Complications of high serum ferritin level after splenectomy in B thalassemic patients</article-title>. <source>Kufa Medical Journal</source>. <year>2009</year>;<volume>12</volume>(<issue>1</issue>):<fpage>243</fpage>&#x02013;<lpage>50</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref158"><label>158</label><mixed-citation publication-type="journal">
<name><surname>Fadhil</surname><given-names>R. S.</given-names></name>, <name><surname>Al-Khalidi</surname><given-names>S. J.</given-names></name>, <name><surname>Hussien</surname><given-names>S. M.</given-names></name>, <name><surname>Hasoon</surname><given-names>H. A.</given-names></name>, <name><surname>Hussien</surname><given-names>R. A.</given-names></name>, <name><surname>Alwan</surname><given-names>L. H</given-names></name>. <article-title>Complications of HBV, HCV and HIV infections in patients with Coolyze Anemia in Baghdad</article-title>. <source>Iraqi Journal of Cancer and Medical Genetics</source>. <year>2012</year>;<volume>5</volume>(<issue>1</issue>):<fpage>59</fpage>&#x02013;<lpage>63</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref159"><label>159</label><mixed-citation publication-type="journal">
<name><surname>Hashem</surname><given-names>N. A.</given-names></name>, <name><surname>Abdel-Rida</surname><given-names>Z. A.</given-names></name>, <name><surname>Taan</surname><given-names>G. M.</given-names></name>, <name><surname>Abdel-Hussein</surname><given-names>A</given-names></name>. <article-title>Spread of viral hepatitis among thalassemic patients in Maysan province</article-title>. <source>Al-Mustansiriyah Journal of Science</source>. <year>2013</year>;<volume>24</volume>(<issue>3</issue>):<fpage>51</fpage>&#x02013;<lpage>6</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref160"><label>160</label><mixed-citation publication-type="journal">
<name><surname>Khaled</surname><given-names>M. D</given-names></name>. <article-title>Prevalence of hepatitis B, hepatitis C and human immunodeficiency virus infection among Thalassemia patients in Ninavha Governorate/Iraq</article-title>. <source>Journal of Biotechnology Research Center</source>. <year>2014</year>;<volume>8</volume>(<issue>2</issue>):<fpage>11</fpage>&#x02013;<lpage>3</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref161"><label>161</label><mixed-citation publication-type="journal">
<name><surname>Khalid</surname><given-names>MD</given-names></name>, <name><surname>Abdullah</surname><given-names>BA</given-names></name>. <article-title>Prevalence of anti-HCV antibodies among thalassemia patients in Mosul City, Iraq</article-title>. <source>Journal of Life Sciences</source>. <year>2012</year>;<volume>6</volume>(<issue>5</issue>):<fpage>489</fpage>&#x02013;<lpage>91</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref162"><label>162</label><mixed-citation publication-type="journal">
<name><surname>Mustafa</surname><given-names>B</given-names></name>. <article-title>The prevalence of hepatitis- B and C serological markers among patients with thalassemia in Mosul</article-title>. <source>Iraqi Journal of Pharmacy</source>. <year>2010</year>;<volume>9</volume> &#x00026; <volume>10</volume>(<issue>1</issue>):<fpage>66</fpage>&#x02013;<lpage>9</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref163"><label>163</label><mixed-citation publication-type="journal">
<name><surname>Omer</surname><given-names>AR</given-names></name>, <name><surname>Salih</surname><given-names>JI</given-names></name>, <name><surname>Al-Nakshabandi</surname><given-names>AA</given-names></name>. <article-title>Frequency of blood-borne viral infections among leukemic patients in central Iraq</article-title>. <source>Saudi medical journal</source>. <year>2011</year>;<volume>32</volume>(<issue>1</issue>):<fpage>55</fpage>&#x02013;<lpage>61</lpage>. Epub 2011/01/08. .<?supplied-pmid 21212918?><pub-id pub-id-type="pmid">21212918</pub-id></mixed-citation></ref><ref id="pone.0135281.ref164"><label>164</label><mixed-citation publication-type="journal">
<name><surname>Omer</surname><given-names>W. A.</given-names></name>, <name><surname>Jamaleldin</surname><given-names>Z. A</given-names></name>. <article-title>Evaluation of some health and social parameters in Beta-thalassemia major patients in Ninawa governorate</article-title>. <source>Iraqi Medical Journal</source>. <year>2011</year>;<volume>57</volume>(<issue>2</issue>):<fpage>106</fpage>&#x02013;<lpage>10</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref165"><label>165</label><mixed-citation publication-type="journal">
<name><surname>Raham</surname><given-names>TF</given-names></name>, <name><surname>Abdul Wahed</surname><given-names>SS</given-names></name>, <name><surname>Alhaddad</surname><given-names>H</given-names></name>. <article-title>N. Prevalence of hepatitis C among patients with Bthalassemia in Diyala-IRAQ</article-title>. <source>Al-Taqani</source>. <year>2011</year>;<volume>24</volume>(<issue>4</issue>):<fpage>113</fpage>&#x02013;<lpage>20</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref166"><label>166</label><mixed-citation publication-type="journal">
<name><surname>Al-Jamal</surname><given-names>M</given-names></name>, <name><surname>Al-Qudah</surname><given-names>A</given-names></name>, <name><surname>Al-Shishi</surname><given-names>KF</given-names></name>, <name><surname>Al-Sarayreh</surname><given-names>A</given-names></name>, <name><surname>Al-Quraan</surname><given-names>L</given-names></name>. <article-title>Hepatitis C virus (HCV) infection in hemodialysis patients in the south of Jordan</article-title>. <source>Saudi journal of kidney diseases and transplantation: an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia</source>. <year>2009</year>;<volume>20</volume>(<issue>3</issue>):<fpage>488</fpage>&#x02013;<lpage>92</lpage>. Epub 2009/05/06. .<?supplied-pmid 19414962?><pub-id pub-id-type="pmid">19414962</pub-id></mixed-citation></ref><ref id="pone.0135281.ref167"><label>167</label><mixed-citation publication-type="journal">
<name><surname>Batchoun</surname><given-names>RG</given-names></name>, <name><surname>Al-Najdawi</surname><given-names>MA</given-names></name>, <name><surname>Al-Taamary</surname><given-names>S</given-names></name>. <article-title>Anti-ENA antibody profile in hepatitis C patients undergoing hemodialysis</article-title>. <source>Saudi journal of kidney diseases and transplantation: an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia</source>. <year>2011</year>;<volume>22</volume>(<issue>4</issue>):<fpage>682</fpage>&#x02013;<lpage>8</lpage>. Epub 2011/07/12. .<?supplied-pmid 21743211?><pub-id pub-id-type="pmid">21743211</pub-id></mixed-citation></ref><ref id="pone.0135281.ref168"><label>168</label><mixed-citation publication-type="journal">
<name><surname>Ghunaimat</surname><given-names>M.</given-names></name>, <name><surname>Al-Mrayat</surname><given-names>Z.</given-names></name>, <name><surname>Abbadi</surname><given-names>R.</given-names></name>, <name><surname>Akash</surname><given-names>N</given-names></name>. <article-title>Point prevalence of hepatitis C antibodies among hemodialysis patients at king Hussein Medical Center</article-title>. <source>Journal of the Royal Medical Services</source>. <year>2007</year>;<volume>14</volume>(<issue>2</issue>):<fpage>63</fpage>&#x02013;<lpage>7</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref169"><label>169</label><mixed-citation publication-type="journal">
<name><surname>Said</surname><given-names>RA</given-names></name>, <name><surname>Hamzeh</surname><given-names>YY</given-names></name>, <name><surname>Mehyar</surname><given-names>NS</given-names></name>, <name><surname>Rababah</surname><given-names>MS</given-names></name>. <article-title>Hepatitis C virus infection in hemodialysis patients in jordan</article-title>. <source>Saudi journal of kidney diseases and transplantation: an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia</source>. <year>1995</year>;<volume>6</volume>(<issue>2</issue>):<fpage>140</fpage>&#x02013;<lpage>3</lpage>. Epub 1995/04/01. .<?supplied-pmid 18583853?><pub-id pub-id-type="pmid">18583853</pub-id></mixed-citation></ref><ref id="pone.0135281.ref170"><label>170</label><mixed-citation publication-type="journal">
<name><surname>Othman</surname><given-names>BM</given-names></name>, <name><surname>Monem</surname><given-names>FS</given-names></name>. <article-title>Prevalence of hepatitis C virus antibodies among health care workers in Damascus, Syria</article-title>. <source>Saudi medical journal</source>. <year>2001</year>;<volume>22</volume>(<issue>7</issue>):<fpage>603</fpage>&#x02013;<lpage>5</lpage>. Epub 2001/08/02. .<?supplied-pmid 11479642?><pub-id pub-id-type="pmid">11479642</pub-id></mixed-citation></ref><ref id="pone.0135281.ref171"><label>171</label><mixed-citation publication-type="journal">
<name><surname>Al-Azzawi</surname><given-names>M. K. K</given-names></name>. <article-title>Study of the spread of viral hepatitis pattern (C) among pregnant women in the city of Baquba</article-title>. <source>Journal of Diyala for Humanity Research</source>
<year>2006</year>;(<issue>22</issue>):<fpage>106</fpage>&#x02013;<lpage>12</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref172"><label>172</label><mixed-citation publication-type="journal">
<name><surname>Al-Doori</surname><given-names>A.M</given-names></name>. <article-title>Prevalence of hepatitis B and hepatitis C among blood donors in Al-Anbar governorate</article-title>. <source>Journal of the Faculty of Medicine of Baghdad</source>. <year>2006</year>;<volume>48</volume>(<issue>2</issue>):<fpage>149</fpage>&#x02013;<lpage>51</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref173"><label>173</label><mixed-citation publication-type="journal">
<name><surname>Al-Duliami</surname><given-names>A. A.</given-names></name>, <name><surname>Al-Kiali</surname><given-names>K. K.</given-names></name>, <name><surname>Hasan</surname><given-names>AR</given-names></name>. <article-title>Is there any relationship between hepatitis C virus infection and skin diseases?</article-title>
<source>Diyala Journal of Medicine</source>. <year>2012</year>;<volume>3</volume>(<issue>1</issue>):<fpage>51</fpage>&#x02013;<lpage>6</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref174"><label>174</label><mixed-citation publication-type="journal">
<name><surname>Al-Hamdani</surname><given-names>A.H.</given-names></name>, <name><surname>Al-Rawy</surname><given-names>S. K.</given-names></name>, <name><surname>Khamees</surname><given-names>H. A</given-names></name>. <article-title>Retrospective seroprevalence study of hepatitis B and C in Iraqi population at Baghdad: a hospital based study</article-title>. <source>Iraqi Journal of Community Medicine</source>. <year>2012</year>;(<issue>3</issue>):<fpage>186</fpage>&#x02013;<lpage>90</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref175"><label>175</label><mixed-citation publication-type="journal">
<name><surname>Ali</surname><given-names>MK</given-names></name>. <article-title>Prevalence of hepatitis B and hepatitis C among blood donors in Baghdad, August 2007-December 2008</article-title>. <source>Journal of the Faculty of Medicine of Baghdad University</source>. <year>2009</year>;<volume>51</volume>(<issue>4</issue>):<fpage>419</fpage>&#x02013;<lpage>22</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref176"><label>176</label><mixed-citation publication-type="journal">
<name><surname>Al-Jebori</surname><given-names>A. S.</given-names></name>, <name><surname>Hassan</surname><given-names>A. S.</given-names></name>, <name><surname>Al-Duliami</surname><given-names>A. A</given-names></name>. <article-title>Seroprevalence of hepatitis B and hepatitis C virus infections in Diyala province during 2003&#x02013;2008</article-title>. <source>Diyala Journal For Pure Science</source>. <year>2010</year>;<volume>6</volume>(<issue>1</issue>):<fpage>292</fpage>&#x02013;<lpage>302</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref177"><label>177</label><mixed-citation publication-type="journal">
<name><surname>Aljooani</surname><given-names>O. AA.</given-names></name>, <name><surname>Al-Hayani</surname><given-names>N. N.</given-names></name>, <name><surname>Mohammed</surname><given-names>M. J</given-names></name>. <article-title>The infection with HBV and HCV and their relationship to ABO blood group among blood donors</article-title>. <source>Journal of the Faculty of Medicine of Baghdad</source>. <year>2012</year>;<volume>54</volume>(<issue>1</issue>):<fpage>52</fpage>&#x02013;<lpage>6</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref178"><label>178</label><mixed-citation publication-type="journal">
<name><surname>Al-Juboury</surname><given-names>A. W. F.</given-names></name>, <name><surname>Salih</surname><given-names>H. A. L. M.</given-names></name>, <name><surname>Al-Assadi</surname><given-names>M. K.</given-names></name>, <name><surname>Ali</surname><given-names>A. M</given-names></name>. <article-title>Seroprevalence of Hepatitis B and C among blood donors in Babylon Governorate-Iraq</article-title>. <source>Medical Journal of Babylon</source>. <year>2010</year>;<volume>7</volume>(<issue>1&#x02013;2</issue>).</mixed-citation></ref><ref id="pone.0135281.ref179"><label>179</label><mixed-citation publication-type="journal">
<name><surname>Al-Kamil</surname><given-names>E. A.</given-names></name>, <name><surname>Al-Yassin</surname><given-names>A. K</given-names></name>. <article-title>Transfusion transmitted diseases among blood donors of Basrah blood bank</article-title>. <source>Journal of the Arab Board of Health Specializations</source>. <year>2011</year>;<volume>12</volume>(<issue>1</issue>):<fpage>35</fpage>&#x02013;<lpage>40</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref180"><label>180</label><mixed-citation publication-type="journal">
<name><surname>Amin</surname><given-names>RM</given-names></name>. <article-title>Prevalence of HBV and HCV in blood donors in Mosul city</article-title>. <source>Al-Taqani</source>. <year>2012</year>;<volume>25</volume>(<issue>2</issue>):<fpage>70</fpage>&#x02013;<lpage>7</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref181"><label>181</label><mixed-citation publication-type="journal">
<name><surname>Ataallah</surname><given-names>TM</given-names></name>, <name><surname>Hanan</surname><given-names>KA</given-names></name>, <name><surname>Maysoun</surname><given-names>KS</given-names></name>, <name><surname>Sadoon</surname><given-names>AA</given-names></name>. <article-title>Prevalence of hepatitis B and C among blood donors attending the National Blood Transfusion Center in Baghdad, Iraq from 2006&#x02013;2009</article-title>. <source>Saudi medical journal</source>. <year>2011</year>;<volume>32</volume>(<issue>10</issue>):<fpage>1046</fpage>&#x02013;<lpage>50</lpage>. Epub 2011/10/20. .<?supplied-pmid 22008925?><pub-id pub-id-type="pmid">22008925</pub-id></mixed-citation></ref><ref id="pone.0135281.ref182"><label>182</label><mixed-citation publication-type="journal">
<name><surname>Chiad</surname><given-names>I. A.</given-names></name>, <name><surname>Al-Rubaii</surname><given-names>A.</given-names></name>, <name><surname>Al-Ani</surname><given-names>W.</given-names></name>, <name><surname>Al-Jaf</surname><given-names>A. A.</given-names></name>, <name><surname>Kadhem</surname><given-names>M</given-names></name>. <article-title>Sero-prevalence of hepatitis B virus, hepatitis C virus and human immuno deficiency virus infections among blood donors in the National Center of Blood Transfusion in Baghdad</article-title>. <source>Iraqi Journal of Community Medicine</source>. <year>2009</year>;<volume>22</volume>(<issue>4</issue>):<fpage>215</fpage>&#x02013;<lpage>7</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref183"><label>183</label><mixed-citation publication-type="journal">
<name><surname>Fawzi</surname><given-names>N.</given-names></name>, <name><surname>Muhsin</surname><given-names>K. A. A</given-names></name>. <article-title>Screening for hepatitis B and hepatitis C viral infection among a sample of pregnant women in Al-Fallujah</article-title>. <source>Iraqi Medical Journal</source>. <year>2011</year>;<volume>57</volume>(<issue>2</issue>):<fpage>119</fpage>&#x02013;<lpage>25</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref184"><label>184</label><mixed-citation publication-type="journal">
<name><surname>Hamim</surname><given-names>S. S</given-names></name>. <article-title>A survey study for the prevalence of hepatitis A, B and C in Thi-Qar province for 2006&#x02013;2010</article-title>. <source>Journal of College of Education for Pure Science</source>. <year>2012</year>;<volume>2</volume>(<issue>1</issue>):<fpage>262</fpage>&#x02013;<lpage>77</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref185"><label>185</label><mixed-citation publication-type="journal">
<name><surname>Hamim</surname><given-names>S. S</given-names></name>. <article-title>Seroprevalence of hepatitis B and C among blood voluntaries in Iraq for 2008 and 2009</article-title>. <source>Journal of College of Education for Pure Science</source>. <year>2012</year>;<volume>2</volume>(<issue>2</issue>):<fpage>125</fpage>&#x02013;<lpage>4</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref186"><label>186</label><mixed-citation publication-type="journal">
<name><surname>Hussain</surname><given-names>A. K.</given-names></name>, <name><surname>Mohammed</surname><given-names>S. H.</given-names></name>, <name><surname>Abd</surname><given-names>K. H</given-names></name>. <article-title>Screening of hepatitis B and C viral markers in Iraqi patients with proteinuria</article-title>. <source>Iraqi Postgraduate Medical Journal</source>. <year>2008</year>;<volume>7</volume>(<issue>4</issue>):<fpage>362</fpage>&#x02013;<lpage>8</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref187"><label>187</label><mixed-citation publication-type="journal">
<name><surname>Hussein</surname><given-names>A. H</given-names></name>. <article-title>Seroprevalence of hepatitis B and C viruses among blood donors in Sulaimani Major Blood Bank for the years 2006 and 2007: a comparative study</article-title>. <source>Journal of Zankoy Sulaimani</source>. <year>2010</year>;<volume>13</volume>(<issue>1</issue>):<fpage>15</fpage>&#x02013;<lpage>20</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref188"><label>188</label><mixed-citation publication-type="journal">
<name><surname>Hussain</surname><given-names>S. M.</given-names></name>, <name><surname>Hasan</surname><given-names>A</given-names></name>. <article-title>Does hepatitis C virus infection is a relevant factor for thyroid dysfunction</article-title>. <source>Diyala Journal for Pure Science</source>. <year>2010</year>;<volume>6</volume>(<issue>3</issue>):<fpage>140</fpage>&#x02013;<lpage>5</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref189"><label>189</label><mixed-citation publication-type="journal">
<name><surname>Jassim</surname><given-names>A. N.</given-names></name>, <name><surname>Abdul-Hadi</surname><given-names>A. M.</given-names></name>, <name><surname>Al-Waysi</surname><given-names>S. A</given-names></name>. <article-title>Epidemiological study of viral hepatitis / Chibayish Marsh Reality in iraq</article-title>. <source>Journal of Baghdad for Science</source>. <year>2011</year>;<volume>8</volume>(<issue>1</issue>):<fpage>23</fpage>&#x02013;<lpage>8</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref190"><label>190</label><mixed-citation publication-type="journal">
<name><surname>Naji</surname><given-names>MY</given-names></name>, <name><surname>Abdulzahra</surname><given-names>AA</given-names></name>, <name><surname>Hmood</surname><given-names>AR</given-names></name>. <article-title>Prevalence of viral hepatitis B and C in newly married persons</article-title>. <source>Kufa Journal for Nursing Sciences</source>. <year>2013</year>;<volume>3</volume>(<issue>3</issue>).</mixed-citation></ref><ref id="pone.0135281.ref191"><label>191</label><mixed-citation publication-type="journal">
<name><surname>Richter</surname><given-names>C</given-names></name>, <name><surname>Ter Beest</surname><given-names>G</given-names></name>, <name><surname>Gisolf</surname><given-names>EH</given-names></name>, <name><surname>VANB</surname><given-names>P</given-names></name>, <name><surname>Waegemaekers</surname><given-names>C</given-names></name>, <name><surname>Swanink</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Screening for chronic hepatitis B and C in migrants from Afghanistan, Iran, Iraq, the former Soviet Republics, and Vietnam in the Arnhem region, The Netherlands</article-title>. <source>Epidemiology and infection</source>. <year>2014</year>:<fpage>1</fpage>&#x02013;<lpage>7</lpage>. Epub 2014/01/09. <pub-id pub-id-type="doi">10.1017/s0950268813003415</pub-id>
.<?supplied-pmid 24398373?><pub-id pub-id-type="pmid">24398373</pub-id></mixed-citation></ref><ref id="pone.0135281.ref192"><label>192</label><mixed-citation publication-type="journal">
<name><surname>Saadoon</surname><given-names>I. H.</given-names></name>, <name><surname>Salih</surname><given-names>N. I.</given-names></name>, <name><surname>Saihood</surname><given-names>S. T</given-names></name>. <article-title>Hepatitis C virus infection and abortion among pregnant women in Mosul city</article-title>. <source>Medical Journal of Tikrit</source>. <year>2008</year>;<volume>1</volume>(<issue>141</issue>):<fpage>161</fpage>&#x02013;<lpage>4</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref193"><label>193</label><mixed-citation publication-type="journal">
<name><surname>Salih</surname><given-names>N. I.</given-names></name>, <name><surname>Saadoon</surname><given-names>I. H</given-names></name>. <article-title>Seroprevalence of hepatitis C virus among risk groups in Mosul city</article-title>. <source>Tikrit Journal of Pharmaceutical Sciences</source>. <year>2007</year>;<volume>3</volume>(<issue>2</issue>):<fpage>138</fpage>&#x02013;<lpage>41</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref194"><label>194</label><mixed-citation publication-type="journal">
<name><surname>Salman</surname><given-names>Y. G</given-names></name>. <article-title>Serological cross reaction among some causative agents of women abortions (Toxoplasma gondii &#x00026; Cytomegalo virus &#x00026; Rubella virus), with the incidence of hepatitis virus (B &#x00026; C)</article-title>. <source>Tikret Journal of Pharmaceutical Sciences</source>. <year>2007</year>;<volume>3</volume>(<issue>2</issue>):<fpage>102</fpage>&#x02013;<lpage>11</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref195"><label>195</label><mixed-citation publication-type="journal">
<name><surname>Toffik</surname><given-names>K. A.</given-names></name>, <name><surname>Al-Diwan</surname><given-names>J. K.</given-names></name>, <name><surname>Al-Hadithi</surname><given-names>T. S.</given-names></name>, <name><surname>Al-Waiz</surname><given-names>M. M.</given-names></name>, <name><surname>Omer</surname><given-names>A. R</given-names></name>. <article-title>Prevalence of the serological markers of hepatitis B, C, and D among patients with sexually transmitted diseases (STDs) in Baghdad, Iraq</article-title>. <source>Journal of the Arab Board of Medical Specializations</source>. <year>2006</year>;<volume>8</volume>(<issue>1</issue>):<fpage>105</fpage>&#x02013;<lpage>9</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref196"><label>196</label><mixed-citation publication-type="journal">
<name><surname>Al Abbadi</surname><given-names>B.</given-names></name>, <name><surname>Al Amr</surname><given-names>M.</given-names></name>, <name><surname>Abasi</surname><given-names>L.</given-names></name>, <name><surname>Saleem</surname><given-names>A.</given-names></name>, <name><surname>Abu Hazeem</surname><given-names>N.</given-names></name>, <name><surname>Marafi</surname><given-names>A</given-names></name>. <article-title>Seroprevalence of HBV, HCV, HIV and syphilis infections among blood donors at Blood Bank of King Hussein Medical Center: a 3 year study</article-title>. <source>Middle East Journal of Family Medicine</source>
<year>2014</year>;<volume>12</volume>(<issue>6</issue>):<fpage>10</fpage>&#x02013;<lpage>3</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref197"><label>197</label><mixed-citation publication-type="journal">
<name><surname>Al-Gani</surname><given-names>FA</given-names></name>. <article-title>Prevalence of HBV, HCV, and HIV-1, 2 infections among blood donors in Prince Rashed Ben Al-Hassan Hospital in North region of Jordan</article-title>. <source>International Journal of Biological &#x00026; Medical Research</source>. <year>2011</year>;<volume>2</volume>(<issue>4</issue>):<fpage>912</fpage>&#x02013;<lpage>6</lpage>.</mixed-citation></ref><ref id="pone.0135281.ref198"><label>198</label><mixed-citation publication-type="journal">
<name><surname>Jbara</surname><given-names>I</given-names></name>, <name><surname>Abu Alshiekh</surname><given-names>NK</given-names></name>, <name><surname>Almomani</surname><given-names>AM</given-names></name>, <name><surname>Khasawneh</surname><given-names>RH</given-names></name>, <name><surname>Omari</surname><given-names>AK</given-names></name>. <article-title>Prevalence of hepatitis C virus antibodies among blood donors at Prince Hashem Hospital, Zarka- Jordan</article-title>. <source>Jordan Medical Journal</source>. <year>2006</year>;<volume>40</volume>(<issue>3</issue>):<fpage>190</fpage>&#x02013;<lpage>3</lpage>. .<?supplied-pmid 2007107899?></mixed-citation></ref><ref id="pone.0135281.ref199"><label>199</label><mixed-citation publication-type="journal">
<name><surname>Irani-Hakime</surname><given-names>N</given-names></name>, <name><surname>Aoun</surname><given-names>J</given-names></name>, <name><surname>Khoury</surname><given-names>S</given-names></name>, <name><surname>Samaha</surname><given-names>HR</given-names></name>, <name><surname>Tamim</surname><given-names>H</given-names></name>, <name><surname>Almawi</surname><given-names>WY</given-names></name>. <article-title>Seroprevalence of hepatitis C infection among health care personnel in Beirut, Lebanon</article-title>. <source>American journal of infection control</source>. <year>2001</year>;<volume>29</volume>(<issue>1</issue>):<fpage>20</fpage>&#x02013;<lpage>3</lpage>. Epub 2001/02/15. .<?supplied-pmid 11172314?><pub-id pub-id-type="pmid">11172314</pub-id></mixed-citation></ref><ref id="pone.0135281.ref200"><label>200</label><mixed-citation publication-type="journal">
<name><surname>Ali</surname><given-names>T</given-names></name>, <name><surname>Daher</surname><given-names>N</given-names></name>. <article-title>Prevalence des infections transmissibles par transfusion chez les donneurs de sang au centre de transfusion sanguine de l'universite de Damas et l'importance des mesures de la securite transfusionelle</article-title>. <source>Damscus University Journal of Health Sciences</source>. <year>2010</year>;<volume>26</volume>(<issue>1</issue>):<fpage>107</fpage>&#x02013;<lpage>23</lpage>.</mixed-citation></ref></ref-list></back></article>